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Acute myeloid leukemia (AML) stem cells (LSC) are capable of surviving 
current standard chemotherapy and are the likely source of deadly, relapsed 
disease. While stem cell transplant serves as proof-of-principle that AML LSCs can 
be eliminated by the immune system, the translation of existing immunotherapies 
to AML have been met with limited success. Consequently, understanding and 
exploiting the unique immune mechanisms of AML LSCs is critical. To identify 
novel immunotherapeutic targets, we sourced multiple large, publicly available 
datasets and identified CD200 as a potential stem-cell specific immune checkpoint 
in AML. We hypothesized that CD200 was a stem-cell specific mechanism of 
evading immune detection and destruction and that anti-CD200 antibody therapy 
could effectively eliminate AML LSCs by engaging the patient’s immune system. 
To study the functional role of CD200 in AML, we established and characterized 
two isogenic cell line models of CD200 expression. Utilizing these cells, we 
investigated the effects of CD200+ leukemia on the effector functions of isolated T 
cells, NK cells, and macrophages in vitro. To study CD200 in a physiological 
	 x	
setting, we established a PBMC-humanized mouse model, in which we could 
characterize progression of CD200+ and CD200- AML in the presence of an 
activate human immune response. Further, we used this model to compare the 
effects of CD200+ AML on the transcriptional activity and functional capacity of the 
human T cells. To therapeutically target CD200+ leukemia, we developed a novel, 
humanized CD200-IgG1 antibody. We investigated the potential of this antibody to 
both inhibit the immunosuppressive signaling through the CD200 receptor and 
initiate an antibody-mediated response. By comparing the therapeutic efficacy in 
both immunocompromised and PBMC-humanized mice, we confirmed that 
CD200-IgG1 could effectively eliminate CD200+ AML only in the presence of T 
cell-mediated response. Taken together, we conclude that CD200 is a marker of 
functional AML stem cells that aids in the escape of immune detection and 
destruction. Furthermore, these studies lay the groundwork for CD200-targeted 
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1.1  Acute Myeloid Leukemia 
Acute Myeloid Leukemia (AML) is a clonal malignancy of the bone marrow 
derived from immature hematopoietic cells. Accumulation of mutations and genetic 
translocations result in malignant transformation of hematopoietic stem cells and 
early myeloid progenitor cells that maintain the ability to self-renew and propagate. 
The rapidly expanding leukemia cells commandeer the available resources in the 
bone marrow and outcompete healthy hematopoiesis. The severe reduction of 
healthy red blood cells, platelets, and neutrophils, result in anemia, 
thrombocytopenia, and neutropenia. These systemic conditions lead to symptoms 
such as lethargy, bruising, and frequent infection. Due to the rapid onset of disease 
and the nondescript symptoms, most AML patients are diagnosed after the blast 
count, or abundance of disease, is high
1,2
.      
While age is typically considered the biggest “risk factor” for developing 
AML, there are few specific genetic and environmental components that 
predispose individuals to disease. Familial or genetic predisposition include 
inherited mutations in the telomerase complex
3
, germline chromosomal 
abnormalities, like Down Syndrome
4





, and Diamond-Blackfan syndrome
7
. 




Certain environmental exposures also increase the odds of developing 
AML. A meta-analysis of 22 studies found a consistent link between high benzene 




Unfortunately, exposure to radiation and chemotherapy, used for the treatment of 
other neoplasms can also increase the odds of developing AML. In fact, therapy-
related AML (t-AML) makes up approximately 10% of all AML cases and have 
been shown to have inferior outcomes when compared to de novo leukemia10.  
Frontline chemotherapy results in remission in up to 80% of patients, 
however, the 5-year survival rate for those with AML is only 50% for younger 
patients and <30% for the elderly patients; statistics that have remained relatively 
unchanged for more than a decade
2
. This discrepancy is due to the fact that most 
patients relapse and relapsed disease is deadly
11
. It has been postulated that 
therapy-resistant leukemia stem cells (LSCs) are the most probable source of 
relapse, implicating LSCs as the critical target for curing AML.  
 
1.2 Acute Myeloid Leukemia Stem Cells 
 The cancer stem cell controversy began in the 19th century when a German 
pathologist, Robert Virchow, remarked on the similarities between cancerous cells 
and cells of embryonal origin
12
. Since then, there have been numerous variations 
of the cancer stem cell hypothesis that all converge upon the notion that there must 
exist a cell, or subset of cells, that represent the origin of disease. The first 
experimental evidence of a cancer stem cell came when it was demonstrated that 
certain subsets of acute myeloid leukemia cells could engraft and recapitulate 
disease in immunocompromised mice
13
.  
  Normal hematopoiesis follows a hierarchical, albeit fluid, structure with a 
well-established, well-characterized hematopoietic stem cell (HSC) residing at the 
	 3	
apex. Thus, it was hypothesized that the malignant versions of these stem and 
progenitor cells would also mimic a hierarchical structure by maintaining self-
renewal while also producing more differentiated, nonfunctional blast cells (Figure 
1)
14
. Work by John Dick and colleagues confirmed the existence of such cells, 




Now, LSCs are functionally defined as those cells capable of engrafting and 
giving rise to disease in sub-lethally irradiated immunodeficient mice
13
. In AML, 
LSCs are generally defined by their immunophenotype as being positive for CD34 
and negative for CD38, with an ever-growing list of exceptions. In most patients, 
LSCs are thought to comprise only a small fraction of the overall disease, however, 
their unique biological properties implicate them as both the initiators of disease 
as well as the most likely source of relapse. Patients with genetic signatures similar 
to LSCs have significantly worse overall survival in multiple patient cohorts
15,16
. 
Further molecular characterization of AML LSCs has demonstrated that 
they, similar to their health HSC counterparts, are largely quiescent, and capable 
of both long-term self-renewal and production of more differentiated cells
17
. Their 
relatively dormant cell cycle make LSCs less vulnerable to therapeutic agents that 
preferentially target dividing cells, like chemotherapy or radiation
18
. LSCs have 
also been shown to selectively upregulate anti-apoptotic proteins, such as BCL-2, 
as an added layer of protection
19
. Taken together, this evidence implicates LSCs 




Figure 1. Schematic of normal hematopoiesis and leukemogenesis. Normal 
hematopoiesis follows a hierarchical structure with hematopoietic stem cells 
residing at the apex. Acquisition of mutations and translocations in myeloid stem 
and progenitor cells give rise to the leukemia stem cell, capable of self-renewal 
and production of blast cells. HSC= hematopoietic stem cell, MPP= multipotent 
progenitor cell, CLP= common lymphoid progenitor. CMP= common myeloid 
progenitor, LSC= leukemia stem cell.  
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1.3 Current therapy 
 Standard of care for acute myeloid leukemia has remained relatively 
unchanged since the introduction of the “3+7” strategy over 30 years ago. Upon 
diagnosis of AML, patients receive induction chemotherapy which consists 3 days 
of an anthracycline (typically either daunorubicin or idarubicin) and 7 days of 
continuous infusion of cytarabine. This approach results in morphological complete 
remission in 60-80% of patients between 18-60 years of age and only 30% in those 
60 and older. Post-remission strategies vary by patient and response and can 
include continued maintenance therapy, intensive chemotherapy, or ablative 
therapy followed by hematopoietic stem cell transplant
2
.  
 One of the few recent changes in frontline care for AML came in 2018, when 
the FDA approved venetoclax, a potent BCL-2 inhibitor, in combination with 
hypomethylating agents (HMA) for the treatment of newly diagnosed AML in older 
patients
20
. This came as a result of the multicenter Phase 1B clinical that 
demonstrated deep, durable responses that significantly outcompeted standard 
chemotherapy
20
. The profound success of venetoclax plus HMA was attributed to 




1.4 Immunotherapy in AML 
  While immunotherapy has gained a great deal of recent publicity for the 
unparalleled successes seen with checkpoint inhibitor therapy in melanoma
22
 and 
non-small cell lung cancer
23
, cancer immunotherapy is no new concept. Curing 




. It was demonstrated that immune cells reconstituted from donor marrow 
were capable of eliminating residual leukemia cells and curing patients. Allogeneic 
stem cell transplant (allo-SCT) after myeloablative chemotherapy is still the best 
option for reducing the likelihood of relapse
25
. The graft-versus-leukemia (GvL) 
response induced by the introduction of foreign immune cells demonstrates that 
LSCs are vulnerable to destruction by the immune system. However, the 
mechanism of allo-SCT success can also be hazardous, resulting in high rates of 
treatment-related mortality and morbidity. Despite this knowledge, immunotherapy 
has not yet been optimally exploited for the treatment of AML. Popular checkpoint 
inhibitors are now being explored in combination therapies in AML patients with 
limited sucess
26
. Immunotherapy clinical trials in AML are broadening to include 
monoclonal antibodies, both drug-conjugated and naked, bispecific engager 
antibodies and chimeric antigen receptor (CAR) T and NK cells to target specific 
leukemia antigens like CD33 and CD123
27
. However, many of these antigen-
specific approaches focus on the bulk disease rather than the stem cell biology. 
Therefore, there is a need for novel approaches to exploit the immune system to 
explicitly eliminate LSCs while limiting toxicity. 
 
1.5 CD200 in Immunology 
Cluster of differentiation 200, or CD200, is a type-1 transmembrane 
glycoprotein that is a member of the immunoglobulin superfamily. CD200 is 
broadly expressed in neurons, B cells, and subsets of endothelial cells
28
. This 
small 41-47kD protein consists of two extracellular immunoglobulin superfamily 
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domains, a single transmembrane domain, and a short cytoplasmic tail
29-31
. 
Because the intracellular portion of CD200 contains no known signaling motifs or 
consensus binding sites for adapter molecules, it has been hypothesized that the 
primary role of CD200 is through its interaction with the CD200 receptor
32
.  
The CD200 receptor, CD200R1, is the only established binding partner for 
CD200
33
. Unlike its ligand, CD200R is almost exclusively expressed on subsets of 
myeloid and lymphoid cells. This pattern of expression has led to the belief that the 
CD200/CD200R signaling axis primarily acts as a local regulator of immune 
response. Like CD200, the receptor consists of two extracellular immunoglobulin 
superfamily domains and a single transmembrane domain. However, the 
intracellular tail is longer and contains 3 tyrosine residues
34
. Most inhibitory 
receptors on lymphocytes, including Programmed cell death protein 1 (PD-1), T 
cell immunoreceptor with Ig and ITIM domains (TIGIT), and T-cell immunoglobulin 
domain and mucin domain 3 (TIM-3), signal by recruiting Src homology domain 
containing protein tyrosine phosphatases (SHP-1 and SHP-2) to immunoreceptor 
tyrosine-based inhibition or switch motifs (ITIMs or ITSMs) which directly 
dephosphorylate proteins downstream of the T cell receptor
35
. CD200 receptor 
lacks ITIM/ITSMs. Instead, upon ligation of CD200, the downstream tyrosine 
kinase (Dok2) adapter protein is recruited to the distal phosphorylation residue 
where it further recruits the SH2 domain containing protein, RAS p21 protein 
activator (RasGAP). The Dok2/RasGAP complex is sufficient to inhibit Ras 
activation, which leads to the subsequent inhibition of the mitogen-activated 
protein kinase (MAPK) signaling cascade (Figure 2)
36
. While CD200R suppression 
	 8	








 C57BL/6 mouse models are viable. While 
grossly normal, CD200
-/-
 mice displayed an increased number of macrophages 
that were more phenotypically activated upon stimulation
38
. These mice were also 
more susceptible to experimental allergic encephalomyelitis (EAE) and collagen-
induced arthritis; both diseases largely regulated by myeloid cells. There was also 
no evidence of abnormalities in the cells that normally expressed CD200. This 
model suggested that the primary role of CD200 was the suppression of myeloid 
and macrophage activity. Complimentary evidence in the CD200R1 knockout 
mouse demonstrated a more potent inflammatory response, as measured by the 
release of tumor necrosis factor alpha (TNFα), in response to lipopolysaccharides 
(LPS), a known stimulator of myeloid cells
39
. These mice are also used as a model 
system to study instances of chronic inflammation and infection
40-42
. 
 Functional studies using CD200R agonists reported that the primary 
molecular mechanisms of CD200-mediated immunosuppression were the 
inhibition of interferon gamma (IFNγ) and interleukin 17 (IL-17) cytokine secretion 
from murine macrophages and downregulation of IL-5 and IL-13 cytokine 
production from human monocytes
43
. Additionally, CD200-Ig fusion proteins 
induce the production of indoleamine 2,3-dioxygenase (IDO) from dendritic cells 







Figure 2. Schematic of CD200R signaling. 
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1.6 CD200 in AML 
 The bulk of our understanding of the role of CD200 in AML has come from 
the labs of Alexander Tonks and Richard Darley. First, Coles et al observed that 
AML patients with high bulk CD200 expression had approximately half the 
frequency of activated natural killer (NK) cells when compared to AML with low 
CD200. Additionally, it was demonstrated that CD200 could have a directly 
suppressive role on cell function by suppressing NK cell degranulation and 
interferon production
45
. In the adaptive immune cell subsets, CD8+ memory T cells 
from AML patients with high levels of CD200 were less capable of producing 
CD107a after ex vivo stimulation. Similarly, CD200-high patients had significantly 
fewer CD4+ memory T cells capable of secreting the inflammatory cytokines, 
TNFα and IL-2, upon artificial stimulation
46
. This could indicate T cell exhaustion 
in patients with high CD200 expression on leukemia cells. Within patients, CD200 
expression on AML cells was also observed to correlate with the abundance of 
FoxP3+CD4+ regulatory T cells, a known immunosuppressive immune cell subset 
that is indicative of poor prognosis
47
.  Finally, it was observed that CD200 on AML 
blasts positively correlated with expression of the immune checkpoint PD-1 on 
cytotoxic CD8+ T cells
48
. Taken together, there is preliminary evidence that CD200 
is an important regulator of immune cell function in AML.  
CD200 has also been reported to be clinically relevant in AML. High CD200 
expression on bulk AML disease was associated with a 50% reduction in odds of 
complete remission and significantly worse overall survival when compared to 
	 11	





1.7 CD200 in Stem Cell Biology 
 CD200 has also been reported as a marker of both normal and cancer stem 
cells. In the normal setting, CD200 has been used to accurately identify colony-
forming follicular stem cells
52
. An unbiased screen of 240 cell-surface markers on 
fat depots revealed that CD200 uniquely differentiated visceral-fat adipose-derived 
stem cells from subcutaneous-fat stem cells
53
. In another screen of plasma 
membrane proteins of mesenchymal stem cells (MSCs), CD200 was identified as 




Kawasaki et al first posited that cancer stem cells may have unique 
mechanisms of evading immune cell detection and destruction. Using cell lines 
derived from prostate, breast, colon, and glioblastoma, they showed that CD200-
expressing cells were rare and almost exclusively found in the stem cell fraction of 
disease
55
. In acute myeloid leukemia, CD200 expression was significantly 
enriched in disease high for CD34, the established AML LSC marker
50
. Early data 








1.8  Existing CD200-targeted therapy 
Samalizumab is a humanized anti-CD200 IgG2/G4 chimeric antibody 
engineered to specifically block CD200 binding to the CD200R without inciting Fc-
mediated effector functions
57
. The decision to use an antibody backbone without 
innate effector function was based on preliminary data suggesting that the IgG2/G4 
version was just as effective at eliminating disease as the effector-engaging IgG1 
version in a subcutaneous model of Non-Hodgkin’s lymphoma
58,59
.  In the Phase 
I, first-in-human, trial of single-agent samalizumab for the treatment of chronic 
lymphocytic leukemia (CLL) and multiple myeloma (MM), 14 out of 21 CLL patients 
experienced a dose-dependent decrease in the frequency of CD200-expressing 
leukemia cells and reduction in overall disease burden. Samalizumab was well 
tolerated and had a good safety profile [NCT00648739]
57
. Single-agent 
samalizumab was also included as a therapeutic arm of the BEAT AML clinical trial 
[NCT03013998] for previously untreated patients with core-binding factor 
leukemias which present with high levels of bulk CD200 expression. The results of 
this arm were not included in the trial summary
60
.   
Another emerging CD200-targeted therapy involves modified T cells with 
immunomodulatory fusion proteins (IFPs)
61
. In this unique strategy, CD8+ 
cytotoxic T cells are engineered to express an artificial protein that contains the 
extracellular CD200 receptor domain fused to the intracellular signaling domain of 
the T cell costimulatory protein, CD28
62
. In response to CD200-expressing 
leukemia cells, the CD200R-CD28 T cells demonstrate enhanced effector function 
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and proliferation by directly converting the previously suppressive CD200 ligand 
into a T cell activator.     
   
1.9 Hypothesis and Research Goals  
 A better understanding of the precise mechanisms employed by LSCs to 
evade immune detection and destruction are critical to developing targeted 
immunotherapy for curing AML. CD200 has been implicated as a stem cell marker 
for certain normal and cancerous tissues. Clinically, CD200 is a poor prognostic 
marker in AML. Functionally, CD200 has been shown to be immunosuppressive 
by inhibiting macrophage and NK cell function and also inducing regulatory T cells. 
Monoclonal antibodies against CD200, like samalizumab, are currently in Phase 
I/II clinical trials. At present, CD200-mediated immunotherapy has not been 
translated to specifically target AML LSCs to facilitate clearance by the patient’s 
immune system. 
The long-term goal of this research project is to understand the patient-
specific immune evasion mechanisms of leukemia stem cell populations to 
improve personalized immunotherapies and, ultimately, eradicate AML. This 
dissertation investigates the intrinsic and extrinsic functions of CD200, a novel 
marker of AML LSCs, and explores the potential therapeutic benefit of targeting 
CD200 on LSCs using monoclonal antibodies. I hypothesize that, in a subset of 
AML, high expression of CD200 is an LSC-specific mechanism for evading both 
innate and adaptive immune-mediated cell death and that CD200 blockade will 
result in the clearance of LSCs by the immune system.  
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To address this hypothesis, I endeavored to (Figure 3): 
1. Validate CD200 as a novel AML stem cell marker by 
 a. evaluating AML LSC gene expression datasets 
 b. performing clonogenic assays with CD200+ AML patient samples 
c. constructing and characterizing 2 isogenic AML cell line models of 
CD200 expression 
2. Determine the role of CD200-expressing AML on the immune system by 
a. performing isolated mixed-lymphocyte reactions with cells from 
both the innate and adaptive immune systems. 
b. evaluating CD200-expressing and non-expressing leukemias in 
humanized mouse models. 
3. Test the pre-clinical utility of a novel CD200-IgG1 antibody by 
a. characterizing the antibody-mediated and CD200 blocking-
mediated effects of anti-CD200 therapy. 
b. evaluating single-agent therapy in immunocompromised and 
humanized mouse models. 
 
Significance and Impact: This dissertation introduces CD200 as a novel marker of 
acute myeloid leukemia stem cells. Further, this work reveals that AML LSCs have 
unique mechanisms by which they interact with and control the neighboring 
adaptive and innate immune systems. Finally, this body of work demonstrates that 
specifically targeting LSCs with a proprietary anti-CD200 monoclonal antibody can 
be a curative approach to AML.  
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Purpose: Accurately targeting acute myeloid leukemia stem cells, particularly with 
immunotherapy, requires a better understanding of the genes and biological 
processes that are uniquely employed by these cells. In this chapter, we used an 
in silico approach, leveraging the wealth of publicly available data, to identify novel 
AML LSC targets. We then performed a series of experiments to validate one of 
these markers, CD200, in both human and murine leukemia.   
 
Experimental design: We sourced 3 large, publicly available datasets that 
contained gene expression profiling on sorted LSCs, blasts, and normal 
hematopoietic subsets and identified CD200 as being uniquely overexpressed in 
LSCs. Primary AML patient samples were screened for CD200 expression by flow 
cytometry. Mass cytometry was performed to track CD200 in patients over the 
course of immunotherapy treatment. Colony formation assay were used to 
challenge AML cell subsets for in vitro repopulation potential. Stem cell function in 
CD200+ murine AML was tested by transplantation assays. Two isogenic cell line 
models were engineered using both CRISPR/Cas9 knockout and overexpression 
to study the functional role of CD200 in AML.  
 
Results: CD200 transcript was identified as significantly overexpressed in LSCs 
compared to blasts and healthy HSCs using publicly available databases. 
Subsequently, using AML patient samples, we confirmed CD200 surface protein 
expression in >90% of primary AML cases. Further, CD200 more specifically 
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identified human AML LSCs than CD34. In a murine model of AML, CD200 also 
identified functional LSCs, which was consistent with our human data. 
Manipulating human CD200 in AML cell lines did not significantly alter growth, 
metabolism, or engraftment but did result in differential transcription and the 
upregulation of genes involved in DNA damage response. CD200+ clones of 
disease persisted in the presence of immunotherapy treatment. 
 
Conclusions: We found that CD200 is a novel marker of LSCs in both human and 
murine models of AML. While not previously described, our data suggests a 
potential intrinsic role of CD200 in regulating cellular response to DNA damage. 
This added protection may explain the persistence of CD200 disease in resistant 













History of AML LSCs. Acute myeloid leukemia (AML) was first shown to mimic a 
normal hematopoietic hierarchy 50 years ago using clonogenic assays
63,64
. Since 
then, seminal work by Dick and colleagues has demonstrated that a small fraction 
of AML cells was capable of engrafting and recapitulating disease in nonobese 
diabetic (NOD) severe combined immunodeficient (SCID) mice, originally termed 
SCID leukemia-initiating cell (SL-IC)
13,14
. These SL-IC had the stem cell properties 
of both long-term self-renewal and differentiation into leukemic blasts and would 
later go on to be called leukemia stem cells (LSCs).   While LSCs are rare, their 
unique biological properties implicate them as both the initiators of disease as well 
as the most likely source of relapse
65
. In fact, LSC gene expression signatures 
have been shown to be independent predictors of worse overall survival in multiple 
patient cohorts
15,16
. Therefore, understanding the biology of LSCs is critical to their 
eradication in AML. 
 
Biological properties of AML LSCs. Similar to their normal hematopoietic stem cell 
(HSC) counterparts, LSCs are characterized by cell cycle quiescence
17
. Treatment 
with 5-fluorouracil (5-FU) is toxic to actively cycling cells and has been traditionally 
used to purify healthy hematopoietic stem and progenitor populations
66
. Terpstra 
et al found that treating AML with 5-FU selected for cells capable of engrafting in 
SCID mice, suggesting that AML stem cells were either more resistant to 5-FU 
cytotoxicity or more quiescent
67
. By partitioning primary AML patient samples by 
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cell cycle status based on 
3
H-thymidine incorporation or DNA content assays, 
Guan et al more definitively demonstrated that the functional leukemia stem cells 
were enriched in the quiescent/G0 cell fractions
68
. LSC quiescence is one of the 
proposed mechanisms by which these cells selectively evade the effect of 
chemotherapeutic agents that rely on active cell cycling for cytotoxicity
18
. 
 In contrast, HSCs and LSCs have different metabolic dependencies. 
Healthy, quiescent CD34+ cells have a decreased dependence on oxidative 
phosphorylation (OXPHOS) and efficiently employ glycolysis to sustain their 
minimal energy requirements
69
. However, studies by our lab and others have 
demonstrated that LSCs are uniquely metabolically dormant and rely almost 
exclusively on mitochondrial respiration for survival
70,71
. This unique metabolic 
dependency on OXPHOS was shown to be mediated by the upregulation of the 
anti-apoptotic B-cell lymphoma 2 (BCL-2) protein and targeting BCL-2 with a BH3 




Immunophenotype of AML LSCs. A seemingly simple yet critical aspect of AML 
LSC research is the ability to accurately and systematically identify these cells in 
heterogeneous disease. Early xenotransplantation studies in SCID or NOD-SCID 
indicated that the only cells with stem capabilities resided exclusively in the 
CD34+CD38- cell fraction
13,14
.  However, with the advent of more immunodeficient 
NOD/SCID/IL2R-γ null (NSG) mouse models and careful consideration of stem cell 
isolation, leukemia stem cells have been identified outside the of CD34+CD38- 
partition
72-76
. In fact, it is now appreciated that approximately half of AML patient 
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samples will also have functional stem cells that are either CD34+CD38+ or even 
CD34-
15
. Goardon et al further demonstrated that 2 molecularly distinct, functional 
stem cell subtypes coexist in a hierarchical relationship within approximately 80% 
of AML patients
77
. Another notable exclusion to the CD34+CD38- stem cell rule 
are AML samples with mutations in nucleophosmin (NPM1). In these samples, 
which make up approximately 30% of de novo AML, the majority of functional stem 
cells are CD34-
78-80
. Thus, CD34 no longer remains a reliable way to partition 
functional leukemia stem cells. Many groups have endeavored to discover more 
universal LSC markers using gene expression studies of immunophenotypically 




















, have been posited as superior identifiers of AML LSCs. However, these 
markers alone have not been able to consistently segregate functional LSCs ex 
vivo. Beyond studying stem cell biology, having a universal AML stem cell marker 
is critical for developing targeted immunotherapeutics. 
 
 
In this chapter, we aimed to (1) identify, (2) validate, (3) and characterize CD200, 




2.3 Materials and Methods 
	
In silico screen. The pre-aligned RNA-seq data from Corces et al was downloaded 
through the NCBI GEO portal under accession number GSE74246
88
. Normalized 
Illumina expression array data generated by de Jonges et al was downloaded 
through NCBI GEO under accession GSE30029
89
. Affymetrix CEL files generated 
by Jung et al were downloaded through NCBI GEO under accession GSE6327090. 
Appendix A contains all scripts used to process and analyze these data. 
 
Flow cytometry and cell sorting of primary human AML. Primary AML bone marrow 
biopsies or peripheral blood draws were collected under the MD Anderson 
Institutional Review Board protocol PA12-0173. PBMCs were isolated by density 
gradient separation. Briefly, whole blood samples were mixed at a 1:1 ratio with 
Dulbecco’s Phosphate-Buffered Saline (PBS) without calcium and magnesium 
(GenDEPOT) and gently added to 15ml Lymphocyte Separation Medium (Lonza; 
cat. 17-829E). Cells were centrifuged at 1,800 RPM for 20 minutes and the 
lymphocyte layer was carefully extracted. If necessary, 5ml ammonium chloride 
solution (Stem Cell Technologies) was used to lyse any residual red blood cells for 
5 minutes on a shaker. After counting, 3x10
5
 cells were transferred to a 5ml FACS 
tube and washed twice with staining buffer (PBS + 0.5% Bovine Serum Albumin 
(Sigma-Aldrich)). Cells were human Fc-blocked with 5µl anti-human Fc receptor 
binding inhibitor (eBioscience Invitrogen) in 100µl staining buffer for 15 minutes 
prior to the addition of CD200-APC-Cy7 (Biolegend; cat.	329221) and CD34-FITC 
(Biolegend) antibodies (1µl/sample). Surface stain was incubated for 30 minutes 
	 23	
at room temperature on an orbital shaker followed by 2 washes with staining buffer. 
Cells were resuspended in 300µl of staining buffer plus 5ul 4',6-Diamidino-2-
Phenylindole, Dihydrochloride (DAPI; 2µg/ml; Invitrogen) for live/dead cell 
discrimination for collection on a LSRII machine (BD). Cell sorting followed the 
same staining protocol with larger cell numbers and was run on the MoFlo Astrios 
cell sorter (Beckman Coulter).  
 
CyTOF mass cytometry. Frozen primary bone marrow samples were thawed and 
immediately incubated in thawing media (10ml Minimum Essential Medium Eagle, 
alpha modification (a-MEM; Sigma Life Science) with 20% heat-inactivated Fetal 
Bovine Serum (FBS; GenDEPOT), 10mM MgSO4, 100µg/ml Heparin, and DNAse 
for 15 minutes at 37°C prior to CyTOF staining. Sample barcoding and metal-
conjugated antibody staining were performed according to Fluidigm’s protocols as 
described below. Briefly, all antibodies were labeled with heavy metals using 
Maxpar-X8 labeling reagent kits (Fluidigm DVS Sciences) according to 
manufacturer’s instructions and titrated for optimal concentration determination. 
For normal and AML bone marrow samples, 1x10
6
 cells were aliquoted into 
separate FACS tubes and washed twice with Maxpar PBS Buffer (Fluidigm; cat. 
201058). For live/dead cell discrimination, cells were resuspended in 200µl of 5µM 
cisplatin (Fluidigm; cat. 201064) for 1 minute on an orbital shaker followed 
immediately by 3 washes in Maxpar Cell Staining Buffer (CSB; Fluidigm; cat. 
201068). Cells were then fixed in 1ml of 1x Fix I Buffer (Fluidigm; cat.	201065) for 
10 minutes followed by 2 washes with 1x Barcode Perm Buffer (Fluidigm; cat. 
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201057). Each unique Palladium Barcode (Fluidigm; Cell-ID 20-Plex Pd Barcoding 
Kit cat. 201060) was suspended in 100µl of Barcode Perm Buffer and immediately 
transferred to cells in 800µl Barcode Perm Buffer. Cells were incubated with 
barcodes for 30 minutes followed by 2 washes with 2ml CSB. Barcoded cells were 
then combined into a single tube for CyTOF staining. The staining factor was 
calculated as the total number of barcoded cells/3x10
6
. Cells were blocked with 5 
μL x staining factor of anti-human Fc receptor binding inhibitor (eBioscience 
Invitrogen) in 45µl x staining factor of CSB for 15 minutes at room temperature. 
Appropriate amount of surface antibody master mix (Table 1) was added directly 
to the tube and incubated for 1 hour at room temperature before 2 washes with 
CSB. For intracellular staining, cells were dissociated in 1ml of Foxp3 
Fixation/Permeabilization Buffer (eBioscience; cat. 00-5523-00) and incubated 
overnight at 4°C followed by 2 washes with 2ml of 1X Permeabilization Buffer. After 
discarding supernatant from the final wash, appropriate amounts of intracellular 
antibody master mix were added to the residual Permeabilization Buffer for 1 hour 
in the dark at room temperature.  For cell discrimination, a metallointercalator 
working solution (2 ml Permeabilization Buffer, 125nM iridium metallointercalator 
(Fluidigm; cat. 201103A)) was added to the sample and incubated overnight at 
4°C. Cells were washed with a minimum of 3mL CSB, then again with 3mL ddH2O 
with 0.1% BSA. Finally, cells were filtered through a 35µm filter and resuspended 
in 100µl ddH2O with 0.1%BSA. The MDACC Flow Cytometry and Cellular Imaging 
Core Facility prepared the antibody cocktails and acquired data on a Helios CyTOF 
machine (DVS Sciences). 
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Table 1. Panel of antibodies used for AML patient CyTOF staining. 
Mass cytometry data analysis. Data was first demultiplexed using the Fluidigm 
Debarcoder software. Individual mass cytometry data files (.fcs) were then filtered 
using FlowJo to remove the normalization beads, debris, doublets, and dead cells 
(Figure 4). Remaining analysis was performed in R (version 3.6.1, The R 





. Processed data was subjected to negative value pruned inverse 
hyperbolic sine transformation and clustered based on the PhenoGraph algorithm 
Isotope Mass Channel Marker Clone Source Custom Catalog #
Surface / 
Intracellular
89Y 89 CD45 HI30 DVS-Fluidigm 3089003B surface
139La 139 CD56 NCAM16.2 BD 559043 surface
141Pr 141 CD27 O323 Biolegend 302802 surface
142Nd 142 CD274 (PD-L1) MIH1 eBioscience 14-5983-82 surface
143Nd 143 CD19 HIB19 DVS-Fluidigm 3142001B surface
144Nd 144 CD11b ICRF44 DVS-Fluidigm 3144001B surface
145Nd 145 CD4 RPA-T4 Biolegend 300502 surface
146Nd 146 CD8a RPA-T8 DVS-Fluidigm 3146001B surface
147Sm 147 CD278 (ICOS) C398.4A Biolegend 313502 surface
148Nd 148 CD34 581 DVS-Fluidigm 3148001B surface
149Sm 149 CD223 (LAG-3) Poly R&D AF2319 surface
150Nd 150 CD86 IT2.2 DVS-Fluidigm 3150020B surface
151Eu 151 CD123 6H6 DVS-Fluidigm 3151001B surface
152Sm 152 CD137 (41BB) 4-1BB BD 555955 surface
153Eu 153 CD272 (BTLA) MIH26 Biolegend 344502 surface
154Sm 154 CD28 CD28.2 Biolegend 302937 surface
155Gd 155 CD117 104D2 Biolegend 313202 surface
156Gd 156 TIM-3 F38-2E2 Biolegend 345002 surface
158Gd 158 OX40 ACT35 DVS-Fluidigm 3158012B surface
159Tb 159 FOXP3 259D/C7 DVS-Fluidigm 3159028A inracellular
160Gd 160 TIGIT MBSA43 eBioscience 16-9500-82 surface
161Dy 161 CD152 (CTLA-4) 14D3 DVS-Fluidigm 3161004B surface
162Dy 162 CD80 (CTLA-4L) 2D10.4 DVS-Fluidigm 3162010B surface
163Dy 163 CD45RA HI100 Biolegend 304102 surface
164Dy 164 CD15 W6D3 DVS-Fluidigm 3164001B surface
165Ho 165 CD200 OX-104 Biolegend 329219 surface
166Er 166 CD41 HIP8 Biolegend 303702 surface
167Er 167 CCR7 G043H7 DVS-Fluidigm 3167009A surface
168Er 168 CD38 HIT2 DVS-Fluidigm 3167001B surface
169Tm 169 CD25 2A3 DVS-Fluidigm 3169003B surface
170Er 170 CD3 UCHT1 DVS-Fluidigm 3170001B surface
171Yb 171 CD200R OX-108 Biolegend 329302 surface
172Yb 172 CD273 (PD-L2) 24F.10C12 DVS-Fluidigm 3172014B surface
173Yb 173 CD33 6C5/2 Abcam ab11032 surface
174Yb 174 HLA-DR L243 BIolegend 307602 surface
175Lu 175 CD279 (PD1) EH12.2H7 DVS-Fluidigm 3175008B surface
176Yb 176 CD127 A019D5 DVS-Fluidigm 3176004B surface
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(k=22) using all cell surface markers
93
. Dimensionality reduction was performed 





Figure 4. CyTOF gating strategy. Cells were first discriminated from 
normalization beads. Doublets were removed using Irridium 193 and event length. 
Cells negative for cisplatin were considered viable. Finally, CD45+ cells were 





























Colony formation assays. Sorted cells were counted and suspended at a 
concentration of 2.5x10
5
 in 400µl of RPMI-1640 (Lonza) + 10% FBS in 15ml Falcon 
tubes. 4ml of MethoCult™ GF M3434 (Stem Cell Technologies; cat. 3434) was 
transferred to each Falcon tube using a 5ml syringe with 18g1½ gauge needle. 
Cells were suspended in the methylcellulose by vortexing for 1 minute. After 15 
minute of rest, 3ml of methylcellulose from each sample were equally distributed 
between 3 wells of a 6-well plate (2.5x10
4
 cells/1ml/well) using a 3ml syringe with 
18g1½ gauge needle. Cells were allowed to grow for 2 weeks before colonies were 
manually counted. Colonies were required to contain at least 25 cells.  
 
Mice. NOD-SCID IL2Rgnull (NSG) and CD45.1 C57BL/6 mice were obtained from 
our breeding colony with breeders originally purchased from Jackson Laboratory. 
C57BL/6 mice were purchased from the MD Anderson Experimental Radiation 
Oncology department. Mice were approximately 5 to 8 weeks old at the time of 
use. All mice were housed in accordance with the Association for Assessment and 
Accreditation of Laboratory Animal Care and NIH standards. All experiments were 
conducted according to protocols 00001146-RN02 and 00001446-RN01 approved 
by the University of Texas MD Anderson Cancer Center Institutional Animal Care 
and Use Committee. 
 
Murine AML model. Transplantable Tet2-/-Flt3ITDCD45.2 murine AML cells were a 
kind gift from Dr. Ross Levine. Cells were expanded in lethally irradiated (950cGy) 
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CD45.1 C57BL/6 mice with support marrow.  Donor CD45.2 leukemic cells were 
collected from the bone marrow and spleen of moribund mice.  
 
AML transplantation assay in vivo. NSG or CD45.1 C57BL/6 mice were sublethally 
irradiated 24 hours prior to injection with doses of 250cGy and 450cGy, 
respectively. Cd200+CD45.2+ and Cd200-CD45.2+ leukemia cells were sorted by 
FACS and 2.5x10
5
 cells were injected i.v. per mouse. Engraftment in mice was 
tracked weekly by flow cytometry assessment of peripheral blood. Briefly, 50µl of 
peripheral blood was collected retro-orbitally and red blood cell-lysed using 
ammonium chloride solution. Remaining leukocytes were Fc receptor blocked for 
15 minutes prior to staining with CD45.1 FITC (Biolegend), CD45.2 PerCP-Cy5.5 
(Biolegend), and Cd200 APC (Biolegend) for 30 minutes at room temperature. 
DAPI staining was used for live/dead cell discrimination.  
 
Electroporation optimization.  For both CRISPR/Cas9 and plasmid DNA delivery, 
we used the Neon electroporation device (Thermo Fisher Scientific, cat.  
MPK5000). To ensure cells were growing in log phase at the time of 
electroporation, cell culture medium was changed daily three days prior to the 
electroporation. The optimal electroporation conditions for the OCI-AML3 and 
Kasumi1 lines were determined using the 24-well plate optimization protocol 
(Thermo Fisher Scientific) with 10µl electroporation volumes (Thermo Fisher 
Scientific, cat. MPK1096). All experiments were carried out using 100µl of R or T 
buffer (Thermo Fisher Scientific, cat. MPK10096). After 48 hours, transfection 
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efficiency was determined by flow cytometry. Optimal conditions were determined 
by GFP positivity and toxicity.  
 
Transfection. OCI-AML3 cells were stably transfected to express the CD200 and 
luciferase constructs using the Sleeping Beauty transposon system
95
. Specifically, 
canonical CD200 and luciferase constructs were inserted into the donor 
transposon plasmid pSBbi-Pur (Addgene plasmid #60523
95
), and 9µg of  the 
transposon plasmid was electroporated together with 5µg of the transposase 
plasmid pCMV(CAT)T7-SB100 (Addgene plasmid #34879
96
) per 1.2 million cells 
in 100µl R buffer. Cells were then re-suspended in 3mL of pre-warmed antibiotic-
free culture media and cultured for 48 hours without disruption. Cells were 
consequently selected for integration by hygromycin B at a final concentration of 
200µg/mL. 
 
CD200 CRISPR/Cas9 knockout. To reduce any off-target effects, two unique 
sgRNAs were selected to target both the canonical, full length and the shorter 
isoform of CD200 (Table 2). The sgRNAs were cloned into hSpCas9 pX330 
backbone vector, a kind gift from Feng Zhang (Addgene plasmid #42230)
97
. Cells 
were transfected using the Neon electroporation device using predetermined 
conditions according to optimization experiments in 100µl R buffer. Cells were re-
suspended in 3mL of pre-warmed antibiotic-free culture media and cultured for 48 
hours without disruption. Knockout was confirmed by surface flow cytometry and 









hSpCas9 (pX330) Common 
exon 
Table 2. CRISPR/Cas9 guide RNA (gRNA) sequences. 
Growth assays. To assess cell proliferation, 2.5x105 cells were seeded in 1mL of 
complete media in 12-well plates. At the indicated time points, 10µl from each well 
were collected and viable cells were counted using trypan blue exclusion with a Vi-
Cell XR Cell Viability Analyze (Beckman Coulter).  
 
Cell cycle assay. 5x105 cells were collected in FACS tubes and washed with cold 
PBS. Cold 70% ethanol was added drop-wise to cells while vortexing. Cells were 
then fixed for 30 minutes at 4°C followed by 2 washes with PBS at 800g. To 
eliminate RNA, cells were treated with 5µg RNAse prior to staining with 200µl 
propidium iodide (50µg/ml; Biolegend, cat. 421301) and 5ul DAPI (2µg/ml). DNA 
abundance of live cells was collected by flow cytometry.  
 
Seahorse metabolism assay. To evaluate metabolic phenotype, in particular the 
impact of CD200 on mitochondrial respiration, oxygen consumption rates (OCR) 
and extracellular acidification rates (ECAR) were measured in parental OCIAML3 
and in OCIAML3 with CD200 overexpression as well as in parental Kasumi cells 
and Kasumi with CD200 knockout, using Seahorse Mito Stress Test (Agilent 
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Technologies). In brief, cells were washed 2 times with PBS and finally 
resuspended in pre-warmed (37°C) Seahorse Basal Medium supplemented with 1 
mM pyruvate, 2 mM glutamine and 5 mM glucose, pH 7.4. 175µl of cells 
suspension at the density of 2 million/ml were plated in 4 replicates on 96-well 
plate. To allow cells to attach the bottom of the plate and create cell monolayer, 
the Seahorse Cell Culture plate was previously precoated with Cell-Tak, according 
to the manufacturer’s instructions and cells once plated were subjected to gentle 
centrifugation for 4 minutes, at 1,000g without break and then repeated the 
centrifugation counterclockwise. Subsequently, the analysis of OCR and ECAR 
was performed in a Seahorse XFe96 analyzer according to the manufacturer’s 
instructions for the Mito-Stress test. First, the OCR and ECAR values were 
obtained during baseline (3 initial measurements) and after the injections of 
Seahorse XF Mito Stress Test Kit reagents: Oligomycin (final concentration 
1.5 μM), FCCP (final concentration 1.0 mM) and Antimycin/Rotenone (final 
concentration 0.5 μM). All measurements were normalized to cell number after 
accomplishing the assay and carried out by the Mito Stress Test Generator (Agilent 
Technologies). 
 
RNA sequencing. Total RNA was extracted from 5x106 cells using the RNeasy 
Mini Kit (Qiagen; cat.	74104). RNA concentration was determined by NanoDrop 
2000 (ThermoFischer Scientific) and RNA quality was assessed with an Agilent 
Bioanalyzer. Approximately 100 million reads per sample were run on Illumina 
Nextseq 500 using PE 75x 75 for stranded whole transcriptome sequencing. Raw 
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sequencing reads were mapped to the GRCh38 human genome using STAR
98
 
and the UCSC GRCh38.92 Known Gene reference transcript database. Analysis 
of differentially expressed genes between CD200+ and CD200- cell lines was 
performed using DESeq
99
 in R. An FDR < 0.05 was considered significant. For 
GSEA, all genes were ordered according to the score obtained by multiplying the 
sign of the fold change by the -log10 p-value. 
 
Western blotting. 5x106 cells were washed twice with cold PBS and lysed with 50µl 
lysis buffer: RIPA (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS; Thermo Scientific, cat. 89901) with Halt™ Protease and 
Phosphatase Inhibitor Cocktail (Thermo Scientific, cat. 78440). Cells were 
incubated on ice for 30 minutes, sonicated, and centrifuged at >13,000g for 13 
minutes at 4°C. Protein concentration was determined using the Pierce BCA 
Protein Assay Kit (Thermo Scientific, cat. 23225). A total of 30µg of protein per 
sample was thoroughly mixed with 4X Protein Loading Buffer (Li-cor) with β-
mercaptoethanol and boiled for 5 minutes at 95°C. Samples were immediately run 
on 4-20% Mini-PROTEAN TGX Gels (Bio-Rad) for 1 hour at 120V and transferred 
to PVDF membrane for 45 minutes at 100V. Membranes were blocked for 1 hour 
with 1X Odyssey Blocking Buffer (Li-cor). The following primary antibodies in 1:1 
Odyssey Blocking Buffer to PBS were incubated overnight at 4°C on a rocker; 
CD200 (goat anti-human; R&D) at 1:1,000; p53 (rabbit anti-human, Cell Signaling 
Technology) at 1:1000; p-γ-H2AX (rabbit anti-human; Cell Signaling Technology) 
at 1:1,000; γ-H2AX (rabbit anti-human; Cell Signaling Technology) at 1:1,000, and 
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β-actin (mouse anti-human; Abcam) at 1:15,000. Following 5 3-minute PBS + 
0.1%v/v TWEEN 20 (PBST) washes, membranes were incubated with the 
appropriate secondary antibodies in 1:1 Odyssey Blocking Buffer to PBS for 30 
minutes at room temperature in the dark; donkey anti-goat 800 (Li-cor) at 1:5,000, 
donkey anti-rabbit 680 at 1:10,000 (Li-cor), donkey anti-mouse 800 (Li-cor) at 
1:4,000. Again, membranes underwent 5 3-minute PBST washes followed by a 
PBS wash. Membranes were imaged and analyzed using the Odyssey Infrared 





In silico discovery of CD200 as an LSC marker. To identify novel leukemia stem 
cell markers, we mined 3 large, publicly available datasets which contained whole 
genome expression data for paired leukemia stem cells and blasts from the same 
patient, as well as healthy hematopoietic controls. The final 3 datasets used for 
discovery varied slightly in the immunophenotypic definition of LSCs and were all 
run on different gene quantification platforms. Jung et al used the 





Table 3. Cell type definitions from Jung et al. 
RNA sequencing was performed on the cell types from Corces et al88 isolated 














Table 4. Cell type definitions from Corces et al. 
And de Jonges et al performed Illumina expression analysis on CD34+ and CD34- 
cells from a large number of both AML and healthy individuals
89
.  
        For each dataset, we performed 2 analyses; 1) identification of genes 
significantly overexpressed in LSC compared to the patient’s corresponding blast 
cells and 2) identification of genes significantly overexpressed in LSCs when 
compared to un-matched healthy HSCs. This two-fold approach would ideally 
detect LSC-specific genes from each dataset. We scored each gene as the product 
of the fold change and –log10 p-value. Genes with scores that exceeded the 
threshold defined below were deemed significant.  
!ℎ#$%ℎ&'( = *$(+,- .$-$%/&#$ + 10 ∗ 456 .$-$%/&#$1.35  
 
The final genes of interest from each dataset were those in the intersection of 
genes significantly upregulated in LSCs when compared to both blasts and healthy 
cells (Figure 5A). We then required that a gene survive this analysis in each of the 
3 distinct datasets (Figure 5B), which gave us a final list of 43 genes (Table 5). 
Status Cell Type Immunophenotype
AML AML LSC Lin– CD34+ CD38– TIM3+ CD99+
AML AML Blast Non-LSC; CD45-Intermediate, SSC-High
Healthy HSC Lin– CD34+ CD38– CD90+ CD10–
Healthy MPP Lin– CD34+ CD38– CD90– CD10–
Healthy LMPP Lin– CD34+ CD38– CD45RA+ CD10–
Healthy CMP Lin– CD34+ CD38+ CD123+ CD45RA– CD10–
Healthy GMP Lin– CD34+ CD38+ CD123+ CD45RA+ CD10–
Healthy MEP Lin– CD34+ CD38+ CD123– CD45RA– CD10–
Healthy Monocyte CD14+
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From here, we implemented a biased screen for genes that were relatively novel 
in AML, had known immunoregulatory properties, and, for therapeutic purposes, 
were expressed on the cell surface. Through this process, we chose to focus our 
following studies on CD200. Across the 3 datasets interrogated, CD200 expression 
was high in early stem and progenitor cells and decreased in expression as cells 
differentiated; a pattern that was mimicked at even higher levels in the leukemia 
hierarchy (Figure 5C-E). This data suggested that CD200 was a novel, robust 
marker of acute myeloid leukemia LSCs.  
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Figure 5. CD200 expression across publicly available gene expression 
datasets. A. Schematic for the cross-platform approach to detecting novel LSC 
markers. B. Overlap of the 3 datasets revealed 43 novel putative LSC markers. (C 
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to E) CD200 mRNA expression across immunophenotypically sorted healthy 
(grey) and leukemic (red) cell populations ordered from left to right by 
differentiation status mined from C. Jung et al90 D. Corces et al88, and E. de Jonges 
et al89. (HSC-hematopoietic stem cells; LMPP- lymphoid-primed multipotent 
progenitors, MPP- multipotent progenitors; GMP- granulocyte-monocyte 
progenitors; CMP- common myeloid progenitors; MEP- megakaryocyte-
erythrocyte progenitors; Mono- mature monocytes; LSC- leukemia stem cell; LPC- 




Table 5. Genes identified as robustly and significantly overexpressed in 
LSCs. The table lists the 43 putative LSC biomarkers. These genes were 
significantly overexpressed in LSCs compared to blast cells and healthy controls 













































CD200 is expressed in primary AML patient samples. In order to validate our in 
silico discovery, we first needed to confirm that CD200 was also expressed at the 
protein level in AML patient samples. To do this, primary AML patient samples from 
both peripheral blood and bone marrow were screened for CD200 surface 
expression along with the classic hematopoietic stem cell marker, CD34, by flow 
cytometry. Similar to the gene expression data, the frequency of CD200 
expressing cells was variable across AML patients but still significantly higher than 
the frequency seen in healthy bone marrow (Figure 6A; Mann-Whitney p=0.0071). 
In investigating the variability of CD200 expression, we made two interesting 
observations. First, while CD34 expression is the standard marker for stem cell 
identification, this protein is largely lost in patients with mutated nucleophosmin 
(NPM1), which represents about one-third of all primary AML
78
. We confirmed that 
while the NPM1 mutant samples in our cohort (n=5) did lose CD34 surface 
expression, maintained strong levels of CD200 (Figure 6B). Second, the only 
samples observed that failed to express any subset of CD200+ cells also harbored 
a rare KMT2A translocation. The low expression of CD200 in KMT2A-rearranged 
leukemia separately was confirmed using the Leucegene AML cohort (Figure 
6C)
100
. We also saw the highest expression of CD200 mRNA in core-binding factor 
(CBF) leukemia. Taken together, these results confirm that CD200 is expressed at 




Figure 6. CD200 is expressed in primary AML patients. A. Frequency of cells 
expressing CD200 surface protein expression in 30 primary AML patient samples 
compared to 3 normal bone marrow biopsies (mean and standard deviation; Mann-
Whitney p<0.01). B. Representative flow cytometry plots of CD34 and CD200 
expression in an NPM1 WT (left) and NPM1 mutant (right) primary patient sample. 
C. CD200 RNAseq expression in the Leucegene AML cohort by genetic subgroup 





CD200 is a functional stem cell marker in human AML. CD200 gene and protein 
expression is almost exclusively confined to stem cell populations as defined by 
CD34+ immunophenotype. To determine whether CD200 is also a maker of 
functional stem cells, CD200+ AML cells were investigated for colony forming 
potential in vitro. Special consideration had to be taken to account for the variability 
in CD200 expression, since in many patient samples CD200 expression correlated 
with CD34, a well-established marker of cells with clonogenic potential
14
. 
Therefore, we looked to see if CD200 could identify functional stem cells within 
CD34+ AML (Figure 7A). The CD34+CD200+ cell fraction formed significantly 
more colonies when compared to CD34+CD200- cells from the same patient 
samples (Figure 7B; Mann-Whitney p=0.317). The gold standard for evaluating 
stem cell potential is the ability of cells to engraft in immunodeficient NSG mice. 
Ng et al produced the first publicly available gene expression dataset 
characterizing functional LSCs by sorting patient samples by CD34/CD38 status 
into 4 groups and tested engraftment in immunocompromised mice. LSC+ 
samples were defined as populations that engrafted in mice
101
. We mined this 
dataset and found that CD200 was significantly overexpressed in fractions of 
engrafting LSC+ cells when compared to non-engrafting LSC- cells from the same 
patient sample (Figure 7C; paired t-test p<0.0001)
102
. Collectively, these data 
suggest that CD200 is a functional AML stem cell marker and may more accurately 
identify stem cells than CD34.  
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Figure 7. CD200 is a marker of human AML leukemia stem cells. A. 
Representative gating strategy for FACS sorting CD200+ and CD200- cells from 
CD34+ AML samples. B. Number of colonies formed in the CD34+CD200- and 
CD34+CD200+ fractions (lines connect paired cells from the same patient; Mann-
Whitney). C. CD200 mRNA expression in cell fractions that either did (LSC+) or 
did not (LSC-) engraft in NSG mice from the dataset generated by Ng et al 
[GSE76009] (lines connect cells from the same AML patient; t-test)
101
. *p<0.05, 















































Cd200 is a functional stem cell marker in a syngeneic murine model of AML. To 





 syngeneic mouse model of AML that faithfully mimics human AML 
and is resistant to standard induction chemotherapy
103
. We wondered whether 
Cd200 could also selectively identify functional AML LSCs in mice. Based on RNA-
sequencing data, Cd200 expression was significantly higher in stem cells (LSK, 
Lin−Sca+cKit+) when compared to more committed granulocyte-macrophage 
progenitors (GMPs, lin−cKit+Sca-1−FcγR+CD34+) in WT mice (p=0.0252). The 
trend in Cd200 expression was mirrored in the Tet2-/-Flt3ITD mice at even higher 
levels (Figure 8A). To test the stem cell functionality of Cd200+ cells, leukemic 




 cells were FACS sorted and 
injected into sub-lethally irradiated CD45.1 C57BL/6 recipient mice (Figure 8B). 
After 2 weeks, only the Cd200+ leukemia cells demonstrated engraftment potential 
and, interestingly, only in male recipient mice (Figure 8C). These Cd200+ male 
recipients were the only mice to die of leukemia (Figure 8D).  To test whether the 
difference in engraftment between male and female mice was immune related, the 
same AML engraftment study was performed with NSG mice. In the absence of an 
intact immune system, Cd200+ cells were capable of engrafting in both male and 
female mice (Figure 8E). However, regardless of the immune status, Cd200 
identified functional leukemia stem cells in this murine model (Figure 8F).  These 













































































































Figure 8. Cd200 is a murine leukemia stem cell marker. A. RNA-seq gene 





 murine leukemia model (GSE57244)
103
. B. Representative gating 
strategy for CD200+ leukemia (Cd45.2) stem cells. C. Frequency of circulating 
leukemic burden in CD45.1 mice at 3 weeks by sex. D. Overall survival for the 
mice in panel C. E. Frequency of circulating leukemic burden in NSG mice at 2 
weeks by sex. F. Combined leukemic burden for NSG and C57Bl/6 mice from 2 
experiments. Leukemia frequencies were compared using two-tailed t-tests; 




In vitro model systems of CD200. To more systematically understand the functional 
role of CD200 in AML stem cells, we established two isogenic cell line model 
systems. First, we used CRISPR/Cas9 to knockout the canonical transcript of 
CD200 in the Kasumi1 cell line, an AML1-ETO model with low basal CD200 
expression (the Kasumi WT cells were denoted as CD200+ cells, while the Kasumi 
KO cells were denoted as CD200- cells). Second, OCI-AML3 cells, which had no 
expression of CD200 at baseline, were used to make stable cells expressing 
CD200 with GFP (CD200+ cells, OCI-AML3 pCD200) or GFP alone (CD200- cells, 
OCI-AML3 pGFP). Frequency and intensity of cell surface CD200 in both isogenic 
systems were assessed by flow cytometry (Figures 9A-B). These data indicate that 
the over expressed CD200 protein is localized to the cell surface. Because CD200 
is reported to function through the CD200 receptor, we next confirmed that these 
cell line models lacked endogenous CD200R expression at both the gene and 
protein level (data not shown). These models were used to functionally 
characterize the potential intrinsic function of CD200. Because stem cells are 
known to be more quiescent than their more differentiated counterparts, we first 
tested the role of CD200 in AML cell cycle and proliferation. Alteration of CD200 
expression had no significant effect on the growth or proliferation of either cell line 
system (Figures 9C-D). Stem cells also have distinct metabolic patterns. However, 
CD200 expression did not alter cellular respiration in either cell line system 
(Figures 9E-F). In conclusion, genetic manipulation of CD200, either 
overexpression or knockout, does not intrinsically alter AML cell line proliferation 
or metabolism.  
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Figure 9. CD200 modulation in vitro does not alter cell growth or metabolism. 
Cell surface flow cytometry of CD200 in the Kasumi (A) and OCI-AML3 (B) 
engineered cell line models. C. Summary of proliferation of CD200+/- Kasumi cells. 
D. Cell cycle analysis of CD200+/- OCI-AML3 cells (%cells in S/G2). E-F) Cellular 
respiration of CD200+/- Kasumi and OCI-AML3 cells.  
Kasumi WT OCI-AML3 pCD200
Kasumi CD200ko OCI-AML3 pGFP




































































CD200 alters DNA damage response. To determine whether CD200 has any 
intrinsic role in AML, RNA sequencing was performed on the CD200+/- in both 
Kasumi and OCI-AML3 lines. We determined the significantly up- and down-
regulated genes in the CD200+ cells within each cell line and then compared 
overlapping genes between the two distinct models. The 65 common 
downregulated genes had significant overrepresentation of genes involved in the 
Tumor Necrosis (TNF) and NF-kB pathways (Figure 10A). The 174 common 
upregulated genes had significant overrepresentation of genes involved in DNA 
damage response (Figure 10B). GSEA was performed on genes with combined 
scores from both cell lines. We found that DNA damage machinery, particularly in 
response to DNA double strand breaks, was significantly enriched in the CD200+ 
cells in either cell line system (Figure 10C). To confirm alterations in DNA damage 
response, we treated OCI-AML3 CD200+/- cells with a low dose of hydroxyurea 
(HU) for 48 hours to induce DNA damage via replication stress. CD200+ cells show 
less evidence of DNA double strand breaks indicated by the decrease in p-γ-H2AX 
and MDM2 activity (Figure 10D). In summary, CD200 does appear to consistently 




Figure 10. CD200 alters DNA repair machinery at the transcriptional level. A. 
Over-representation analysis of common genes enriched in CD200- cells based 
on BioPlanet 2019 (adj-p<0.01). B. Over-representation analysis of common 
genes enriched in CD200+ cells based on BioPlanet 2019 (p<0.01). C. GSEA of 
DNA double strand break response based on combined gene scores. D. Western 
blot of DNA damage induced by hydroxyurea (HU) in OCI-AML3 CD200+/- cells.  
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CD200+ cells are expressed in resistant AML. AML LSCs are also hypothesized 
to be more resistant to standard chemotherapy treatment. To test this hypothesis, 
we examined RNA-seq data from 19 paired diagnosis and relapse samples from 
the Leucegene AML cohort
100
. CD200 expression was significantly higher in a 
given patient’s disease after relapsing from standard therapy (Figure 11A; Wilcoxin 
paired test p=0.05).  We next wondered whether CD200 was overexpressed in 
disease resistant to immunotherapy. To this end, bone marrow and peripheral 
blood samples were collected from 6 patients prior to treatment with azacitidine 
and a PD-L1 inhibitor, avelumab, and after cycles 1, 3, and 5 (as available). 
Samples from a given patient were barcoded, stained with a panel of 36 antibodies 
that included immunophenotypic markers to distinguish AML stem cells and blasts 
from the healthy, adjacent immune cells (including T, B, NK cells and monocytes) 
and analyzed by mass cytometry.  Five out of the 6 patients examined had a 
CD200+ AML cell clone at baseline that persisted throughout immunotherapy 
treatment. In 2 cases, we saw the emergence of a new AML clone that was also 
CD200+ (Figure 11B). The CD200+ AML correlated with other immune 
checkpoints including TIGIT and PD-L2; indicating a potential role of CD200 in the 
coordinated immunosuppression (Figure 11C). Taken together, these results 
suggest that CD200 may play a role in AML resistance to both standard 




Figure 11. CD200 is present in therapy-resistant AML. A. RNA-seq shows 
CD200 expression levels in paired patients at diagnosis and relapse. Lines 
connect samples from the same patient and colored by an increase (red) or 
decrease (green) in CD200 abundance. B. Representative CyTOF plots of the 
same patient’s disease at baseline (top) and after 4 cycles of immunotherapy 
(bottom). Dots represent individual cells colored by CD200 protein expression. C. 
Heatmap showing the expression of known immunosuppressive genes across 





This study leveraged publicly available data to essentially perform 
“biological replicates” of RNA expression experiments on primary patient samples 
to identify novel leukemia stem cell markers.  The fact that the data was generated 
by multiple research teams, each using a unique set of immunophenotypic 
definitions to distinguish cell subsets, and quantifying expression with 3 different 
platforms, makes the discovery gene set far more robust than that of a single RNA 
sequencing experiment. Of the 43 genes identified using this algorithm, CD200 
was identified as the optimal first target for validation because it has been shown 
have immunosuppressive function and it is expressed on the cell surface, making 
it readily targetable by antibody-based therapies. In fact, an anti-CD200 antibody, 
samalizumab has already been shown to be well tolerated in humans
57
. 
In acute myeloid leukemia, CD200 has been implicated as a marker of poor 
prognosis (excluding core binding factor leukemia)
51
. Our evaluation of primary 
patient sample data was consistent with previously published assessments of bulk 
CD200 expression; namely, that CD200 was highest in core binding factor 
leukemias (t(8;21) and inv(16)) and that CD200 was largely absent in patients with 
KMT2A translocations
50
. However, this study was the first to look at the 
heterogeneity of CD200 at the protein expression level and across within the LSC 
compartment of disease. CD200 was frequently co-expressed with the established 
stem cell marker, CD34, however the mutual exclusivity of these markers varied 
drastically between patients. Notably, patients with NPM1 mutations (which 
constitute almost a third of all primary AML) lack CD34 expression but maintain 
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high frequency of CD200 positive cells, thus potentially providing a way to identify 
LSC populations in this cohort of patients.  
Our study also exposed the variability in stem cell potential even within the 
CD34 compartment of disease. Due to the wide range of CD200 expression within 
bulk CD34+ leukemia, we were able to dissect certain patient samples into 
CD34+CD200+ and CD34+CD200-. The CD200+ fraction contained more 
functional stem cells than the CD200- even though CD34 levels were comparable 
between the two groups. This suggests that CD200 may be a superior marker for 
identifying functional stem cells. 
CD200 is highly conserved between human and mouse, so we anticipated 





 model demonstrated that only a small fraction (10-15%) of the 
leukemic cells were positive for mouse CD200 and that this fraction was more 
prevalent in the bone marrow and spleen when compared to peripheral blood; 
consistent the traditional distribution of AML stem cells. We found that only the 
CD200+ subset of cells was capable of engrafting in sublethally irradiated C57BL/6 
male mice. Interestingly, these same cells were not able to persist in matched 
female mice. Because the OCI-AML3 cells were originally derived from a male 
donor, we believe this phenomenon is a result of H-Y alloimmunity
104-106
. In 
transplant biology, mismatching gender to test graft rejection is a well 
characterized model to challenge the immune system. In fact, such a model has 
been utilized to show that CD200 significantly attenuates skin graft rejection
107
. 




. To confirm that the differences in engraftment seen here were 
not solely immune related, we performed the same experiment in NSG mice. In 
the immunocompromised model, again we saw only engraftment of the CD200+ 
cells but now equally across gender.  
 To further study the intrinsic and extrinsic function of CD200, we established 
two isogenic models of CD200-high and CD200-null cells using both CRISPR 
knockout and engineered overexpression. Initially, we were concerned by the lack 
of any stark functional changes in cell growth, metabolism, or engraftment after 
CD200 modulation. However, while cell lines are useful models, they are not a not 
necessarily an accurate representation of patient stem cells. The significant and 
consistent transcriptional alterations between CD200+/- cells in both lines suggest 
that there is, in fact, an intrinsic role of CD200, even in the absence of the CD200 
receptor. Gorczynski et al recently reported that the c-terminal tail of the surface 
CD200 protein could be cleaved and potentially regulate transcription
109
. While the 
transcriptional changes identified in our AML model do not overlap with their 
proposed transcription factors, this certainly offers a possible explanation. Stem 
cells, including cancer stem cells, have been intimately linked to DNA damage 
pathways
110
. Thus, the upregulation of the DNA damage machinery could be either 
a passenger effect of the CD200+ cells adopting a more stem-like phenotype or a 
direct result of CD200 intrinsic function.  
An increase in DNA damage surveillance and response could contribute to 
the therapy resistance of CD200+ leukemia cells.  These findings also support the 
observational studies that found that CD200 is a predictor of poor overall survival 
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in AML patients, with the exception of core-binding factor leukemias which respond 
well to standard chemotherapeutic agents.  
  In Chapter 2, we have identified and validated a novel marker of AML LSCs 
in both human and mouse, as well as uncovered a previously unknown intrinsic 
mechanism of CD200. However, the extrinsic function of CD200 in relation to the 
stem cell microenvironment remains unknown. In Chapter 3, we will systematically 
examine the role of CD200 on members of the innate and adaptive immune 















CD200 suppresses both the innate and adaptive immune 




Purpose: AML LSCs must be capable of evading immune detection and 
destruction in order to initiate leukemia and drive relapse. We hypothesized that 
LSCs were protected by upregulation of unique immune regulators, like CD200, 
that allowed these cells to selectively escape immune surveillance. We have 
previously identified CD200 as a novel marker of functional AML LSCs that is 
significantly overexpressed when compared to normal HSCs and corresponding 
blast cells and has been implicated in immune function.  
 
Experimental design: A series of mixed lymphocyte reactions with isolated 
effector T cells, NK cells, or macrophages and target isogenic AML cell lines 
(CD200 knockout and CD200 overexpression) were used to mechanistically tease 
out the effect of CD200 on innate and adaptive effector functions as well as AML 
cell killing. PBMC-humanized mouse models with the isogenic OCI-AML3 cell lines 
were employed to validate these findings in vivo.  
 
Results: CD200 receptor expression was mutually exclusive with CD200 ligand 
expression and highest in mature populations of CD4/CD8 T cells and 
monocytes/macrophages. AML cell line models with CD200 expression 
significantly suppressed T cell MAPK and STAT3 signaling when compared to their 
non-expressing counterparts. Alterations in signaling translated functionally to 
impaired T cell proliferation and cytokine production in the presence of CD200+ 
AML that could be restored by blocking the CD200/CD200R interaction. Ectopic 
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CD200 abrogated cytokine secretion of healthy macrophages but did not 
significantly affect basal phagocytic function. NK cell cytokine profiles were largely 
independent of CD200 presence on AML cells, however, high levels of surface 
CD200 correlated with reduced NK cell cytotoxicity. In vivo in PBMC-humanized, 
CD200 protected AML cells from immune-mediated rejection. Cytokine production 
in PBMC-humanized mice was significantly compromised in those with CD200-
expressing leukemia. T cell composition was also significantly altered in the 
presence of AML with and without CD200. Transcriptome analysis revealed that T 
cells from humanized mice exposed to CD200 expressing disease were 
metabolically quiescent.  
 
Conclusions: CD200 plays an important immunosuppressive role primarily in T 
cells and macrophages in vitro by significantly suppressing cytokine secretion in 
response to AML. In a PBMC-humanized mouse model, the presence of cell-
surface CD200 was sufficient to protect AML cells from immune-mediated 






Immune surveillance in AML. Avoiding immune-mediated destruction is now 
classified as one of the emerging hallmarks of cancer
111
. Particularly in leukemia 
where it is known that the drivers of disease come from the same source as healthy 
immune cell subsets, leukemia stem cells must be capable of evading detection 
and/or destruction by neighboring immune cells. AML LSCs have been reported to 









Immunosuppression through CD200 receptor signaling. CD200 triggers robust 
immunosuppression through its interaction with the CD200 receptor (CD200R) on 
effector cells. As part of the original characterization of the CD200 receptor family, 
Wright et al identified a single inhibitory receptor in both human and mouse 
(CD200R1), a related human gene (CD200R1L), and 4 related murine genes 
(CD200RLa-d)
114
. However, it was later demonstrated that the related proteins did 
not bind CD200
33
. The distribution of CD200R was variable across populations of 
circulating lymphocytes and reported the highest levels in peripheral T cells, 
granulocytes, and monocytes.  It was mentioned, but not shown, that CD200R 
expression was increased in mature macrophages or dendritic cells when 
compared to monocytes. It was also observed that only a small subset of NK cells 
expressed any CD200R
114
. The CD200 receptor signaling pathway was first 
described by Zhang et al in myeloid cells where it was shown that CD200R 
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activation resulted in the recruitment of RasGAP which interfered downstream with 




CD200 regulation of myeloid cells. It has been shown that CD200 knockout mice 
had higher numbers of both activated and total macrophages when compared to 
controls and were more susceptible to collagen-induced arthritis (CIA) and 
experimental autoimmune encephalomyelitis (EAE); both autoimmune diseases 
primarily regulated by monocytes
38,116
. In immunocompetent mice, it has been 
demonstrated that macrophage production of IFNγ- and IL-17 could be inhibited 
by engaging the CD200 receptor with artificial binding agents. These same 
CD200R agonists could also reduce the production of IL-5 and IL-13 from human 




CD200 regulation of T cells. In the context of chronic lymphocytic leukemia, it was 
shown that cells transfected with CD200 expression plasmids were capable of 
suppressing antigen specific T cell production of IFNγ and IL-2
117
. In the murine 
setting, antibodies against the CD200RLa, but not CD200R, could activate the 
differentiation of dendritic cells that recruit CD4+CD25+ Tregs
118
. Coles et al also 
observed a correlation between CD4 Treg frequency and CD200 expression on 
AML blasts. CD8+ memory T cells from AML patients with high levels of CD200 
demonstrated a 50% reduction in degranulation capacity after artificial stimulation. 
Similarly, CD200-high patients had significantly fewer TNFα and IL-2 producing 
CD4+ T cells
46
. CD200 was further proposed to play an immunosuppressive role 
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CD200 regulation of NK cells. Coles et al observed that patients with high CD200 
expression on AML blasts had a 50% reduction in the frequency of activated NK 
cells. Additionally, they were the first to suggest that CD200 had a direct 




Humanized murine models. A significant challenge in studying CD200/CD200R 
interaction in a systemic setting is the lack of adequate in vivo models, thus most 
of the work the role of CD200 in AML has been done in vitro. Humanized mouse 
models have gained traction as a way to mimic the interaction between human 
disease and the human immune system, however these approaches are still 
subject to limitations. Models of humanization involving transplantation of human 
hematopoietic stem cells into neonate mice accurately recapitulate human 
hematopoiesis in the mouse without causing graft-versus-host disease (GvHD)
119-
121
. However, these murine educated T cells will be more prone to attack foreign 
epitopes on leukemia derived from a human donor. On the other hand, peripheral 
blood mononuclear cell (PBMC) transfer into NSG mice elicits GvHD and may 
more accurately mimic the scenario observed in AML patients after bone marrow 
transplantation
122
.      
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In this chapter, we utilized our previously established isogenic AML cell line models 
(CD200 knockout and CD200 overexpression) to individually characterize the 
effects of AML surface CD200 on isolated members of the innate and adaptive 
immune systems in vitro. Further, we employed a PBMC-humanized mouse model 
to study the effects of CD200+ AML in an inflammatory, engraftment model of 
leukemia.   
	  
	 65	
3.3 Materials and Methods 
	
PBMC collection and target cell isolation. Buffy coat was obtained from healthy 
donors. PBMCs were isolated by Ficoll density gradient centrifugation. Briefly, 
sample was mixed at a 1:1 ratio with Dulbecco’s Phosphate-Buffered Saline (PBS) 
without calcium and magnesium (GenDEPOT) and gently added to 15ml 
Lymphocyte Separation Medium (Lonza; cat. 17-829E). Cells were centrifuged at 
1,800 RPM for 20 minutes and the lymphocyte layer was carefully extracted. If 
necessary, 5ml ammonium chloride solution (Stem Cell Technologies) was used 
to lyse any residual red blood cells. CD3+ T cells were isolated using the 
EasySep™ Release Human CD3 Positive Selection Kit (Stem Cell Technologies; 
cat. 17751). NK cells were negatively selected from total PBMCs using magnetic 
column separation (Miltenyi Biotec, cat. 130-092-657). Monocytes were negatively 
selected from PBMCs using the EasySep™ Human Monocyte Isolation Kit (Stem 
Cell Technoligies; cat. 19359). T and NK cells were cultured in RPMI-1640 media 
with 10% heat-inactivated Fetal Bovine Serum (FBS; GenDEPOT) and 200U/ml 
recombinant interleukin 2 (IL-2; Peprotech).  
 
Macrophage differentiation and culture. Macrophages were differentiated as 
previously described
113
. Briefly, sorted CD14+ monocytes from healthy PBMCs 
were cultured in RPMI-1640 media with 10% FBS and 20 ng/mL recombinant 
human macrophage colony stimulating factor (M-CSF; Peptrotech) for 7-10 days 
with media changes every 3 days. Mature macrophages were detached using 
StemPro Accutase Cell Dissociation Reagent (ThermoFisher Scientific) on ice for 
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20 minutes and counted. Cells were re-plated at a density of 4x10
4
 cells/well in 48-
well plates and allowed to reattach for 48 hours prior to use.  
 
Flow cytometry. 3x105 cells were transferred to a 5ml FACS tube and washed twice 
with staining buffer (PBS + 0.5% Bovine Serum Albumin (Sigma-Aldrich)). Cells 
were Fc-blocked with either 5µl anti-human or anti-mouse Fc receptor binding 
inhibitor (eBioscience Invitrogen) in 100µl staining buffer for 15 minutes prior to the 
addition of anti-human CD200R (PE; Biolegend), anti-human CD47 (PerCP-Cy5.5; 
Biolegend), anti-human CD45 (APC-Cy7; Biolegend), anti-human CD4 (PerCP-
Cy5.5; Biolegend), anti-human CD8 (PE-Cy7; Biolegend), or anti-mouse CD45 
(APC; Biolegend) antibody (1µl/sample). Surface stain was incubated for 30 
minutes at room temperature on an orbital shaker followed by 2 washes with 
staining buffer. Cells were resuspended in 300µl of staining buffer plus 5µl 4',6-
Diamidino-2-Phenylindole, Dihydrochloride (DAPI; 2ug/ml; Invitrogen) for live/dead 
cell discrimination for collection on a LSRII machine (BD).  
 
T cell signaling western blotting. 4x106 CD3+ T cells were co-cultured with 2 x106 
AML cells in 1 ml of T cell media (RPMI-1640 + 10%FBS + 100 U/ml recombinant 
human IL-2 (PeproTech; cat. 200-02)) for 24 hours at 37°C. CD3+ T cells were re-
selected using the same T cell positive selection marker. Isolated T cells were 
washed twice with cold PBS and lysed with 30µl lysis buffer: RIPA (25 mM Tris-
HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS; 
Thermo Scientific, cat. 89901) with Halt™ Protease and Phosphatase Inhibitor 
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Cocktail (Thermo Scientific, cat. 78440). Cells were incubated on ice for 30 
minutes, sonicated, and centrifuged at >13,000g for 13 minutes at 4°C. Protein 
concentration was determined using the Pierce BCA Protein Assay Kit (Thermo 
Scientific, cat. 23225). A total of 30µg of protein per sample was thoroughly mixed 
with 4X Protein Loading Buffer (Li-cor) with β-mercaptoethanol and boiled for 5 
minutes at 95°C. Samples were immediately run on 4-20% Mini-PROTEAN TGX 
Gels (Bio-Rad) for 1 hour at 120V and transferred to PVDF membrane for 45 
minutes at 100V. Membranes were blocked for 1 hour with 1X Odyssey Blocking 
Buffer (Li-cor). The following primary antibodies in 1:1 Odyssey Blocking Buffer to 
PBS were incubated overnight at 4°C on a rocker; p-STAT3 (rabbit anti-human; 
Cell Signaling Technology) at 1:1000, total STAT3 (rabbit anti-human; Cell 
Signaling Technology) at 1:1,000, p-ERK1/2 (rabbit anti-human; Cell Signaling 
Technology) at 1:1000, total ERK2 (mouse anti-human; Santa Cruz) at 1:1,000, 
and β-actin (mouse anti-human; Abcam) at 1:15,000. Following 5 3-minute PBST 
(0.1%) washes, membranes were incubated with the appropriate secondary 
antibodies in 1:1 Odyssey Blocking Buffer to PBS for 30 minutes at room 
temperature in the dark; donkey anti-rabbit 680 at 1:10,000 (Li-cor), donkey anti-
mouse 800 (Li-cor) at 1:5,000. Again, membranes underwent 5 3-minute PBST 
washes followed by a PBS wash. Membranes were imaged and analyzed using 
the Odyssey Infrared Imaging System (Li-cor). 
 
Peptide-specific CTL lines. Peptide-specific cytotoxic T cells (CTLs) were prepared 
as previously described
123-125
. Briefly, T2 cells were pulsed with 20µg/ml cathepsin 
	 68	
G or negative control peptide for 90 minutes at 37°C. Peptide-pulsed cells were 
then irradiated with 7500 cGy and cultured with freshly isolated PBMCs from 
healthy HLA-A*0201 individuals at a 1:1 ratio in RPMI-1640 medium supplemented 
with 10% human serum.  PBMCs were re-stimulated with peptide-pulsed T2 cells 
weekly for 3 weeks. Final peptide-specific CTLs were the transferred to culture 
media supplemented with 20 IU/ml of recombinant human interleukin-2 (IL-2; 
Peprotech). 
 
T cell mediated cytotoxicity assay. Calcein AM assays for cytotoxicity were 
performed as previously described
126,127
. Briefly, target AML cells were washed 2x 
with PBS and stained at a concentration of 1x10
6
 cells/ml of calcein AM staining 
media (10µg/ml calcein AM in 1ml PBS) for 90 minutes at 37°C. Residual calcein 
was quenched with 3 washes in 15ml complete media. Then, 1,000 stained cells 
in 10µl IL-2 media were co-cultured with 10µl of peptide-specific CTLs at varying 
effector to target (E:T) ratios for 4 hours at 37°C. After which, 5μL of Trypan blue 
was added to each well and fluorescence was measured using a CytoFluor II plate 
reader (PerSeptive Biosystems). Percent specific cytotoxicity was calculated as 
follows:  
%/;!&!&<+/+!; =




T cell growth assay. To assess T cell proliferation, 2.5x104 T cells were seeded at 
a 1:1 ratio with irradiated AML cell lines in 1mL of complete media supplemented 
with 100 IU/ml IL-2 in 12-well plates. Negative and positive controls included 
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untreated T cells and cells treated with ImmunoCult™ Human CD3/CD28 T Cell 
Activator (Stem Cell Technologies; cat. 10971), respectively. After 5 days, cells 
were collected and live CD4 and CD8 T cell numbers were determined by flow 
cytometry using Precision Count Beads (Biolegend; cat. 424902).   
 
Cytokine profiling. 2x105 effector cells were co-cultured at a 1:1 ratio with desired 
target cells and treatments in 200µl in 96-well U-bottom plates and incubated for 
16-24 hours. Plates were spun down at 500g for 5 minutes. 25µl of supernatant 
from each well was transferred to a new 96-well U-bottom plate. Secreted cytokine 
abundance was determined using one of the following Legendplex kits 
(Biolegend); Human CD8/NK Panel (cat. 740267), Human T Helper Cytokine 
Panel (cat. 740722), Human Macrophage/Microglia Cytokine Panel (cat. 740503). 
Briefly, cell supernatant was incubated with 25µl of pre-mixed analyte capture 
beads and 25µl detection antibodies for 2 hours at room temperature on a shaker 
(at approximately 600 RPM). Without washing, 25µl streptavidin-PE was added to 
each well and incubated another 30 minutes at room temperature on a shaker. 
Beads were washed twice and collected using a High Throughput Sampler (HTS; 
BD). For cytokines within range, cytokine concentration was interpolated based on 
the standards. For cytokines outside of the standard range, MFI was reported. 
 
Phagocytosis. Target leukemia cells were labeled with 5µM carboxyfluorescein 
succinimidyl ester (CFSE; ThermoF) for 5 minutes at 37°C followed by a 5-minute 
quench with 5ml complete media at 37°C. Labeled AML cells were co-cultured at 
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a 2:1 ratio with differentiated macrophages (7-10 days old) for 4 hours at 37°C.  
Cells were detached using StemPro Accutase Cell Dissociation Reagent 
(ThermoFisher Scientific) on ice for 20 minutes and transferred to 5ml FACS tubes. 
Cells were stained with 1µl/sample CD206 PerCP-Cy5.5 for 30 minutes at room 
temperature prior to assessment by flow cytometry. Macrophages that had 
undergone phagocytosis of AML cells were identified as CFSE+CD206+. 
Percentage of activated macrophages was calculated as the fraction of double 
positive cells to total CD206+ cells. 
 
Calcein AM release assay for NK-cell mediated ADCC. NK cells were cultured in 
RPMI-1640 media + 20% FBS + 200 IU/ml recombinant human IL-2 (PeproTech; 
cat. 200-02) for no more than 24 hours before use. AML target cells were washed 
2x with PBS and stained at a concentration of 1x10
6
 cells/ml of calcein AM staining 
media (2µg/ml calcein AM in 1ml PBS) for 1 hour at 37°C. Residual calcein was 
quenched with 3 washes in 15ml complete media. 2.0x10
4
 target cells were 
plated/well in 96-well U-bottom plates. Varying numbers of NK cells were added in 
a final volume of 100µl IL-2 media. Antibody treatments either 100nM 
samalizumab, 100nM CD200-IgG1, or PBS-only were added to appropriate wells 
in triplicate. 2% Triton-X was added to positive controls (maximum calcien 
release). Plates were spun down at 500g for 1 minute before incubating 4 hours at 
37°C. Following incubation, cells were spun down at 500g for 5 minutes. 75µl of 
supernatant per well was transferred to a black bottom, black walled 96-well plate. 
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Fluorescence was measured using a Victor X3 fluorescent plate reader 






Mice. Female NOD-SCID IL2Rgnull (NSG) mice were obtained from our breeding 
colony with breeders originally purchased from Jackson Laboratory. Mice were 
approximately 5 to 8 weeks old at the time of use. All mice were housed in 
accordance with the Association for Assessment and Accreditation of Laboratory 
Animal Care and NIH standards. All experiments were conducted according to 
protocols 00001146-RN02 and 00001446-RN01 approved by the University of 
Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee. 
 
PBMC-humanized mice. Healthy PBMCs were extracted from buffy coat the day 
of injection. 10x10
6
 cells in 100µl PBS were injected intravenously and allowed 
one week to engraft. T cell engraftment was confirmed day 7 by detection of human 
CD45+CD3+ in peripheral blood by flow cytometry. Mice were then randomized to 
receive 5x10
4 
of either pGFP or pCD200 OCI-AML3 cells in 100µl of sterile PBS 
i.v. 
 
In vivo leukemia monitoring. Firefly luciferase was used to track the engraftment 
of OCI-AML3 cells in mice. The luciferase substrate, d-luciferin (100μL of 30 
mg/mL in PBS; Gold Biotechnology, Inc.), was injected i.p. 5 minutes prior to IVIS 
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imaging (IVIS-Xenogen 100 system; Caliper Lifesciences). Leukemia burden was 
determined to be to total flux minus the total flux of the background.  
 
Serum collection. 100µl of whole blood was collected by retro-orbital eye bleeding 
from anesthetized mice in microtainers containing K2EDTA (BD, cat. 365974). 
Blood was transferred to Eppendorf tubes and centrifuged at 4°C for 20 minutes 
at 500g. The top plasma layer was carefully extracted, transferred to fresh 
Eppendorf tubes, and stored at -80°C until testing. 
 
Complete blood count. 50µl of whole blood was collected by retro-orbital eye 
bleeding from anesthetized mice in microtainers containing K2EDTA (BD, cat. 
365974). Blood was mixed at a 1:1 ratio with 50µl PBS. CBC analysis was 
performed using an ABX Pentra analyzer (Horiba). 
 
CyTOF mass cytometry. Human CD45+ cells were collected from mouse bone 
marrow and spleen and selected using the EasySep™ Mouse/Human Chimera 
Isolation Kit (Stem Cell Technologies, cat. 19849). Sample barcoding and metal-
conjugated antibody staining were performed according to Fluidigm’s protocols as 
described below. Briefly, all antibodies were labeled with heavy metals using 
Maxpar-X8 labeling reagent kits (Fluidigm DVS Sciences) according to 
manufacturer’s instructions and titrated for optimal concentration determination. 
For each mouse evaluated, 3x10
6
 cells were aliquoted into separate FACS tubes 
and washed twice with Maxpar PBS Buffer (Fluidigm; cat. 201058). For live/dead 
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cell discrimination, cells were resuspended in 200µl of 5µM cisplatin (Fluidigm; cat. 
201064) for 1 minute on an orbital shaker followed immediately by 3 washes in 
Maxpar Cell Staining Buffer (CSB; Fluidigm; cat. 201068). Cells were then fixed in 
1ml of 1x Fix I Buffer (Fluidigm; cat.	201065) for 10 minutes followed by 2 washes 
with 1x Barcode Perm Buffer (Fluidigm; cat. 201057). Each unique Palladium 
Barcode (Fluidigm; Cell-ID 20-Plex Pd Barcoding Kit cat. 201060) was suspended 
in 100µl of Barcode Perm Buffer and immediately transferred to cells in 800µl 
Barcode Perm Buffer. Cells were incubated with barcodes for 30 minutes followed 
by 2 washes with 2ml CSB. Barcoded cells were then combined into a single tube 
for CyTOF staining. The staining factor was calculated as the total number of 
barcoded cells/3x10
6
. Cells were blocked with 5μL x staining factor of anti-human 
Fc receptor binding inhibitor (eBioscience Invitrogen) in 45µl x staining factor of 
CSB for 15 minutes at room temperature. Appropriate amount of surface antibody 
master mix (Table 6) was added directly to the tube and incubated for 1 hour at 
room temperature before 2 washes with CSB. For intracellular staining, cells were 
dissociated in 1ml of Foxp3 Fixation/Permeabilization Buffer (eBioscience; cat. 00-
5523-00) and incubated overnight at 4°C followed by 2 washes with 2ml of 1X 
Permeabilization Buffer. After discarding supernatant from the final wash, 
appropriate amounts of intracellular antibody master mix were added to the 
residual Permeabilization Buffer for 1 hour in the dark at room temperature.  For 
cell discrimination, a metallointercalator working solution (2ml Permeabilization 
Buffer, 125nM iridium metallointercalator (Fluidigm; cat. 201103A)) was added to 
the sample and incubated overnight at 4°C. Cells were washed with a minimum of 
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3mL CSB, then again with 3mL ddH2O with 0.1% BSA. Finally, cells were filtered 
through a 35µm filter and resuspended in 100µl ddH2O with 0.1% BSA. The 
MDACC Flow Cytometry and Cellular Imaging Core Facility prepared the antibody 
cocktails and acquired data on a Helios CyTOF machine (DVS Sciences). 
	
Table 6. Panel of antibodies used for lymphocyte CyTOF staining.  
Mass cytometry data analysis. Data was first demultiplexed using the Fluidigm 
Debarcoder software. Individual mass cytometry data files (.fcs) were then filtered 
using FlowJo to remove the normalization beads, debris, doublets, and dead cells 
(Figure 4). Remaining analysis was performed in R (version 3.6.1, The R 
Isotope Mass Channel Marker Clone Source Custom Catalog #
Surface / 
Intracellular
89Y 89 CD45 HI30 DVS-Fluidigm 3089003B surface
139La 139 CD56 NCAM16.2 BD 559043 surface
141Pr 141 CD27 O323 Biolegend 302802 surface
142Nd 142 CD274 (PD-L1) MIH1 eBioscience 14-5983-82 surface
143Nd 143 CD357 (GITR) 621 Biolegend 311602 surface
145Nd 145 CD4 RPA-T4 Biolegend 300502 surface
146Nd 146 CD8a RPA-T8 DVS-Fluidigm 3146001B surface
147Sm 147 CD278 (ICOS) C398.4A Biolegend 313502 surface
148Nd 148 CD34 581 DVS-Fluidigm 3148001B surface
149Sm 149 CD223 (LAG-3) Poly R&D AF2319 surface
150Nd 150 CD11c Bu15 Biolegend 337221 surface
151Eu 151 CD123 6H6 DVS-Fluidigm 3151001B surface
152Sm 152 CD137 (41BB) 4-1BB BD 555955 surface
153Eu 153 CD62L DREG-56 Biolegend 304802 surface
154Sm 154 CD28 CD28.2 Biolegend 302937 surface
155Gd 155 CD25 M-A251 BD 555430 surface
156Gd 156 TIM-3 F38-2E2 Biolegend 345002 surface
158Gd 158 IFNg B27 DVS-Fluidigm 3158017B inracellular
159Tb 159 FOXP3 259D/C7 DVS-Fluidigm 3159028A inracellular
160Gd 160 TIGIT MBSA43 eBioscience 16-9500-82 surface
161Dy 161 CD152 (CTLA-4) 14D3 DVS-Fluidigm 3161004B surface
162Dy 162 CD69 FN50 DVS-Fluidigm 3162001B surface
163Dy 163 CD19 HIB19 Biolegend 302202 surface
165Ho 165 CD200 OX-104 Biolegend 329219 surface
166Er 166 NKG2D ON72 BD A08934 surface
167Er 167 CCR7 G043H7 DVS-Fluidigm 3167009A surface
168Er 168 CD38 HIT2 DVS-Fluidigm 3167001B surface
169Tm 169 CD45RA HI100 Biolegend 304102 surface
170Er 170 CD3 UCHT1 DVS-Fluidigm 3170001B surface
171Yb 171 CD200R OX-108 Biolegend 329302 surface
172Yb 172 CD273 (PD-L2) 24F.10C12 DVS-Fluidigm 3172014B surface
173Yb 173 Granzyme B GB11 DVS-Fluidigm 3173006B surface
174Yb 174 HLA-DR L243 BIolegend 307602 surface
175Lu 175 CD279 (PD1) EH12.2H7 DVS-Fluidigm 3175008B surface
176Yb 176 Ki67 Ki-67 Biolegend 350502 inracellular
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. Processed data was subjected to negative value pruned inverse 
hyperbolic sine transformation and clustered based on the PhenoGraph algorithm 
(k=22) using all cell surface markers
93
. Dimensionality reduction was performed 




RNA sequencing. Human CD45+ cells were collected from mouse bone marrow 
and spleen and selected using the EasySep™ Mouse/Human Chimera Isolation 
Kit (Stem Cell Technologies, cat 19849). Total RNA was extracted from 5x10
6
 cells 
using the RNeasy Mini Kit (Qiagen; cat.	 74104). RNA concentration was 
determined by NanoDrop 2000 (ThermoFisher Scientific) and RNA quality was 
assessed with an Agilent Bioanalyzer. Approximately 100 million reads per sample 
were run on Illumina Nextseq 500 using PE 75x 75 for stranded whole 
transcriptome sequencing. Raw sequencing reads were pseudoaligned using 
Kallisto v0.44.0
128
 with 30 bootstrap samples to a transcriptome index based on 
the human GRCh38.92 release (Ensembl). Abundance data was further analyzed 
with Sleuth v0.30.0
129
 using models with covariates for condition. Gene-level 
abundance estimates were calculated as the sum of transcripts per million (TPM) 
estimates of all transcripts mapped to a given gene. For GSEA, all genes were 
ordered according to the score obtained by multiplying the sign of the fold change 




Statistics. Unless otherwise specified, data analysis performed using GraphPad 
Prism version 8.  Statistical tests and methods for correcting for multiple testing 





CD200 receptor is expressed in subsets of mature lymphocytes. The primary role 
of CD200 is thought to be through its interaction with the suppressive CD200 
receptor on effector cells
114
. To begin to better characterize the role of CD200 
expressed on AML cells with the immune system, we first looked at the distribution 
of the CD200 receptor across healthy immune cell subsets using the RNA-seq 
data generated by Corces et al88. In contrast to the pattern seen with CD200 
expression, CD200R mRNA levels increased throughout differentiation and were 
highest in mature T cells and monocytes (Figure 13A). In fact, looking at CD200 
and CD200R expression within the same cell fractions revealed almost complete 
mutual exclusivity of these genes (Figure 13B). This suggests that the 
CD200/CD200R signaling pathway is not utilized in an autocrine fashion but, 
rather, to communicate with or control neighboring cell types, which may be in 
different states of differentiation. To confirm this pattern of expression at the protein 
level, CyTOF analysis was performed on 3 pooled normal bone marrow biopsies. 
CD200 receptor expression was highest on the surface of subsets of CD4 and CD8 
T cells (Figure 14A). We were also interested in the CD200R expression of cell 
types not present at an appreciable abundance in PBMCs, namely, differentiated 
macrophages. We saw a significant increase in CD200R expression on paired 





Figure 13. CD200R is expressed in mature leukocytes. A. CD200R1 mRNA 
expression across immunophenotypically sorted healthy hematopoietic subsets 
ordered left to right by differentiation status from Corces et al88. B. Mutual 




































Figure 14. CD200R protein expression in healthy immune cells. A. CD200 
receptor expression, at the protein level, by CyTOF analysis of 3 pooled normal 
bone marrow samples. B. Flow cytometry analysis of CD200R expression on 
paired monocytes and differentiated macrophages.  
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CD200 expression on leukemia cells alters T cell signaling in vitro. Based on the 
high levels of CD200R in mature T cell subsets, we first asked whether T cell 
signaling was altered in the presence of leukemia cells that expressed CD200 
compared to the same cells without CD200. The engineered cell lines described 
in Chapter II provide two isogenic systems with either moderate (Kasumi1 WT) or 
high (OCI-AML3 pCD200) cell-surface CD200 expression that can be used to more 
precisely determine the role of CD200 in immune cell interaction. Healthy T cells 
were co-cultured with either the CD200+ or CD200- version of each cell line at a 
1:1 ratio for 24 hours before reselecting T cells for western blot analysis (Figure 
15A). T cell signaling through the MAPK pathway, as measured by ERK1/2 
phosphorylation, was activated in response to co-culture with both OCI-AML3 cell 
lines but significantly attenuated in the presence CD200, consistent with the 
proposed CD200R signaling pathway (representative donor; Figure 15B). T cells 
failed to signal through the MAPK pathway in response to either Kasumi1 cell line. 
However, both Kasumi1 and OCI-AML3 AML models invoked T cell STAT3 
signaling that was consistently suppressed, in a dose dependent manner, in the 






Figure 15. AML-CD200 suppresses CD3+ T cell signaling in vitro. A. 
Schematic of the T cell:AML co-culture system. B) Representative western blot 
analysis of healthy T cells purified after 24-hour co-culture at a 1:1 ratio with AML 
cells. Primary antibodies against phosphorylated and total STAT3 and ERK were 
used.  
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CD200 does not directly alter T cell-mediated killing in vitro. Because CD200 
expression on AML cells was sufficient to alter multiple intracellular signaling 
pathways, we next asked if CD200 expression was also sufficient to influence T 
cell killing of AML cells. We chose to test both peptide-specific killing (to model the 
interaction within a patient’s own immune system) and allogeneic killing (to model 
graft-vs-leukemia as a result of bone marrow transplant). The OCI-AML3 cell line 
expresses the minor histocompatibility antigen HLA-A*0201, which has been 
shown to present a novel peptide derived from the cathepsin G protease
130
. Zhang 
et al further demonstrated that these peptide-presenting cells can be selectively 
eliminated by cathepsin G- cytotoxic T lymphocytes (CG-CTL)
123
. These same CG-
CTLs in the presence of a leukemia without HLA-A*0201, like Kasumi1, will be 
limited to allogeneic killing in response to recognition of foreign antigens. Peptide-
specific and allogeneic T cell killing of OCI-AML3 and Kasumi cells, respectively, 
was measured by calcein AM release.  There was no significant, reproducible 
difference in T cell-mediated killing of AML cells with or without CD200 expression 
in either the peptide-specific (Figure 16A) or the allogeneic setting (Figure 16B). In 
fact, even at the highest effector to target ratios, we saw less than 50% AML cell 
killing. We further employed other T effector cells, including artificially stimulated T 
cells, CD123 CAR-T cells, and bulk PBMCs, in an attempt to improve AML 
cytotoxicity (data not shown). However, the AML cell lines were consistently 





Figure 16. Ectopic CD200 expression does not significantly alter T cell killing 
of AML. Calcein AM retention in AML cells exposed to increasing numbers of CG-
CTLs relative to a spontaneous release control. A. Peptide-specific cell killing of 
the HLA-A2 OCI-AML3 cell line by CG-CTLs from two donors. A. Allogeneic cell 
































































































































CD200 suppresses T cell proliferation in vitro. We next asked whether the 
differences in T cell signaling in response to CD200 resulted in altered T cell 
proliferation. To examine T cell cycle response to AML cells with or without CD200 
expression, growth-arrested AML cell lines were co-cultured with healthy T cells 
for 4 days. CD4 and CD8 T cells were counted by flow cytometry. Across 3 healthy 
donors of varying gender and age, we only saw consistent expansion of CD4 and 
CD8 T cells exposed to AML cells without CD200 expression (OCI-AML3 pGFP), 
albeit to differing degrees (Figure 17). T cell proliferation in the co-cultures with the 
CD200 overexpressing cell line (OCI-AML3 pCD200) could be partially restored 
using a nanobody (Nb) to block the interaction between CD200 on the AML cells 






Figure 17. CD200 abrogates T cell proliferation. Bulk T cells from 3 healthy 
donors were cultured at a 1:1 ratio with proliferation-blocked CD200+ (pCD200) or 
CD200- (pGFP) OCI-AML3 AML cells for 4 days prior to counting the number of 
CD4 and CD8 T cells by flow cytometry. 
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CD200 suppresses T cell cytokine production in vitro. Signal transducer and 
activator of transcription (STAT) family proteins are important regulators of 
cytokine production and response
131
. Based on the differences in STAT3 signaling, 
we next wondered if CD200 expression functionally suppressed T cell cytokine 
production in vitro. Again, the isogenic models of moderate and high CD200 
expression were co-cultured with healthy T cells for 24 hours before measuring 
cytotoxic enzyme and cytokine secretion by flow cytometry. First, we observed that 
the same T cells appeared to mount unique cytokine responses to either OCI-
AML3 or Kasumi cells. Cytokines including IL-6, IL-4 and TNFα were produced 
predominantly in response to Kasumi cells, while cytotoxic enzymes like 
granzymes and perforin and important pro-inflammatory cytokines including IFNγ 
were exclusively secreted in response to the OCI-AML3 model (Figure 18). Similar 
to the western blot profiling, T cells appeared to be more activated when exposed 
to the OCI-AML3 model. This inflammatory cytokine response was almost 
completely blocked in the presence of high CD200 and could be partially restored 
using the blocking CD200 nanobody. In the Kasumi model, only IL-6, IL-4, and IL-




Figure 18. CD200 expressing AML suppresses T cell cytokine secretion. 
Cytokines were compared pairwise between groups using multiple t-tests with the 
two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli to correct 
for multiple comparisons.  Comparisons with a q-value < 0.05 were considered 




CD200 does not alter phagocytosis in vitro. CD200 has been implicated as a 
regulator of macrophage function and had been posited to play a similar role to 
CD47 in marking cells as safe from phagocytosis
132
. Based on these observations 
and the high levels of CD200R on mature macrophages, we next investigated 
whether ectopic CD200 was sufficient to inhibit phagocytosis of AML cells. To test 
this hypothesis, we first needed to confirm that the established “don’t eat me” 
signal, CD47, was not differentially expressed between AML cells with and without 
CD200. Both OCI-AML3 and Kasumi1 model systems had comparable frequency 
and intensity of cell surface CD47 regardless of CD200 status (Figure 19A).  
It is now appreciated that one of the undesirable consequence of 
tumorigenic cellular stress is the upregulation of damage-associated molecular 
patterns (DAMPs). These markers activate effector functions, namely 
phagocytosis, of innate immune scavengers. Thus, we next looked at well-
characterized immunogenic cell death signal genes in both cell systems
133
. While 
not statistically significant after correcting for multiple testing, in both models there 
was an increase in pro-phagocytic markers, at the mRNA level, in the CD200+ 
versions of both cell line (Figure 19B). 
Finally, we co-cultured CFSE labeled target cells with differentiated 
macrophages and determined phagocytosis by flow cytometry. At baseline, we 
saw no significant difference in phagocytosis, suggesting that presence or absence 





Figure 19. CD200 does not significantly alter phagocytosis of AML. A. Flow 
cytometry assessment of CD47 expression. B) Immunogenic gene expression by 
RNA-seq. C. Functional phagocytosis of AML cell lines by healthy macrophages 
(OCI-AML3 n=7 donors; Kasumi n=3 donors).  
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CD200 suppresses macrophage cytokine production in vitro. Although we did not 
see substantial basal phagocytosis, we next challenged macrophage cytokine 
production in response to the CD200-expressing and non-expressing OCI-AML3 
cells (Figure 20). Healthy macrophages were capable of mounting a robust 
inflammatory response in the presence of wild type leukemia cells. Production of 
all cytokines profiled was significantly abrogated by ectopic CD200 expression. 
Interestingly, only secretion of a subset of these inflammatory cytokines and 
chemokines, including IL1-Ra, IL-12p70, CXCL10, and CCL17, could be restored 





Figure 20. Macrophage cytokine secretion suppressed in response to 
CD200+ AML cells. Cytokines secreted by healthy macrophages in the presence 





CD200 may affect NK cell-mediated cytotoxicity in vitro. Previous work by Coles 
et al showed a correlation between high AML CD200 surface expression and 
reduction in the frequency of activated NK cells, as well as impaired cytolytic 
capacity of CD16/CD56+ NK cells in the presence of ectopic CD200
45
. However, 
a major limitation of this study was the lack of isolated NK cell co-culture 
experiments to explicitly determine NK cell-mediated killing of AML.  Using calcein 
release assays with purified NK cells from 2 donors, we found no consistent, 
significant difference in NK cell-mediated cell lysis between the CD200- (KO) and 
CD200+ (WT) Kasumi cells (Figure 21A).  However, in 3 out of 4 donors, CD200- 
(pGFP) OCI-AML3 cells were killed at a significantly higher rate than the 
corresponding CD200+ (pCD200) cells (two representative donors; Figure 21B). 






Figure 21. High CD200 expression on AML cells may protect cells from NK 
cell-mediated killing in vitro. A. Specific cell lysis of Kasumi WT and CD200KO 
cells at varying NK:AML cell ratios with two different NK cell donors. B. Specific 
cell lysis OCI-AML3 pCD200 and pGFP cells at varying effector NK:AML cell ratios 
with two different NK cell donors. Two-sample t-tests; *p<0.05, **p<0.01, 


















































































CD200 suppresses a subset of NK cell cytokine secretion in vitro. Next, we 
checked the ability of NK cells to mount an inflammatory response after exposure 
to CD200+ and CD200- OCI-AML3 cells. In contrast to the pattern seen in T cells 
and macrophages, the majority of cytokines and cytotoxic enzymes were secreted 
in response to AML, regardless of CD200 status (Figure 22). However, IFNγ, IL-
10, and IL-6 secretion were mildly attenuated by CD200 and restored by blocking 






Figure 22. NK cell cytokine response to AML is independent of CD200 
expression. Cytokines secreted by healthy NK cells in the presence of CD200- 




CD200 prevents T cell-mediated leukemia rejection in vivo. We next sought to 
confirm the CD200-mediated effects in vivo. First, we checked that the isogenic 
AML model systems had similar properties in NSG mice. Briefly, 50,000 luciferase 
labeled pGFP or pCD200 OCI-AML3 cells were injected intravenously into 
immunodeficient NSG mice and monitored without intervention by weekly 
luciferase imaging (Figure 23A). We saw no significant difference in the 
engraftment or progression of disease (Figure 23B) or overall survival (Figure 23C) 
between lines based on CD200 status. However, when the NSG mice were 
humanized with healthy human PBMCs one week prior to leukemia introduction 
(Figure 24A), we then saw significant differences in the progression of leukemia 
with CD200 expression (Figure 24B). While all mice had comparable engraftment 
at days 4 and 7 as measured by bioluminescent imaging, around day 14 the 
system began to diverge with CD200+ OCI-AML3 cells progressing while CD200- 
OCI-AML3 cells were eliminated. In fact, in this experiment, all mice receiving 
CD200- leukemia died without detectable disease. This translated to a significant 
increase in overall survival (Figure 24D), however all mice eventually succumbed 
to symptoms of histologically confirmed graft-versus-host disease (Figure 25). 
Expansion of human CD45+ lymphocytes (>90% CD3+) was also tracked over the 
course of the experiment (Figure 24C). There was no significant difference in the 
fraction of human CD45+ cells between the two groups, though at day 18, when 
the leukemia models began to diverge, there was a trend towards suppressed 





Figure 23. Ectopic CD200 expression does not alter AML engraftment or 
progression in immunocompromised NSG mice. A. Schematic of murine 
transplant model. B. Leukemia burden determined by luciferase imaging. C. 









































Figure 24. CD200 enables AML progression in PBMC-humanized mice. A. 
Schematic of the humanized mouse model. B. Total leukemia burden by 
bioluminescence imaging. C. Frequency of circulating human lymphocytes in 
peripheral blood (human CD45/total CD45+). D. Overall survival (Mantel-Cox log-




Figure 25. PBMC-humanized mice develop GvHD. Representative H&E 
sections from organs of healthy NSG and PBMC-humanized mice. 
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Cytokine secretion in humanized mice. We performed the PBMC-humanized 
mouse model experiments again in order to monitor cytokine production in vivo. At 
7 days post leukemia injection, mice from both the pGFP and pCD200 models 
were confirmed to have equal engraftment as determined by luciferase imaging 
(Figure 26A, B). At this time point, mice also had comparable fractions of human 
CD45+ lymphocytes in peripheral blood, however both leukemia models had 
significantly more human lymphocytes when compared to the humanized-only 
control mice (Figure 26C).  Serum from peripheral blood of each mouse was 
profiled for secreted inflammatory cytokines by flow cytometry (Figure 26D). 
Despite the similar frequency of human lymphocytes, mice with leukemia cells 
expressing CD200 had significantly reduced IFNγ, granzyme A (GZMA), 
granulysin (Gran), and IL-10 abundance when compared to those without (t-tests 
with two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli 
correction for multiple testing, q-value<0.05). Humanized-only controls also had 
high variability of inflammatory cytokine production, indicative of heterogeneous 




Figure 26. CD200+ AML suppresses cytokine production in vivo. A. Luciferase 
image of mice at day 7. B. Total flux summary of luciferase image. C. Frequency 
of circulating human lymphocytes in peripheral blood (human CD45/total CD45+).  
D. Normalized cytokine production for each mouse. Multiple t-tests compared 
cytokine production in pGFP vs pCD200 mice. *q<0.05. 
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CD200+ AML alters T cell composition in vivo. We next asked whether the 
significant alterations in cytokine production could be explained by differential T 
cell composition in the presence of CD200+ AML. To test this hypothesis, another 
PBMC-humanized mouse model was established following the schematic 
described in Figure 24A with a different healthy donor. At day 10 after leukemia 
cell injection, comparable disease burden in both pGFP and pCD200 mice was 
confirmed by luciferase imaging (Figure 27A). Complete blood count (CBC) and 
flow cytometry was performed on peripheral blood. While mice from both leukemia 
groups had the same frequency of human CD45+ lymphocytes (Figure 27C), there 
was a trend, albeit not statistically significant, towards higher white blood cell 
numbers in mice with CD200-expressing disease (Figure 27B). Based on flow 
cytometry analysis of CD4 and CD8 expression, pGFP mice tended to have a 
higher ratio of CD4/CD8 T cells when compared to pCD200 or humanized-only 
controls (Figure 27D).  
 High resolution immune profiling of the lymphocytes in these mouse models 
was performed using mass cytometry (CyTOF) analysis to simultaneously profile 
the 35 proteins in Table 6.  The majority of human lymphocytes present across all 
mice were CD4 and CD8 T cells. The residual non-T cell fraction of lymphocytes 
was comprised of B and plasma cells. There was no evidence of NK cell presence 
in these models (Figure 28A). Further partitioning CD4 and CD8 T cells into 
functional subsets, we found that pGFP mice had a significantly higher fraction of 
CD4+CD45RA-CCR7+ central memory cells while pCD200 and humanized only 
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mice were enriched for CD8+CD45RA-CCR7- effector memory cells (Figure 28B; 
*q<0.05). 
 CyTOF profiling also allowed for the interrogation of checkpoint expression, 
markers of activation and exhaustion, and cell cycle among the 
immunophenotypically defined subset. There were no significant differences in 
classical markers of activation across T cells in the presence of CD200+ leukemia. 
There were, however, significantly fewer actively cycling T cells (as measured by 




Figure 27. Characteristics of humanized mouse model. A. Representative 
bioluminescence image of mice at day 7. B. Summary of total flux in these mice.  
C. WBC from all mice at time of collection. D. Fraction of human CD45+ cells in 
circulation. E. CD4/CD8 ratio in circulating human T cells.   
	 105	
	
Figure 28. T cell profile of humanized mice by CyTOF. A. UMAP projection of 
T human CD45+ lymphocytes in the humanized mice from Figure 25. B. Cell 
fraction frequency by model type. ANOVA; *p<0.05.  
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CD200 significantly alters T cell transcription. With the same cells used for CyTOF 
profiling, we also performed bulk RNA sequencing to look for specific 
transcriptional pathways altered by CD200-expressing leukemia. We expected to 
see differentially expressed genes in primarily pathways involved in cytokine 
production and response. We did see an upregulation of genes involved in T cell 
response and inflammation in T cells from mice with CD200-expressing leukemia 
(Figure 29). More strikingly, however, was the observation that T cells from mice 
with CD200-expressing disease had significantly downregulated metabolically 
related genes (Figure 30). In fact, based on gene set enrichment analysis, these 
cells were significantly devoid of active metabolic signaling through glycolysis and 
oxidative phosphorylation.   
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Figure 29. Heatmap of differentially expressed genes between T cells from 
mice with CD200+ or CD200- OCI-AML3 leukemia.  
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Figure 30. GSEA analysis of genes enriched in T cells from mice CD200+ 
leukemia compared to T cells from mice with CD200- leukemia. A. Summary 
of a subset of enriched pathways. B. Individual enrichment plots.  
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3.4  Discussion 
 Our data showed that the highest expression of CD200 receptor, at both the 
protein and gene level, seen in CD4 T cells, followed by CD8 T cells, and then 
monocytes, in line with the findings of Wright et al114. We showed, for the first time, 
that CD200R increases during monocyte differentiation into macrophages. Based 
on these results, and previous reports by Coles et al, we chose to focus our in vitro 
studies on the interaction of AML-bound CD200 with T cells, NK cells, and 
macrophages.  
CD200 was originally discovered as a regulator of myeloid cell 
function
38,116,43
. By directly challenging macrophages with leukemia cells both with 
and without CD200 expression, we confirmed that CD200 significantly abrogated 
their effector cytokine production. A subset of the cytokines interrogated, including 
IL1-Ra, IL-12p70, CXCL10, and CCL17, could be restored by blocking the 
CD200/CD200R interaction using a CD200 nanobody without Fc receptor-
mediated effects.  However, the expression of the remaining cytokines, including 
Arginase, TNFα, and IL-1β, could not be restored. This suggested that the isogenic 
pCD200 model may have additional layers of immunosuppression (independent of 
CD200 status) or that the CD200 is suppressive through an additional unknown 
mechanism in macrophages. We also found that CD200 alone does not act as a 
“don’t eat me” signal as no significant differences were seen in phagocytosis of the 
isogenic cell lines. It would be interesting to explore whether CD200 could 
suppress phagocytosis in scenarios of AML cell duress, such as chemotherapy 
treatment or hypoxia. 
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CD200 has also been implicated in directly suppressing NK cell 
degranulation and IFNγ production
45
. While we did find that ectopic CD200 
reduced NK cell cytotoxicity, this finding was restricted to the OCI-AML3 model. 
Further studies would be required to determine whether this difference in NK cell-
mediated killing was the direct result of CD200 dose or an unrelated intrinsic 
difference between the cell line models. Additionally, CD200 appeared to only 
regulate a subset of NK cell cytokines, including TNFα, IL-10, and IL-6, rather than 
the global cytokine shifts seen with macrophages and T cells.  
 Co-culture experiments with T cells showed a strong activation of the MAPK 
signaling pathway, as measured by p-ERK, in response to OCI-AML3 leukemia 
cells. However, this activity was significantly diminished in the presence of ectopic 
CD200. This demonstrated that the signaling pathway originally identified in mast 
cells is conserved in lymphoid cells
115
. Interestingly, there was no activation of 
MAPK in response to Kasumi leukemia cells. However, in both isogenic models, 
we saw consistent downregulation of the STAT3 signaling pathway with CD200. 
Whether this was a direct result of CD200 suppression through an uncharacterized 
mechanism or a feedback loop would require further investigation.   
 We next tested whether this altered signaling translated functionally to 
changes in T cell proliferation, cytokine production, or cytotoxicity. Based on the 
isolated co-culture systems, T cell cytokine production was the most significantly 
impacted by the presence or absence of CD200 on AML cells. These findings were 
consistent with previous reports that CD200 was capable of suppressing 
inflammatory cytokines from T cells
46,117
. However, unlike previous reports, this 
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suppression appeared to be universal and also include the downregulation of anti-
inflammatory cytokines including IL-6, IL-10, and IL-13
134
.  This suggests that 
CD200R signaling in T cells does not selectively regulate pro-inflammatory 
cytokines but, rather, may act as a master regulator of all cytokine production. The 
partial restoration of cytokine production upon treatment with a CD200 nanobody 
that selectively blocks the CD200/CD200R interactions without any potential Fc-
mediated effects substantiates the claim that CD200 directly regulates cytokine 
production through interaction with the CD200 receptor.  The substantial shift in 
cytokine production could also contribute to the subtle changes in T cell 
proliferation; however, this requires further investigation.  
 Based on the low levels of AML cell killing in vitro, we were surprised to see 
that CD200-expressing AML was spared from immune-mediated destruction in 
vivo. The 2-week lag time in the clearance of AML cells in the PBMC-humanized 
mouse model suggests a more complex mechanism by which CD200 alters the 
immune microenvironment. Kretz-Rommel et al previously demonstrated that 
subcutaneous co-injection of PBMCs and CD200-null chronic lymphocytic 
leukemia (CLL) resulted in significant reduction in the rate of tumor growth but no 
difference in outcome was seen in this CD200-expressing CLL model
59
. However, 
subcutaneous models for leukemia are highly criticized as they do not accurately 
represent the disseminated nature of the disease. We show here, for the first time, 
that CD200 expression alone is sufficient to protect AML cells in a physiologically-
relevant humanized mouse model of GvHD.  
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 Using the PBMC-humanized mouse model, we were also able to confirm 
that CD200-expressing leukemia was also capable of suppressing T cell cytokine 
secretion in vivo. The delayed clearance of CD200-null disease provided a window 
where we could study the cytokine profiling of T cells in the presence of equal 
disease burden. We were also able to confirm that differential cytokine production 
was not confounded by differences in human CD45+ abundance.  
 Previous reports suggested that CD200 can alter the T cell repertoire, 
specifically by allowing for Treg expansion
47,118
 and increases in exhausted PD-1+ 
cytotoxic T cells. Based on our humanized in vivo system, we were unable to 
confirm either of these results with no significant differences seen in either 
CD4+FOXP3+ Tregs nor CD8+PD-1+ T cells between the two leukemia groups. 
We did, however, observe that the T cell profile of mice with CD200-expressing 
leukemia was made up of more effector memory CD8 T cells and fewer central 
memory CD4 T cells when compared to those from the CD200-null leukemic mice. 
Taken together with the T cell signaling data, our findings are consistent with 
previous studies that STAT3 signaling is indispensable for the maturation of central 
memory cells
135
.   
	 The most unexpected finding of this study was the transcriptional profile of 
T cells extracted from humanized mice after one week of exposure to either 
pCD200 or pGFP leukemia. While T cells from the CD200-expressing leukemia 
mice did show evidence of upregulation of genes involved in inflammatory 
response, these cells were almost completely metabolically quiescent when 
compared to T cells obtained from the mice exposed to CD200-null leukemia.  This 
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corroborates the diminished cell cycle activity, as measured by Ki67, seen in the T 
cells exposed to CD200+ leukemia by CyTOF analysis. Tumor metabolism can 
significantly alter T cell function by manipulating pH, nutrient availability, and 
oxygen abundance in the tumor microenvironment
136
. Further studies are 
necessary to understand the contribution of CD200 to T cell metabolism.    
 In Chapter III, we have shown that CD200 suppresses members of both the 
innate and adaptive immune systems, primarily by impeding cytokine production 
in vitro. Further, we demonstrated, for the first time, that CD200 rescued AML cells 
from immune clearance in a humanized model and that this effect was largely due 
to altering the cytokine milieu and driving T cells into metabolic quiescence. In 
































Purpose: We have now demonstrated that CD200 is a robust marker of AML LSCs 
that provides direct immunosuppression to subsets of T cells, NK cells, and 
macrophages through interaction with the CD200 receptor. To exploit these 
findings therapeutically, a fully humanized IgG1 antibody against CD200 (CD200-
IgG1) was developed to specifically target AML LSCs by (1) reversing the 
immunosuppressive effects by blocking its interaction with the CD200 receptor and 
(2) inducing potent antibody-dependent cellular cytotoxicity and phagocytosis. 
 
Experimental design: A series of mixed lymphocyte reactions with isolated 
effector T cells, NK cells, or macrophages and target isogenic AML cell lines 
(CD200 knockout and CD200 overexpression) treated with CD200-antibodies and 
nanobodies were used to assess the contribution of CD200-receptor blocking 
versus Fc-mediated effects. Both immunodeficient and immunocompetent mouse 
models with the isogenic OCI-AML3 cell lines were employed to evaluate the 
efficacy of anti-CD200 antibody therapy in vivo. 
 
Results: Both CD200-IgG1 and the clinically available benchmark IgG2/G4 
antibody, samalizumab, partially restored inflammatory cytokine production by T 
cells in response to CD200+ leukemia. CD200-IgG1, but not samalizumab, 
induced NK cell cytokine secretion and CD200-specific antibody-dependent cell 
cytotoxicity. With macrophages, both CD200-IgG1 and samalizumab stimulated 
inflammatory cytokine production and promoted phagocytosis of AML cells with 
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surface CD200 expression. In immunocompromised NSG mice, anti-CD200 
therapy selectively reduced engraftment of CD200+ AML and prolonged overall 
survival. In the PBMC-humanized model, graft-versus-host activity combined with 
antibody therapy could completely eliminate disease and substantially alter the 
composition of the T cell compartment.    
 
Conclusions: The novel CD200-IgG1 antibody improves anti-leukemic response 
from components of both the innate and adaptive immune system by both reducing 
the immunosuppressive effects of CD200 and by stimulating NK cells and 
macrophages in vitro. Only in the immunocompetent model could CD200-






Antibody therapy in AML. Since the approval of the first monoclonal antibody for 
the treatment of Non-Hodgkin’s lymphoma in 1997
137
, there has been a rapid influx 
of targeted therapies aiming to use antibodies to eliminate AML. Currently, 
antibody therapy can be classified into 3 different types; unconjugated, multivalent, 
and toxin-conjugated
138
. Within the unconjugated antibody category, there exist 
two unique strategies.  
The first is to exploit the powerful cytotoxic properties of naturally occurring 
antibodies. When a cell is flagged by an antibody, the primary mechanism of cell 
clearance is NK cell antibody-dependent cellular cytotoxicity (ADCC). During this 
process, Fc-receptors on the NK cells recognize the constant regions of the 
antibody on the target cell and initiate the production of inflammatory cytokines 
and release of cytotoxic granules containing perforin and granzymes
139
. These 





 pathways. Cell-bound 
antibodies can also be recognized by Fc-receptors on macrophages and 
neutrophils that trigger antibody-dependent cellular phagocytosis, or ADCP. 
During ADCP, antibody-labeled cells are engulfed, degraded within internal 
phagosomes, and presented as antigens to further enhance adaptive immune 
response
142
. Finally, antibody-coated cells can also induce the classical pathway 
of complement-dependent cellular cytotoxicity (CDC). Briefly, complement 
recognizes antibody and forms membrane attack complexes that result in osmotic 
cell lysis
143














 The second unconjugated antibody strategy is used when Fc-mediated 
effector functions are unwanted or could be deleterious. In this case, antibodies 
are employed as tool compounds to specifically cross-link or disrupt the 
interactions between cell surface molecules. Ablation of Fc-receptor or 
complement binding can be accomplished by introducing point mutations at 
various residues in the constant region of the antibody
149
.  Another common 
approach is to leverage the properties of different IgG subclasses to engineer 
cross-subclass Fc regions
150
. For example, the IgG2/G4 chimera combines the 
constant domain of IgG2 which has weak affinity for Fc-receptor binding with the 
constant domain of IgG4 that has low affinity for complement binding to create a 




IgG subclasses. Humans have four, highly conserved subclasses of 
immunoglobulin G; IgG1, IgG2, IgG3, and IgG4, that differ in their constant 
domains
152
. These differences are sufficient to alter their affinity for various Fc 
receptors and complement activity. Generally, IgG1 and IgG3 are reported to be 
the most potent activators of both Fc-mediated effector function and complement 




Samalizumab. Samalizumab is a humanized anti-CD200 IgG2/G4 antibody that is 
currently being used as a checkpoint inhibitor in clinical trials of chronic 
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lymphocytic leukemia and multiple myeloma
57
. The choice to develop the clinical 
antibody without effector function was based on work by Kretz-Rommel et al who 
demonstrated in a subcutaneous mouse model of Burkitt’s lymphoma that the 
IgG2/G4 anti-CD200 antibody was moderately more effective at reducing solid 
tumor size when compared to the IgG1 version
58
. This was believed to be caused 
by the off-target destruction of activated T cells that upregulated CD200. However, 
this mechanism was not validated in the murine model. Additionally, reports from 
the same group had previously shown that the IgG1 and IgG2/G4 antibodies 
derived from the same anti-CD200 Fab B7 had identical efficacy in vivo59. 
Samalizumab was recently included as a therapeutic arm of the BEAT AML clinical 
trial [NCT03013998] for the treatment of previously untreated leukemia with high 
levels of bulk CD200 expression, however, the results were not included in the trial 
summary
60
.   
 
MD Anderson anti-CD200. In light of these results, we chose to develop our 
therapeutic antibody using a fully humanized IgG1 backbone. Using the same 
variable region as samalizumab, we ensure that this novel antibody binds the same 
epitope that is characterized to block CD200 receptor binding while also 
harnessing the potent Fc-mediated effector functions of an IgG1 antibody. 
 In this chapter, we sought to characterize the effect of the novel CD200-
IgG1 antibody on isolated innate and adaptive effector cell subsets when 
compared to samalizumab. We also tested the efficacy of CD200-IgG1 as a single 
agent against CD200-expressing leukemia in the context of immunodeficient and 
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immunocompetent mouse models.  We hypothesized that the IgG1 backbone of 
the new antibody would enhance anti-leukemic potency of immune cells and that 




4.3 Materials and Methods 
	
PBMC collection and target cell isolation. Buffy coat was obtained from healthy 
donors. PBMCs were isolated by Ficoll density gradient centrifugation. Briefly, 
sample was mixed at a 1:1 ratio with Dulbecco’s Phosphate-Buffered Saline (PBS) 
without calcium and magnesium (GenDEPOT) and gently added to 15ml 
Lymphocyte Separation Medium (Lonza; cat. 17-829E). Cells were centrifuged at 
1,800 RPM for 20 minutes and the lymphocyte layer was carefully extracted. If 
necessary, 5ml ammonium chloride solution (Stem Cell Technologies) was used 
to lyse any residual red blood cells. CD3+ T cells were isolated using the 
EasySep™ Release Human CD3 Positive Selection Kit (Stem Cell Technologies; 
cat. 17751). NK cells were negatively selected from total PBMCs using magnetic 
column separation (Miltenyi Biotec, cat. 130-092-657). Monocytes were negatively 
selected from PBMCs using the EasySep™ Human Monocyte Isolation Kit (Stem 
Cell Technologies; cat. 19359). T and NK cells were cultured in RPMI-1640 media 
with 10% heat-inactivated Fetal Bovine Serum (FBS; GenDEPOT) and 200 IU/ml 
recombinant interleukin 2 (IL-2; Peprotech).  
 
Macrophage differentiation and culture. Macrophages were differentiated as 
previously described
113
. Briefly, sorted CD14+ monocytes from healthy PBMCs 
were cultured in RPMI-1640 media with 10% FBS and 20ng/mL recombinant 
human macrophage colony stimulating factor (M-CSF; Peprotech) for 7-10 days 
with media changes every 3 days. Mature macrophages were detached using 
StemPro Accutase Cell Dissociation Reagent (ThermoFisher Scientific) on ice for 
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20 minutes and counted. Cells were re-plated at a density of 4x10
4
 cells/well in 48-
well plates and allowed to reattach for 48 hours prior to use.  
 
Flow cytometry. 3x105 cells were transferred to a 5ml FACS tube and washed twice 
with staining buffer (PBS + 0.5% Bovine Serum Albumin (Sigma-Aldrich)). Cells 
were Fc-blocked with either 5µl anti-human or anti-mouse Fc receptor binding 
inhibitor (eBioscience Invitrogen) in 100µl staining buffer for 15 minutes prior to the 
addition of anti-human CD200R (PE; Biolegend), anti-human CD47 (PerCP-Cy5.5; 
Biolegend), anti-human CD45 (APC-Cy7; Biolegend), anti-human CD4 (PerCP-
Cy5.5), anti-human CD8 (PE-Cy7; Biolegend), or anti-mouse CD45 (APC; 
Biolegend) antibody (1µl/sample). Surface stain was incubated for 30 minutes at 
room temperature on an orbital shaker followed by 2 washes with staining buffer. 
Cells were resuspended in 300µl of staining buffer plus 5µl 4',6-Diamidino-2-
Phenylindole, Dihydrochloride (DAPI; 2µg/ml; Invitrogen) for live/dead cell 
discrimination for collection on a LSRII machine (BD).  
 
Cytokine profiling. 2x105 effector cells were co-cultured at a 1:1 ratio with desired 
target cells and treatments in 200µl in 96-well U-bottom plates and incubated for 
16-24 hours. Plates were spun down at 500g for 5 minutes. 25µl of supernatant 
from each well was transferred to a new 96-well U-bottom plate. Secreted cytokine 
abundance was determined using one of the following Legendplex kits 
(Biolegend); Human CD8/NK Panel (cat. 740267), Human T Helper Cytokine 
Panel (cat 740722), Human Macrophage/Microglia Cytokine Panel (cat. 740503). 
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Briefly, cell supernatant was incubated with 25µl of pre-mixed analyte capture 
beads and 25µl detection antibodies for 2 hours at room temperature on a shaker 
(at approximately 600 RPM). Without washing, 25µl streptavidin-PE was added to 
each well and incubated another 30 minutes at room temperature on a shaker. 
Beads were washed twice and collected using a High Throughput Sampler (HTS; 
BD). For cytokines within range, cytokine concentration was interpolated based on 
the standards. For cytokines with concentrations outside of the standard range, 
MFI was reported. 
 
Calcein AM release assay for NK-cell mediated ADCC. NK cells were cultured in 
RPMI-1640 media + 20% FBS + 200 IU/ml recombinant human IL-2 (PeproTech; 
cat. 200-02) for no more than 24 hours before use. AML target cells were washed 
2x with PBS and stained at a concentration of 1x10
6
 cells/ml of calcein AM staining 
media (2µg/ml calcein AM in 1ml PBS) for 1 hour at 37°C. Residual calcein was 
quenched with 3 washes in 15ml complete media. 2.0x10
4
 target cells were 
plated/well in 96-well U-bottom plates. Varying numbers of NK cells were added in 
a final volume of 100µl IL-2 media. Antibody treatments either 100nM 
samalizumab, 100nM CD200-IgG1, or PBS-only were added to appropriate wells 
in triplicate. 2% Triton-X was added to positive controls (maximum calcein 
release). Plates were spun down at 500g for 1 minute before incubating 4 hours at 
37°C. Following incubation, cells were spun down at 500g for 5 minutes. 75µl of 
supernatant per well was transferred to a black bottom, black walled 96-well plate. 
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Fluorescence was measured using a Victor X3 fluorescent plate reader 






Phagocytosis by flow cytometry. Target leukemia cells were labeled with 5uM 
carboxyfluorescein succinimidyl ester (CFSE; ThermoFisher) for 5 minutes at 37°C 
followed by a 5-minute quench with 5ml complete media at 37°C. Labeled AML 
cells were co-cultured at a 2:1 ratio with differentiated macrophages (7-10 days 
old) for 4 hours at 37°C.  Cells were detached using StemPro Accutase Cell 
Dissociation Reagent (ThermoFisher Scientific) on ice for 20 minutes and 
transferred to 5ml FACS tubes. Cells were stained with 1µl/sample CD206 PerCP-
Cy5.5 for 30 minutes at room temperature prior to assessment by flow cytometry. 
Macrophages that had undergone phagocytosis of AML cells were identified as 
CFSE+CD206+. Percentage of activated macrophages was calculated as the 
fraction of double positive cells to total CD206+ cells. 
 
Phagocytosis by Incucyte. Cell lines were labeled with pH-sensing fluorescent dye 
using the IncuCyte® pHrodo® Red Cell Labeling Kit for Phagocytosis (IncuCyte 
Sartorius; cat 4649). Prior to functional studies, optimal staining concentration was 
determined for each cell line. Antibody-mediated cellular phagocytosis assays 
were performed by following the IncuCyte non-apoptotic phagocytosis protocol. 
Briefly, 48 hours prior to the experiment, effector macrophages were detached 
using StemPro Accutase Cell Dissociation Reagent (ThermoFisher Scientific) on 
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ice for 20 minutes and counted. Macrophages were re-plated at a density of 4x10
4
 
cells/well in 48-well plates. On the day of experimentation, target AML cells were 
washed once with IncuCyte pHrodo Cell Wash Buffer and resuspended in 
IncuCyte pHrodo Cell Labeling Buffer to a density of 1x10
6
/ml. Cells were stained 
with the optimal concentrations of IncuCyte pHrodo Red Cell Labeling Dye for 1 
hour at 37 °C followed by 2 washes in complete media. 8x10
4
 target cells and 
antibody treatments (10µg/ml) were added simultaneously to effector cells and 
immediately placed in the IncuCyte Live-Cell Imaging System (IncuCyte Sartorius). 
Red fluorescence and bright field images were collected every 15 minutes for 4 
hours. The number of engulfed AML cells was determined using the IncuCyte Live-
Cell Analysis Software. 
 
Mice. Female NOD-SCID IL2Rgnull (NSG) mice were obtained from our breeding 
colony with breeders originally purchased from Jackson Laboratory. Mice were 
approximately 5 to 8 weeks old at the time of use. All mice were housed in 
accordance with the Association for Assessment and Accreditation of Laboratory 
Animal Care and NIH standards. All experiments were conducted according to 
protocols 00001146-RN02 and 00001446-RN01 approved by the University of 
Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee. 
 
PBMC-humanized mice. Healthy PBMCs were extracted from buffy coat the day 
of injection. 10x10
6
 cells in 100µl PBS i.v. were injected and allowed one week to 
engraft. T cell engraftment was confirmed day 7 by detection of human 
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CD45+CD3+ in peripheral blood by flow cytometry. Mice were then randomized to 
receive 5x10
4 
of either pGFP or pCD200 OCI-AML3 cells in 100µl sterile PBS i.v. 
 
In vivo leukemia monitoring. Firefly luciferase was used to track OCI-AML3 disease 
progression in mice. The luciferase substrate, d-luciferin (100μL of 30mg/mL in 
PBS; Gold Biotechnology, Inc.), was injected i.p. 5 minutes prior to IVIS imaging 
(IVIS-Xenogen 100 system; Caliper Lifesciences). Leukemia burden was 
determined to be to total flux minus the total flux of the background.  
 
Serum collection. 100µl of whole blood was collected by retro-orbital eye bleeding 
from anesthetized mice in microtainers containing K2EDTA (BD, cat 365974). 
Blood was transferred to Eppendorf tubes and centrifuged at 4°C for 20 minutes 
at 500g. The top plasma layer was carefully extracted, transferred to fresh 
Eppendorf tubes, and stored at -80°C until testing. 
 
CyTOF mass cytometry. Human CD45+ cells were collected from mouse bone 
marrow and spleen and selected using the EasySep™ Mouse/Human Chimera 
Isolation Kit (Stem Cell Technologies, cat 19849). Sample barcoding and metal-
conjugated antibody staining were performed according to Fluidigm’s protocols as 
described below. Briefly, all antibodies were labeled with heavy metals using 
Maxpar-X8 labeling reagent kits (Fluidigm DVS Sciences) according to 
manufacturer’s instructions and titrated for optimal concentration determination. 
For each mouse evaluated, 3x10
6
 cells were aliquoted into separate FACS tubes 
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and washed twice with Maxpar PBS Buffer (Fluidigm; cat. 201058). For live/dead 
cell discrimination, cells were resuspended in 200µl of 5µM cisplatin (Fluidigm; cat. 
201064) for 1 minute on an orbital shaker followed immediately by 3 washes in 
Maxpar Cell Staining Buffer (CSB; Fluidigm; cat. 201068). Cells were then fixed in 
1ml of 1x Fix I Buffer (Fluidigm; cat.	201065) for 10 minutes followed by 2 washes 
with 1x Barcode Perm Buffer (Fluidigm; cat. 201057). Each unique Palladium 
Barcode (Fluidigm; Cell-ID 20-Plex Pd Barcoding Kit cat. 201060) was suspended 
in 100µl of Barcode Perm Buffer and immediately transferred to cells in 800µl 
Barcode Perm Buffer. Cells were incubated with barcodes for 30 minutes followed 
by 2 washes with 2ml CSB. Barcoded cells were then combined into a single tube 
for CyTOF staining. The staining factor was calculated as the total number of 
barcoded cells/3x10
6
. Cells were blocked with 5μL x staining factor of anti-human 
Fc receptor binding inhibitor (eBioscience Invitrogen) in 45µl x staining factor of 
CSB for 15 minutes at room temperature. Appropriate amount of surface antibody 
master mix (Table 6) was added directly to the tube and incubated for 1 hour at 
room temperature before 2 washes with CSB. For intracellular staining, cells were 
dissociated in 1ml of Foxp3 Fixation/Permeabilization Buffer (eBioscience; cat. 00-
5523-00) and incubated overnight at 4°C followed by 2 washes with 2ml of 1X 
Permeabilization Buffer. After discarding supernatant from the final wash, 
appropriate amounts of intracellular antibody master mix were added to the 
residual Permeabilization Buffer for 1 hour in the dark at room temperature.  For 
cell discrimination, a metallointercalator working solution (2ml Permeabilization 
Buffer, 125nM iridium metallointercalator (Fluidigm; cat. 201103A)) was added to 
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the sample and incubated overnight at 4°C. Cells were washed with a minimum of 
3mL CSB, then again with 3mL ddH2O with 0.1% BSA. Finally, cells were filtered 
through a 35µm filter and resuspended in 100µl ddH2O with 0.1%BSA. The 
MDACC Flow Cytometry and Cellular Imaging Core Facility prepared the antibody 
cocktails and acquired data on a Helios CyTOF machine (DVS Sciences). 
 
Mass cytometry data analysis. Data was first demultiplexed using the Fluidigm 
Debarcoder software. Individual mass cytometry data files (.fcs) were then filtered 
using FlowJo to remove the normalization beads, debris, doublets, and dead cells 
(Figure 4). Remaining analysis was performed in R (version 3.6.1, The R 





. Processed data was subjected to negative value pruned inverse 
hyperbolic sine transformation and clustered based on the PhenoGraph algorithm 
(k=22) using all cell surface markers
93
. Dimensionality reduction was performed 




Statistics. Unless otherwise specified, data analysis performed using GraphPad 
Prism version 8.  Statistical tests and methods for correcting for multiple testing 
are reported in-line.   
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4.4  Results 
Development of a blocking CD200 antibody. The anti-CD200 IgG1 antibody 
(CD200-IgG1) was developed in collaboration with UT MD Anderson’s Oncology 
Research for Biologics & Immunotherapy Translation platform. This antibody was 
engineered to bind to the same epitope as the clinically available antibody, 
samalizumab, and thus similarly block the interaction between CD200 and its 
receptor. In addition, CD200-IgG1 was hypothesized to enhance AML LSC 
clearance by inducing potent ADCC and ADCP with the humanized IgG1 constant 
region. Before studying the effector function of the CD200-IgG1 antibody, a series 
of biomolecular binding kinetics assays using the Octet platform were performed 
to characterize the interactions between CD200, CD200R and the anti-CD200 
antibody (Figure 32A-B; Figure 32A courtesy of MDACC ORBIT). First, we 
validated that CD200-IgG1 efficiently bound to the CD200 ligand with a KD of 
0.38nM (Figure 32C). It was also confirmed that the CD200 ligand interacted with 
the CD200 receptor at a lower avidity, with a KD of 14nM (Figure 32D). By 
screening the binding of CD200R-Fc protein to antibody treated CD200 ligand, it 
was also demonstrated that the CD200-IgG1 effectively blocked ligand/receptor 





Figure 32. CD200-IgG1 antibody development. A-B. Identity and biophysical 
characterization of CD200-IgG1. C. Kinetics of CD200 binding to the CD200-IgG1 







CD200-IgG1 restores the production of a subset of inflammatory cytokines in T 
cells. In Chapter III, we demonstrated that healthy T cells mounted inflammatory 
responses in the presence of AML cells that were abrogated in AML cells with 
ectopic CD200 expression. The suppression of cytokine production could be 
partially restored by a CD200-blocking nanobody that inhibited the interaction with 
the CD200 receptor without invoking any Fc-mediated immune responses. We 
hypothesized that the two blocking antibodies, CD200-IgG1 and samalizumab, 
would have similar effects on T cell cytokine production compared to the blocking 
nanobody (represented by the pattern of IL-4 expression in response to OCI-
AML3; Figure 33). However, the data indicated that different cytokines were 
preferentially restored in the presence of either CD200-blocking nanobody or 
antibodies. In the presence of CD200+ OCI-AML3 cells, only IL-4, IL-6, granulysin, 
and TNFα were restored by both the nanobody and antibody treatments. 
Granzyme A, IL-9, and IL-10 were only produced after treatment with the IgG1 
version of the antibody. The T cells co-cultured with CD200+ Kasumi cells offered 
a completely different cytokine pattern. Here, IFNγ, IL-9, and IL-21 were 
preferentially restored upon either nanobody or antibody treatment, while IL-6 
production partially returned only after nanobody treatment. This may suggest a 
more complex interaction between T cells and various antibodies as well as a less 




Figure 33. CD200-IgG1 partially restores T cell cytokine production in 
response to AML. Profile of inflammatory cytokines secreted in response to 
various co-cultures with either OCI-AML3 (top) or Kasumi (bottom) cells in the 
presence or absence of blocking antibodies or nanobodies. 
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CD200-IgG1 induces robust, antibody-dependent cytokine production in NK cells. 
NK cells express high levels of the Fc receptor CD16 that trigger effector functions 
against antibody-flagged cells or pathogens. We previously showed that NK cells 
upregulated cytokine production in response to AML cells regardless of CD200 
status. We next wondered whether CD200 antibody therapy could increase the 
inflammatory response by enhancing cytokine secretion. Healthy NK cells were 
co-cultured with CD200+ cells and either the chimeric IgG2/4 samalizumab or IgG1 
anti-CD200 antibody for 24 hours. Most of the cytokines profiled increased in the 
presence of either antibody, independent of IgG isotype (Figure 34A). However, 
the IgG1 antibody significantly outcompeted samalizumab in the production of the 
critical inflammatory proteins TNFα, IFNγ, and granzyme B (Figure 34B, Kruskal-
Wallis with Dunn’s multiple comparisons test; p<0.05)  
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Figure 34. CD200-IgG1 induces NK cell-mediated cytokine production. A. 
Relative NK cell cytokine production in response to co-culture with OCI-AML3 cells 
in the presence or absence of blocking antibodies or nanobodies. B. MFI of specific 
inflammatory cytokines across treatment groups. Kruskal-Wallis with Dunn’s 
multiple comparison test; *p<0.05.  
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CD200-IgG1 induces NK cell-mediated ADCC. In addition to regulation of 
cytokines, engagement of the Fc receptor on NK cells also initiates a cytotoxic 
response. Thus, we next wondered whether the CD200-IgG1 could enhance the 
destruction of CD200+ leukemia cells by inducing NK cell-mediated ADCC in vitro. 
Using the OCI-AML3 isogenic cell system, we found that the CD200-IgG1 antibody 
induced potent ADCC only in the cells expressing the surface CD200 protein 
(Figure 35A).  By design, samalizumab should not engage antibody-dependent 
cell-mediated cytotoxicity due to the cross-subclass Fc region. Therefore, we next 
asked if the IgG1 version of the antibody could outcompete samalizumab by 
augmenting NK cell killing via ADCC.  When treated with the same concentration 
of antibody targeting the same epitope, the IgG1 version of the anti-CD200 
antibody resulted significantly more cell lysis compared to samalizumab at all 
effector-to-target ratios in both Kasumi WT (Figure 35B) and OCI-AML3 pCD200 




Figure 35. CD200-IgG1 antibody induces potent, CD200-specific NK cell-
mediated ADCC. A. Specific cell lysis of OCI-AML3 pGFP and pCD200 cells with 
and without 100nM CD200-IgG1 antibody at varying NK:AML cell ratios (t-tests 
compare treated vs untreated pCD200 (red) and pGFP (green) cells. B-C. Specific 
cell lysis of Kasumi WT (B) and OCI-AML3 pCD200 (C) treated with either 100nM 
samalizumab or 100nM CD200-IgG1 at varying effector NK:AML cell ratios (t-tests 
compare CD200-IgG1 vs samalizumab). *q<0.05, **q<0.01, ***q<0.001, 
****q<0.0001.   

































































CD200 antibodies induce antibody-dependent cytokine production in 
macrophages. As macrophages also express a wide range of Fc receptors and 
are known players in antibody-mediated responses, we next examined the 
cytokine secretion from these cells in the presence of anti-CD200 treated AML 
cells. All cytokines profiled were upregulated in the presence of antibody-treated 
leukemia cells but not nanobody-treated cells (Figure 36A-B). This suggests that 
the mechanism of action is through potential Fc interactions rather than blocking 
of the CD200 receptor. The cross-subclass Fc design of samalizumab precludes 
Fc receptor engagement. However, the data here shows an almost identical 
cytokine response to either antibody treatment, regardless of Fc design. The 
cytokine abundance from macrophages in the presence of antibodies was 






Figure 36. Anti-CD200 antibodies induces macrophage-mediated cytokine 
production. A. Relative macrophage cytokine production in response to co-culture 
with OCI-AML3 cells in the presence or absence of blocking antibodies or 
nanobodies. B. MFI of specific inflammatory cytokines across treatment groups. 
Kruskal-Wallis with Dunn’s multiple comparison test; *p<0.05.  
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CD200-IgG1 induces robust phagocytosis of CD200-expressing AML. One of the 
primary mechanisms of action of monoclonal antibodies is to engage macrophages 
and induce antibody-dependent cellular phagocytosis (ADCP). To test whether 
both anti-CD200 antibodies were capable of inducing specific ADCP, CFSE-
labeled CD200+ and CD200- leukemia cells were co-cultured with mature 
macrophages and treated simultaneously with equal concentrations of 
samalizumab and CD200-IgG1. We first used microscopy to manually look for 
evidence of phagocytosis after 4 hours of co-incubation. In the presence of the 
CD200 antibodies, we saw numerous CFSE+ leukemia cells within the perimeter 
of a given macrophage (Figure 37A). This suggested that the macrophages were 
capable of engulfing the AML cells and that these cells maintained fluorescence 
immediately after phagocytosis. These observations allowed for the development 
of a more high-throughput assay to evaluate phagocytosis by flow cytometry. Now, 
cells that stained positive for both the mannose receptor (CD206), which was 
exclusively expressed on macrophages, as well as CFSE, could be counted as 
macrophages that had phagocytosed at least one AML cell. This method was 
limited in that it could only indicate evidence of phagocytosis and could not 
estimate how many cells were consumed per macrophage. Using the OCI-AML3 
isogenic cell lines, we found that anti-CD200 antibody treatment significantly 
increased the fraction of phagocytosing macrophages exclusively with CD200-
expressing leukemia (Figure 37B). Similar to the macrophage cytokine data, even 
with the cross-subclass Fc region, samalizumab was still capable of inducing 
phagocytosis, albeit with less intensity than its IgG1 counterpart. CD200-IgG1 also 
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induced phagocytosis of wild type Kasumi cells with low basal CD200 expression 
(Figure 37B). 
 The interpretation of these results relies on the assumption that engulfment 
of cells ultimately results in AML destruction by lysosomal degradation. To test this 
hypothesis, we employed a novel phagocytosis assay that directly measures cell 
entry into lethal phagosomes. Cells were labeled with a pH-sensing fluorescent 
dye that increased in intensity as the acidity of the environment also increased. 
This allowed for visualization of cells migrating from a relatively pH neutral 
extracellular environment to the highly acidic phagosomes (Figure 37C).  Live-
image software was used to capture these events over 4 hours. Interestingly, with 
this approach, only the CD200-IgG1 antibody induced phagocytosis. However, 
more replicates are required to rule out donor-specific macrophage variability. 
Live-cell imaging also provided a time-course of phagocytosis, with peak 




Figure 37. CD200-IgG1 induces potent, CD200-specific ADCP. A. 
Representative images of phagocytosed CFSE-labeled leukemia at baseline (left) 
and with CD200-IgG1 treatment (right) after 4-hour co-incubation with healthy 
macrophages. B. Flow cytometry analysis of phagocytosis of OCI-AML3 (left) or 
Kasumi (right) cells. C. Representative images of phagocytosed pHrodo red-
labeled leukemia at baseline (left) and with CD200-IgG1 treatment (right) after 4-
hour co-incubation with healthy macrophages. D. Time course of phagocytosis by 




CD200-IgG1 delays and redistributes CD200+ leukemia. Based on the ability of 
CD200-IgG1 to induce potent phagocytosis of CD200+ cells, we next assessed 
the efficacy of single-agent antibody therapy in the immunocompromised NSG 
mouse model. While NSG mice lack B, T, and NK cells, it has been reported that 
these mice retain functional effector phagocytes, including macrophages
154
. Mice 
were engrafted with either the CD200+ (pCD200) or CD200- (pGFP) OCI-AML3 
cell line and randomized to receive 6 doses of CD200-IgG1 (10 mg/kg) or vehicle 
control starting 1 week after injection (Figure 38A).  Before antibody administration, 
both cohorts had similar disease burden. After 2 doses (i.e. one week), there was 
a significant decrease in the disease burden of CD200+ CD200-IgG1-treated mice. 
However, the remaining 4 doses appeared largely ineffective, as the disease 
burden began to increase at the same rate as the control treated mice (Figure 
38B). This delay in leukemia expansion translated to significantly prolonged 
survival (p<0.0001), with a 74% increase in median survival (Figure 38C). 
Interestingly, all mice in the pCD200 antibody treated group died as a result of 
large, intraperitoneal chloromas.      
 Because the leukemia cells were luciferase-labeled, we could use 
bioluminescent imaging to track the distribution of disease. In the untreated model, 
OCI-AML3 cells preferentially engrafted in the liver and progressed to the bone 
marrow (Figure 39A). After 2 doses of CD200-IgG1, there was essentially 
complete clearance of disease in these locations and a concentrated disease 
burden in the spleen (Figure 39B). This area is where leukemia cells remained for 
the duration of the experiment. Post-mortem investigation revealed that the 
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disease in the treated pCD200 mice was exclusively in the spleen and the adjacent 
solid tumor. In some instances, leukemia can evade targeted therapy by down-
regulating the protein of interest. Therefore, we performed flow cytometry on 
single-cell suspensions from the spleen and chloroma from these mice. Human 
CD45+ cells maintained CD200 expression (Figure 39C), negating this potential 




Figure 38. CD200-IgG1 delays CD200+ leukemia progression. A. Schematic of 
the humanized mouse model. B. Total leukemia burden by bioluminescence 
imaging (ANOVA with Dunnett’s test for multiple comparisons; ****p<0.0001). C. 
Overall survival (Mantel-Cox log-rank test; ****p<0.0001).  
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Figure 39. CD200-IgG1 alters CD200+ leukemia distribution. Representative 
bioluminescent images of pCD200 OCI-AML3 mice after two doses of the vehicle 
control (A) or CD200-IgG1 (B). Flow cytometry analysis of CD200 expression in 
human CD45+ cells (c) and H&E (d) of a CD200-IgG1-treated chloroma.  
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CD200-IgG1 can eliminate disease in the presence of graft-vs-leukemia. To test 
whether the presence of adaptive immune cells could improve antibody-therapy, 
we next assessed the efficacy of single-agent antibody therapy in two PBMC-
humanized NSG mouse models using two different healthy donors. Human 
PBMCs were engrafted into NSG mice one week before injection of AML cells. 
Seven days after the introduction of leukemia, mice were treated with 6 doses of 
CD200-IgG1 (10 mg/kg) or vehicle control. In the first donor, which had potent 
graft-versus-leukemia potential, anti-CD200 therapy resulted in significant 
reduction in disease burden (Figure 40A-B) and ultimate clearance of leukemia (as 
assessed by flow cytometry at time of death). While strong GvL/GvHD was 
beneficial in anti-leukemia activity in this model, it made overall survival 
uninterpretable, as mice died almost immediately upon disease elimination. In a 
second humanized model with significantly less GvHD, we still saw that CD200-
IgG1 single-agent therapy significantly reduced the disease burden (Figure 40B). 
This translated to a significant improvement in overall survival (p=0.028) with an 
increase in median survival of 33.5 days (117.5% increase) (Figure 40D). 
Interestingly, the leukemia treated mice also survived significantly longer than the 
humanized only controls. Using this model, we also confirmed that the CD200-
IgG1 treatment had no significant effect on the expansion of humanized cells in 





Figure 40. CD200-IgG1 significantly reduces leukemia in humanized mice. A. 
Bioluminescent images of humanized mice over the course of CD200-IgG1 
treatment. B. Total leukemia burden in 2 humanized models (ANOVA with 
Dunnett’s test for multiple comparisons). C. Flow cytometry of human PBMC 
expansion in humanized mice (ANOVA with Dunnett’s). D. Overall survival for mice 
humanized with PBMCs from Donor 2 (Mantel-Cox log-rank test). *p<0.05, 




CD200-IgG1 treated mice revert to an anti-inflammatory state after treatment. 
Based on the observation that humanized-mice, after CD200-IgG1 treatment, lived 
significantly longer than the humanized-only control mice, we next investigated the 
human immune cell composition in a representative mouse from each 
experimental arm by mass cytometry (Figure 41A). Based on the amount of 
residual leukemia at this time point, we hypothesized that the CD200-IgG1 treated 
mice would resemble the mice with CD200- disease (pGFP). However, we found 
that the composition of T cells present in the antibody treated mouse was 
drastically different from either leukemic mouse or humanized control (Figure 41B). 
After treatment with anti-CD200 antibody, there was little evidence of activated 
CD8+ T cell subsets and an enrichment of both naïve and Treg CD4+ cells. This 
unique pattern of T cells suggests that the CD200-IgG1 antibody has functional 






Figure 41. CD200-IgG1 alters T cell composition in humanized mice. A. 
Bioluminescent images of humanized mice at time of PBMC collection. B. 
Composition of human lymphocytes present in a representative mouse from each 
group based on CyTOF analysis.    
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4.5  Discussion 
Antibody design. Samalizumab is a clinically available, anti-CD200 
humanized monoclonal antibody engineered with a cross-subclass IgG2/G4 
backbone to minimize Fc-mediated effector functions. This design was based on 
the hypothesis that blocking the CD200/CD200R interaction alone would produce 
therapeutically favorable response. We believed we could enhance the therapeutic 
efficacy of the CD200 antibody by replacing the chimeric Fc region with that of the 
potent IgG1 subclass. This would allow us to specifically target AML cells by (1) 
blocking the immunosuppressive activity of CD200 while simultaneously (2) 
engaging Fc-mediated effector cells for AML destruction. 
T cell response to antibody treatment. While our data consistently show that 
CD200-expressing cells abrogate cytokine production in the isogenic cell line 
setting, the data pertaining to the restoration of cytokine production has proved to 
be more complicated to interpret.  If the reversal of T cell cytokine suppression was 
as simple as disrupting the ligand/receptor interaction, the blocking nanobody, 
samalizumab, and CD200-IgG1 should have had similar effects on T cell cytokine 
secretion in response to CD200 expression on AML. However, the data indicated 
that different cytokines were preferentially secreted in the presence of either the 
CD200-blocking nanobody or antibodies. This could suggest that the interaction 
kinetics between the various blocking agents are different. Still, it is more likely that 
the different types of blocking agents (i.e. foreign nanobodies, or antibodies with 
differential Fc regions) have their own independent ability to alter T cell cytokine 
secretion. In other experiments, we have shown that nanobodies against CD200 
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without receptor blocking properties may also partially “restore” cytokine 
production, which may suggest that nanobody presence alone is capable of 
inducing a T cell-mediated cytokine response. Despite early reports of low-affinity 
Fc receptor expression on subsets of T cells, their functional role remains relatively 
unstudied
155
. However, recent studies have suggested that Fc receptors on CD4+ 
cells may provide costimulatory signals in the absence of the classical 
costimulatory pathway through CD28
156-158
. Direct signaling through the Fc 
receptor on CD4+ T cells in response to antibody treatment may confound our 
ability to interpret the CD200 receptor blocking with antibody therapy. Taken 
together, we believe that CD200+ cells potently suppress T cell cytokine 
production; however, this process does not seem to be restored by attempting to 
competitively block receptor interaction with antibodies or nanobodies. In fact, 
these biological agents have their own effects on T cell cytokine production.     
 Innate immune system response to CD200-IgG1 treatment. In the previous 
chapter, we showed that AML cells with CD200 expression could also abrogate 
the cytokine production in NK cells and macrophages. This dampened 
inflammatory response did not directly translate to impaired cytotoxic or phagocytic 
function. Yet, the inherent benefit of antibody therapy is that these functions can 
be explicitly invoked by design. The clinically available anti-CD200 antibody, 
samalizumab, was constructed with an IgG2/G4-kappa constant region. Such 
chimeric antibodies, termed “benign blockers”, were originally engineered to target 
protein interactions where effector function would be undesirable, or even fatal. 
Studies indicate that such antibodies should have little to no Fc-receptor binding 
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and, thus, no subsequent effector activity
151
. However, data presented here 
suggest that this chimeric antibody is still capable of activating components of the 
innate immune system to different degrees. Samalizumab was able to induce 
moderate cytokine production in NK cells but did not induce ADCC. In 
macrophages, samalizumab induced both potent inflammatory cytokine secretion 
as well as low levels of ADCP. 
Here, we show that by changing the constant region of the same antibody 
from an IgG2/G4 to an IgG1, we can significantly enhance inflammatory cytokine 
production from both NK cells and macrophages specifically in the presence of the 
cell-bound anti-CD200 antibody. CD200-IgG1 antibody treatment also induced 
potent, specific antibody-dependent NK cell cytotoxicity of CD200+ AML cells. We 
also demonstrated, for the first time, that the CD200-IgG1 antibody can be used to 
specifically flag CD200+ cells for phagocytosis.   
 Antibody clearance of AML requires the adaptive immune system. Next, we 
evaluated the utility of the CD200-IgG1 antibody as a single agent in vivo. By 
design, NSG mice lack critical immune components including B, T, and NK cells 
but maintain macrophages and dendritic cells. Due to the non-obese diabetic 
genetic background of this model, it was originally reported that these remaining 
members of the innate system were defective
159
. However, more recent studies 
have reported phagocytic potential of NSG derived macrophages ex vivo154,160. 
Therefore, we speculated that the primary mechanism of AML clearance as a 
result of CD200-IgG1 antibody treatment was through phagocytosis. What we did 
not anticipate was the re-distribution of leukemia cells upon antibody therapy. The 
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OCI-AML3 cells rarely take up residence in the spleen until the mouse is overcome 
by disease burden. However, upon administration of CD200-IgG1, we saw disease 
that was concentrated in the spleen. This disease did not disseminate after 
cessation of treatment, instead, it led to the formation of solid AML tumors that 
branched off of the spleen.  
 In humanized models, we saw a very similar pattern where disseminated 
disease converged on the spleen after antibody treatment. However, in the 
presence of human T cells-mediated graft-versus-host, this residual disease was 
cleared from the spleen and did not go on to form solid tumors. In the second 
donor, where GvHD was mild, there were antibody-treated mice that did not 
completely eradicate disease. In these cases, disease appeared to be restricted 
to organs in the genitourinary tract. Taken together, these findings suggest that 
clearance of CD200+ AML by targeted antibody therapy requires components of 
both the innate and adaptive immune systems.  
Lastly, our data suggests that CD200-IgG1 antibody treatment not only aids 
in eliminating CD200+ leukemia, but also considerably alters the T cell composition 
in these mice. Further studies need to be performed to validate these findings and 
link changes in T cell composition to changes in the cytokine milieu.       
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5.1 Overall Summary 
	
 Acute myeloid leukemia is a deadly cancer of the blood that affects both 
children and adults.  Using traditional chemotherapies, up to 80% of patients will 
achieve remission, a state when disease is no longer detectable. However, the 
majority of these patients will relapse and no longer be responsive to traditional 
treatment. Leukemia, and the subsequent relapsed disease, are hypothesized to 
arise from rare, primitive cells that are capable of evading chemotherapies known 
as leukemia stem cells (LSCs). Thus, LSCs are the critical target for curing AML. 
Stem cell transplantation is a proof-of-principle that AML LSCs can be eliminated 
by a functional immune system. However, the mechanisms by which AML LSCs 
escape immune surveillance and destruction remain largely unknown. The work 
presented in this thesis aims to bridge this gap in knowledge by identifying and 
characterizing CD200 as a novel marker of functional LSCs, demonstrating its role 
as a master regulator of both the innate and adaptive immune systems, and 
translating this scientific discovery into a potential therapeutic strategy for AML.  
In Chapter I, we summarized our current understanding of the biology of 
acute myeloid leukemia and the available treatment regimens. The controversial 
history of the cancer stem cell hypothesis and its experimental validation with the 
discovery of the leukemia stem cell was discussed. In particular, we focused on 
the concept of eliminating LSCs as the crux for curing AML. We provided evidence 
that some of the earliest implementations of “immunotherapy” in the form of stem 
cell transplant could eradicate AML LSCs. We then introduced the novel AML LSC 
marker, CD200, and summarized existing literature pertaining to its role in stem 
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cell biology and immunology. Emerging immunotherapeutic strategies designed to 
specifically target CD200-expressing cells was also reviewed.  
We hypothesized that, in the majority of AML, CD200 expression was 
ectopically expressed specifically in LSCs as a mechanism for evading members 
of both the innate and adaptive immune system. In order the address this 
hypothesis, we had to (1) establish CD200 as a novel marker of functional AML 
LSCs, (2) characterize the interaction between CD200+ AML and important 
immune cell subsets, including T-, NK-cells, and macrophages, and (3) assess the 
feasibility of therapeutically targeting CD200+ AML with a novel antibody.  
 In Chapter II, we sourced the wealth of publicly available data to generate 
a master AML LSC database that contained genome-wide expression from 3 
different publications.  By treating each dataset as an independent biological 
replicate, we were able to robustly identify CD200 as a novel marker of AML LSCs 
at the gene expression level. We independently confirmed that >90% of AML cases 
contained a subset of leukemia cells that expressed cell-surface CD200 protein 
and that expression of CD200 largely correlated with the established stem cell 
marker, CD34. We further demonstrated that even within CD34+ cells, CD200 
more accurately identified functional AML LSCs using colony formation assays.  
The ability of CD200 to identify LSCs was conserved in a model of murine AML.  
 To study CD200 more systematically, we generated 2 isogenic cell lines 
models. In one of the only AML cell lines to express CD200 at appreciable levels 
in the wild type setting, Kasumi1, we performed CRISPR/Cas9 to knockout 
expression. In the OCI-AML3 model, which lacked detectable CD200 expression 
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at both the gene and protein level, we introduced high levels of the canonical 
CD200 isoform using electroporation integration. In cell lines, manipulation of 
CD200 resulted in no obvious phenotypic changes in cell growth or metabolism; 
negating CD200 as an essential gene. This is consistent with the observation that 
Cd200 null mice are viable. However, RNA-seq of both isogenic cell systems 
revealed that the CD200+ version of each line transcriptionally upregulated genes 
involved in the double-strand DNA repair response. This translated to differential 
response to DNA-damaging agents; a novel observation that needs to be studied 
in greater detail.  
 Finally, leveraging mass cytometry clinical trial data of refractory/relapsed 
AML treated with hypomethylating agents in combination with an anti-PD-L1 
inhibitor, we observed that CD200 was present in subsets of disease resistant to 
this particular immunotherapy. Upon further investigation, CD200 was also found 
to correlate with critical immune checkpoints including PD-L2 and TIGIT, 
implicating CD200 as a relevant marker of immunosuppression. In light of these 
findings, we next set out to methodically characterize the role of CD200 in the 
interaction between AML and immune cells.  
 In Chapter III, we first prioritized subsets of immune cells with high levels of 
the CD200 receptor at both the gene and protein level. Based on these results, we 
then focused on the isolated interactions between CD200+ and CD200- leukemia 
cell lines and (1) T cells, (2) NK cells, and (3) macrophages. Using co-culture 
experiments, we confirmed that CD200+ AML suppressed the MAPK signaling 
pathway in adjacent T cells. We also found that CD200+ leukemia robustly 
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abrogated signaling through the STAT3 pathway; a major regulator of cytokine 
production. Functionally, altered T cell signaling translated to a significant 
suppression of T cell production of inflammatory cytokines and cytotoxic enzymes 
as well as stunted proliferation.  However, this did not directly result in differential 
killing of AML cells.  
 In the interaction of AML and innate immune cells, we demonstrated that 
CD200 significantly suppressed inflammatory cytokine production from 
macrophages but did not appear to regulate basal phagocytosis. CD200+ OCI-
AML3 cells were significantly protected from NK cell-mediated cytotoxicity, 
however, CD200 did not appear to play a critical role in regulating NK cell cytokine 
production.  
CD200 expression on OCI-AML3 AML cells does not alter the ability of cells 
to engraft and expand in an immunocompromised NSG mouse model. However, 
when the same NSG mice were humanized one week prior to leukemia exposure 
using healthy human PBMCs, CD200 presence became critical. While both 
CD200+ and CD200- OCI-AML3 cells were capable of engrafting in humanized 
mice, only CD200+ AML was able to persist in the presence of graft-versus-
leukemia and graft-versus-host disease. In fact, this response could completely 
eliminate AML cells lacking CD200. CD200 status did not significantly alter the 
expansion of healthy human CD45+ cells. However, cytokine secretion in mice 
exposed to CD200+ AML was significantly reduced. Further, these same T cells 
were universally metabolically quiescent at the transcriptional level. Based on 
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these results, we next asked whether anti-CD200 antibody therapy could mimic or 
even enhance the anti-leukemic effects seen in the CD200- cell lines.  
In Chapter IV, we developed and characterized a novel, fully-humanized 
anti-CD200 antibody with an IgG1 backbone. We chose to leverage the variable 
region of the existing anti-CD200 antibody, samalizumab, well characterized to 
block the interaction of CD200 with its cognate receptor. However, replacing the 
chimeric IgG2/G4 constant region with that of IgG1 allowed for a therapeutic that 
would (1) remove the suppressive CD200 signal while (2) potently engaging 
members on the innate immune system.  
CD200-IgG1 bound the CD200 antigen with sub-digital nanomolar avidity 
and could efficiently block binding to CD200R. While there was evidence of 
cytokine secretion from T cells in the AML co-cultures treated with both CD200-
IgG1 and samalizumab, neither antibody was capable of completely restoring 
cytokine production in the presence of CD200+ AML. CD200-IgG1, but not 
samalizumab, potently induced NK cell cytokine secretion and CD200-specific 
ADCC. In macrophages co-cultured with AML, both CD200-IgG1 and 
samalizumab promoted cytokine production and induced phagocytosis of CD200+ 
AML cells.  
In immunocompromised NSG mice, anti-CD200-IgG1 therapy selectively 
reduced and redistributed CD200+ AML from the liver and bone marrow to the 
spleen, that translated to prolonged overall survival. In the PBMC-humanized 
model, graft-versus-host combined with anti-CD200-IgG1 therapy could 
completely eliminate disease and substantially alter the T cell composition. In 
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summary, novel CD200-IgG1 therapy improves anti-leukemic efficacy by both 
removing the immunosuppressive effects of CD200 and by stimulating NK cells 
and macrophages in vitro. Only in the humanized mouse model could CD200+ 
leukemia be completely eliminated with CD200-IgG1 therapy, suggesting the 
requirement of a cooperative effort from both innate and adaptive immune cells.   
 Taken together, these experiments suggest that CD200 is a novel AML 
stem cell-specific regulator of immune function. CD200+ AML robustly suppressed 
cytokine production from various members of immune cells including T cells, NK 
cells, and macrophages. Importantly, anti-CD200 antibody therapy, combined with 
cellular immune response, could completely eradicate CD200+ disease in a 




5.2 Future Investigations 
	
Confirm CD200 is a functional stem cell marker in vivo.  
Our data indicates that even within CD34+ cells, CD200 can further refine 
AML LSCs in vitro. However, the definite test of functional AML LSCs is the ability 
of cells to engraft in sublethally irradiated NSG mice. While published data from 
Ng et al suggest that CD200 expression is significantly higher in functional stem 
cells in vivo, this needs to be explicitly tested. Preliminary experiments by Ho et al 
showed that in AML cases where CD200 was expressed at appreciable levels 
(>5% of blasts), all cells capable of engrafting in mice were CD200+
56,161
. This 
included cells that were both CD34+ and CD34-. In accordance with our findings, 
they also observed the utility of CD200 as a marker for LSCs in cytogenetically 
normal NPM1 mutant AML cases that lack CD34 expression. To better understand 
the molecular mechanisms that differentiate functional AML LSCs, single-cell 
RNA-seq should be performed on paired CD200+CD34+, CD200-CD34+, 
CD200+CD34-, and CD200-CD34- cells from the same patient. It would also be of 
interest to collect human AML cells immediately after engraftment and assess the 
distribution of known and predicted stem cell markers by CyTOF.   
 
Elucidate the intrinsic function of CD200.  
The cell line models used for in vitro characterization of CD200 function 
lacked endogenous CD200 receptor expression, therefore, we did not expect to 
see any intrinsic phenotype. Indeed, we saw no obvious differences in the growth, 
metabolism, or engraftment potential of cells with or without CD200 expression. 
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However, we were surprised find that in both isogenic models, CD200+ cells were 
enriched for gene signatures associated with the DNA damage response. Genetic 
components of the Fanconi Anemia pathway and double-strand DNA repair 
response were consistently upregulated in CD200+ AML regardless of the cell line 
background or the method used to genetically modify CD200 (i.e. CRISPR/Cas9 
or electroporation integration), largely negating the likelihood of technical artifacts. 
In a preliminary experiment, our results demonstrated that these transcriptional 
differences did, in fact, translate to functional changes in the response to DNA 
damaging agents like hydroxyurea. The precise mechanism by which CD200 
participates in the control of these pathways remains to be discovered. We 
hypothesize that CD200 regulates the transcription of DNA damage machinery by 
either (1) autocrine signaling through an undiscovered binding partner or (2) a 
novel mechanism of signaling through the cytoplasmic tail of the CD200 protein.  
   Identify of novel CD200 binding partners. The majority of existing literature 
indicates that the CD200 receptor is the exclusive binding partner of the CD200 
ligand. However, emerging data suggests that there may be other, well-
characterized receptors that can recognize and signal in response to CD200 
ligation. In the central nervous system, recombinant CD200 has been shown to 
induce neurite outgrowth and survival
162
. The growth phenotype could be reversed, 
in a dose dependent manner, using an inhibitor of the fibroblast growth factor 
receptor (FGFR) or by introducing a dominant negative FGFR. These results, 
along with the discovery of an FGFR binding motif in the first Ig-like module of 
CD200, suggest that CD200 functions as a novel ligand for FGFR in neurons.  
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 Based on our RNA-seq data, Kasumi cells express high levels of the FGFR1 
transcript while OCI-AML3 cells have very little. To confirm if FGFR1 is also a 
receptor of CD200 in AML, first, protein expression of the receptor needs to be 
confirmed in the cell line model systems and primary AML patient samples by flow 
cytometry or western blot analysis. Next, activity of components of the FGFR1 
signaling pathway, including MAPK, PI3K-AKT, PLCγ, and STAT, should be 
assessed by western blot in the CD200+ and CD200- cell lines. If there is 
differential activity at baseline that can be reversed using an FGFR1 inhibitor, this 
would indicate that CD200 may induce autocrine signaling through FGFR1 in AML.  
 In light of these results, the possibility that even more unidentified CD200 
binding partners exist should further investigated. This could be pursued by 
multiple avenues. Binding motif analysis could be performed to identify a number 
of receptor candidates for in vitro validation. Alternatively, we could employ a 
genome-wide CRISPR activation screen to unbiasedly identify all potential 
activating receptors for the CD200 ligand
163
.   
 Determine signaling potential of the CD200 cytoplasmic tail. Until recently, 
the only reported role of CD200 was through its extracellular interaction with 
neighboring immune cells. This exclusive functionality was based on the 
observation that the short, intracellular portion of the CD200 protein lacked an ITIM 
or docking site for other signaling molecules. Chen et al have now offered an 
alternative signaling mechanism by which the CD200 cytoplasmic domain, or C-
tail, can act directly as a transcription factor in chronic lymphocytic leukemia
109
. 
More specifically, they proposed that upon γ-secretase cleavage, C-tail could 
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translocate to the nucleus where it directly binds DNA and alters expression of 6 
transcription factors; KLF5, DACH1, TSSC1, ARGLU1, POTEA and PLEKHG4B. 
While compelling, this study had numerous limitations. First, this phenomenon was 
not present at baseline but required external stimulation in the form of phorbol 12-
myristate 13-acetate (PMA). PMA is a potent activator of protein kinase C (PKC) 
that results in the release of Ca
++
 and initiation of a non-specific T cell signaling 
cascade
164
. Thus, the transcriptional alterations reported cannot necessarily be 
attributed to the C-tail. Second, induction of constitutive C-tail expression in CLL 
cells alone did not appear to have a significant functional effect. Finally, the readout 
of C-tail activity was strictly confined to the expression of the 6 genes identified 
using ChIP-seq. However, the ChIP-seq screen was performed without an 
appropriate antibody-only control. Therefore, the true functional effect of the C-tail 
may not have been adequately captured by these experiments. Despite these 
limitations, there is strong evidence that CD200 can be cleaved and result in a 
small intracellular protein fragment whose precise role requires further 
investigation.  
 Understand the interaction between CD200 and cathepsin G. We 
performed preliminary co-immunoprecipitation experiments with mass 
spectrometry to identify potential CD200-interacting proteins that might play a role 
in cleavage and subsequent internal signaling. These experiments unbiasedly 
identified cathepsin G (CTSG) as a potential protein of interest. CTSG is a 
azurophil granule protease that is broadly expressing in AML and has been well 
characterized as an immunotherapeutic target
123,165
. CTSG is traditionally thought 
	 169	
to function as part of the innate host defense and neutrophil-mediated immune 
response
166
. However, cathepsin G also plays an important role in cleaving a 
variety of proteins to produce functionally unique substrates. For example, CTSG 
has been reported to cleave full length IL-33 to produce more highly bioactive 
forms that may function as signals of endogenous danger
167
. CTSG is also 
responsible for producing the cleaved form of STAT5 (STAT5 γ) that contributes 
to myeloid cell differentiation
168
. In AML, CTSG has also been reported to cleave 
the AML1 portion of the AML1-ETO fusion protein, resulting in proteasomal 
degradation and partial recovery of differentiation
169
. 
 In a preliminary experiment, we found that recombinant human CD200 was 
cleaved by CTSG to produce a fragment protein <10kDa similar to the previously 
reported C-tail (Figure 43). To confirm this cleavage product is in fact a peptide of 
CD200, the low molecular weight protein should be confirmed by mass 
spectrometry. Next, the isogenic cell lines with and without CD200 should be 
examined by western blot analysis to look for presence and abundance of CTSG 
and CD200 cleavage products. Further, the CD200+ cells could also be treated 
with recombinant CTSG to confirm that cleavage can be induced exogenously. 
These same western blot experiments should also be repeated with primary AML 
patient samples that express appreciable levels of CD200.  
While the above experiments are focused on CTSG, there exist numerous 
other proteases, including granzymes
170
 and matrix metalloproteases
171
, that have 
been implicated in pre-processing full-length cytokines and proteins. The potential 
interaction of the proteases with CD200 warrants further investigation. 
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 To functionally characterize the C-tail fragment of CD200, I would propose 
the following experiments. First, confocal microscopy should be performed on AML 
cell lines and patient samples to detect the presence and distribution of CD200 C-
tail in the cytoplasm and nucleus. Next, we could perform ChIP-seq with 
appropriate controls to determine whether CD200 does, in fact, directly bind DNA. 
I would also propose that co-immunoprecipitation with mass spectrometry be 
performed on both a CD200+ cell line and patient sample to more definitively 
identify potential interacting partners. Together, these experiments would provide 
insight on the potential role of CD200 as part of a transcriptional complex and as 
to whether CD200 C-tail is directly responsible for the changes seen in DNA 
damage machinery. To confirm these findings, we could construct cell lines 
engineered to conditionally express either full-length CD200 or C-tail protein. The 
functional contribution of each version of CD200 would be compared using cell 




Figure 43. Cathepsin G cleaves CD200. Recombinant human CD200 was 
incubated with increasing concentrations of CTSG and assessed by western blot 
for the detection of CD200 cleavage. The same membrane was probed first for 




Investigate AML cell resistance to cytotoxic lymphocytes.  
The two primary mechanisms of NK- and T cell-mediated cytotoxicity are 
(1) through activation of the FAS receptor pathway on target cells or (2) by the 
production of granules containing cytotoxic enzymes
172
.  In the first, FAS ligand, 
both effector cell-bound and soluble, binds the FAS receptor on target cells and 
leads to trimerization, activation of the FAS-associated death domain signaling 
pathway, and subsequent apoptosis via caspase 8
173
. The second, more dominant 
mechanism of cytotoxicity involves the exocytosis of granules equipped with 
perforin and granzymes
174
. The perforin released from cytotoxic effectors can 
either aggregate at the surface of target cells causing osmolysis or act as a 
transport medium through the cell membrane for the adjacent granzymes
175
. Once 
inside the cell, granzymes, particularly granzyme B, activate programmed cell 
death through the activation of caspase 8 and caspase 3
176
.    
Our data presented in Chapter III indicate that the AML cell lines OCI-AML3 
and Kasumi appear largely resistant to T and NK cell cytotoxicity, with the highest 
effector to target ratios achieving only roughly 50% killing. Other groups have also 
demonstrated that leukemia, in general, is largely resistant to FAS-mediated cell 
death, while myeloid leukemias are uniquely perforin-resistant
177,178
. In line with 
previous reports, RNA-seq data of the AML cell lines indicated very low levels of 
FAS receptor, suggesting downregulation of the receptor as a potential mechanism 
of resistance
179
. The nature of AML resistance to perforin-mediated cytotoxicity 
may be attributable to the underlying myeloid biology. As first responders of the 
innate immune system, polymorphonuclear cells, derived from monocytes, are 
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involved in the inflammatory response and constitutively express perforin
180,181
. 
Thus, such cells must have intrinsic defenses in place to protect them from their 
own cytotoxic response.   
Previous studies have attempted to elucidate the molecular mechanisms by 
which cytotoxic cells escape self-killing. Early biochemical experiments suggested 
the presence of an inhibitory protein on the surface of perforin-resistant cells that 
was capable of inducing a conformational change in the perforin that rendered it 
inactive and prohibited the membrane pore formation
182,183
. Multiple proteins have 
since been proposed to fulfill this protective role in cytotoxic lymphocytes including 
cathepsin B (CTSB)
184
, serpin B9 (SERPINB9)
185
, and LAMP1 (CD107a)
186
. While 
now studied in the lymphoid compartment, their contribution to perforin-resistance 
of myeloid cells, including myeloid leukemias remains unknown. Using the publicly 
available RNA-seq data from Corces et al88, we assessed the gene expression of 
CTSB (Figure 44A), SERPINB9 (Figure 44B), and CD107a (Figure 44C) in healthy 
hematopoietic cells, AML LSCs, and blasts. Although identified in cytotoxic 
lymphocytes, all 3 genes had the highest expression in monocytes. Myeloid 
leukemia cells also expressed high levels of the reported perforin-resistance 
genes. In a preliminary flow cytometry experiment, we confirmed that CD107a was 
expressed at the protein level in the Kasumi AML cell lines at a log-fold higher 
abundance than activated T cells (Figure 44D). Taken together, our data suggests 
that AML cells may be inherently resistant to the perforin-mediated cytotoxicity 
invoked by effector T and NK cells. 
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To test this hypothesis, we should first generate and characterize CTSB, 
SERPINB9, and CD107a knockout AML cell lines using CRISPR/Cas9. Differential 
AML cell killing could then be evaluated using the mixed lymphocyte assays 
described in detail in Chapter III. To confirm that the effect is specifically though 
the inactivation of cell-bound perforin, cell lines could be treated with isolated 
cytotoxic granules or recombinant perforin protein to assess cell membrane 
integrity and lysis. Novel mechanisms of perforin resistance specifically to AML 
should be identified by performing a CRISPR/Cas9 screen. Briefly, a custom-made 
library of guide RNAs targeting AML cell surface proteins and known 
immunoregulators will be delivered by lentivirus to the AML cell line. Cells will then 
be treated with recombinant perforin or cytotoxic granules. Surviving cells will be 
sequenced to back calculate which guide RNAs resulted in increased perforin 
sensitivity. Clinically, it would be of interest to know if expression of these perforin-
resistant proteins on primary AML patient samples act as poor prognostic markers 
or identify cases that fail to respond to existing immunotherapies. The results of 
such studies would be critical to consider in the context of emerging 
immunotherapies that attempt to eliminate AML by directly engaging cytotoxic 






Figure 44. Perforin-resistant genes are expressed in healthy monocytes and 
AML. A-C. RNA-seq gene expression of CTSB (A), SERPINB9 (B), and CD107a 
(C) across healthy components of hematopoiesis (green) as well as AML (red), 
ordered by increasing differentiation. D. Flow cytometry analysis of cell surface 
CD107a expression in WT and CD200ko Kasumi cells compared to artificially 









Determine the role of CD200 and anti-CD200 therapy in humanized mouse models 
without GvHD.  
 To study the interactions between human AML and components of the 
human immune system in a physiological setting, we chose to use a PBMC- 
humanized mouse model. It has been previously shown that transplantation of 
healthy, human mononuclear cells into NSG mice results in the almost exclusive 
(>93% of hCD45+ cells) expansion of polyclonal T cells
187
. These human-educated 
T cells homed to various organs where they become activated and mediated 
GvHD. Translationally, this model mimics the scenario seen in AML patient 
samples after allogeneic stem cell transplant. In this setting, our data showed that 
CD200 played a critical role in protecting AML cells from immune-mediated 
clearance in the presence of aggressive GvHD and that effective antibody therapy 
against CD200+ AML required human T cells.  
 To understand the interaction between the immune system and CD200+ 
leukemia cells without the GvHD component, we need to employ a different form 
of humanized mice. The Hans-Peter lab has developed a system in which human 
CD34+ hematopoietic stem and progenitor cells are transplanted into the livers of 
irradiated neonatal NSG mice, essentially replacing the murine hematopoietic 
system for human
121
. With this approach, human T cells, B cells and monocytes 
are differentiated and educated within the mice and persist without attacking the 
host for more than 8 months. In a preliminary experiment in this in vivo system, we 
confirmed that both CD200+ and CD200- OCI-AML3 cells were capable of 
engrafting and expanding in the presence of a murine-raised human immune 
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system. To see if the pattern of cytokine inhibition was similar to that in the PBMC-
humanized model, we performed flow cytometry analysis on the serum of a 
representative mouse from each group, using a CD34-humanized mouse without 
leukemia as a control. In contrast to the PBMC-humanized model where we saw 
global inhibition of cytokine production, the CD34-humanized mice demonstrated 
a distinct immune response to either CD200+ or CD200- leukemia (Figure 45). 
While critical inflammatory cytokines including IL-4, IL-6, IL-17a, and TNFα were 
suppressed in the presence of CD200+ leukemia, there appeared to be an 
enrichment of cytotoxic enzymes like perforin, granzyme A, and soluble Fas. This 
suggests that murine-raised T cells are capable of activation in response to human 
AML cells but that CD200 still suppresses cytokine secretion.  
 To complete this investigation, we plan to expand this study and engraft 
CD34-humanized mice with either CD200+ or CD200- OCI-AML3 cells (20 mice 
per group with 10 control mice). After engraftment is confirmed by bioluminescence 
imaging, we will treat a subset of each leukemia group (10 mice each) with the 
CD200-IgG1 similar to the design presented in Chapter IV. At the end of the 
antibody administration, 3 mice per cohort will be sacrificed to characterize the 
immune cell composition by both CyTOF and single-cell RNA-seq. For the 
remaining mice, circulating lymphocytes and serum cytokine concentrations will be 
monitored weekly by flow cytometry and overall disease burden will be assessed 
by bioluminescence. We anticipate that CD200 will provide an immune advantage 
for the leukemia cells and anti-CD200 antibody therapy will similarly result in 
disease clearance and prolonged overall survival.   
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Figure 45. Secreted cytokines in CD34-humanized mice. A. Bioluminescence 
imaging of CD34-humanized mice with OCI-AML3 leukemia at the time of blood 
collection. B. Summary flow cytometry data of secreted cytokines in the plasma 
of each mouse in panel A. 
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Assess the role of CD200 in reprogramming immune cell metabolism. 
 One of the most surprising findings of this study was the universal 
suppression of lymphocyte metabolism in humanized mice exposed to pCD200 
OCI-AML3 leukemia when compared to those exposed to pGFP cells. Despite 
similar abundance and composition of T cells, human cells harvested from mice 
exposed to the CD200+ leukemia showed evidence of inhibited oxidative 
phosphorylation (OXPHOS), glycolysis, glucogenesis, pyrimidine metabolism, and 
fatty acid metabolism (Chapter III). The ability of T cells to proliferate and perform 
appropriate effector functions is dependent on a significant increase of 
bioenergetic production. In order to meet these vast energy demands, activated T 
cells undergo metabolomic reprogramming from OXPHOS and fatty acid oxidation, 
sufficient for naïve cell maintenance, to glycolysis and glucogenesis
188
. However, 
our data suggests that both naïve and activated lymphocytes in mice with CD200+ 
leukemia are metabolically impaired. Insufficient T cell metabolism could explain 
the diminished cytokine production in these mice. The alterations in 
immunometabolism could be explained by either (1) a direct mechanism through 
CD200/CD200R signaling or (2) unique differences in the tumor microenvironment 
created by CD200+ leukemia.  
 To address the first regulatory mechanism, I would propose the following 
experiments. T cells will be treated with either excess blocking CD200 antibody or 
a control IgG prior to exposure to either CD200+ of CD200- OCI-AML3 cell lines. 
After 24 hours, T cells will be reselected and tested for metabolic fitness using 
Seahorse technology. If the primary regulator of T cell metabolism is through 
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CD200R signaling, we will see impaired T cell function only in those exposed to 
CD200+ leukemia without blocking antibody. If the effect is due to leukemic 
contribution to the microenvironment, we will see impaired metabolism in T cells 
exposed to CD200+ leukemia with or without blocking antibody therapy.  
 Tumors can also have significant effects on lymphocyte function even 
without direct interaction through nutrient deprivation, waste accumulation, pH 
alterations, and oxygen availability
189
. To determine if CD200+ cells differentially 
alter the microenvironment, metabolomics profiling should be performed on the 
supernatant from the AML:T cell co-culture experiments as well as serum obtained 
from the humanized mice. Similarly, pH and oxygen concentrations of these 
samples should also be evaluated. Taken together, this data could provide 
evidence that CD200 plays a novel in modifying the metabolic microenvironment.  
 Furthermore, the discussion above focuses primarily on the metabolic 
reprogramming of T cells, as those were the most abundant cell population 
evaluated by RNA-seq. However, all effector cells are regulated by the systemic 
metabolic changes induced by leukemia. For instance, macrophage differentiation, 
polarization, and activation can be directly influenced by nutrient availability
190
. 
Similarly, NK cells rely significantly on glycolysis and OXPHOS for cytokine 
production and cell-mediated cytotoxicity
191
. Thus, I would propose similar co-
culture experiments of CD200+ and CD200- leukemia with isolated NK cells and 




Compare and contrast the roles of CD200 and CD47 in AML. 
 CD200 and CD47 have been both reported as negative regulators of 
macrophage function through the binding of their respective receptors, CD200R 
and SIRPα, that share structural similarities
192,193
. The unique patterns of 
ligand/receptor distribution are also similar for CD200/CD200R and CD47/SIRPα, 
with broad expression of the ligand and receptor expression restricted to myeloid 
and a subset of lymphoid cells
132
. However, using publicly available gene 
expression datasets, we found that the pattern of CD200 and CD47 differs within 
the hematopoietic compartment (Figure 46A). More specifically, CD200 is 
expressed at appreciable levels only in undifferentiated stem/progenitor cells and 
B cells, while CD47 is ubiquitously expressed across all hematopoietic cell 
subsets, including mature myeloid cells like macrophages.  
In AML, only CD47 has been investigated as a therapeutic target for 
leukemia stem cells. The lab of Irving Weissman was the first to demonstrate that 
hematopoietic stem and progenitor cells from CD47-null mice were incapable of 
engrafting in wild type recipient mice as a result of increased phagocytosis of these 
cells
194
. Interestingly, and consistent with the original study identifying CD47 as a 
regulator of phagocytosis, this phenomenon appeared to occur only when CD47-
null target cells interacted with CD47-expressing phagocytes
195
. Furthermore, they 
showed that monoclonal antibodies against CD47 could preferentially lead to 
targeted phagocytosis of AML cells and impaired engraftment
113
. These 
discoveries have since been translated to the development of the clinical anti-
CD47 antibody, Hu5F9-G4, that is now in a variety of clinical trials for leukemias, 
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lymphomas, and other solid tumors
196
. While generally well-tolerated, many 
patients experienced transient anemia as a result of the elimination of CD47+ 
erythrocytes
197
. The ubiquitous expression of CD47 also mandated that antibody 
therapy be administered at higher doses for a longer duration than other antibody 
strategies.      
Taken together, we hypothesize that anti-CD200 is a more rational 
therapeutic strategy for specifically targeting AML LSCs. In Chapter III, we 
confirmed that CD200 expression does not alter CD47 levels. We performed 
preliminary experiments to compare the efficacy of our CD200-IgG1 antibody 
against the clinically available Hu5F9-G4 (5F9). In the Kasumi cells, that 
expressed low levels of CD200 in the wild type setting, we found the same 
frequency of phagocytosis of CD200+ cells after treatment with either antibody 
(Figure 46B). This result was surprising as Kasumi cells express much higher 
levels of CD47 when compared to CD200. However, in the OCI-AML3 line, with 
substantial over-expression of CD200, we found significant phagocytosis only of 
CD200+ cells treated with the CD200-IgG1 antibody (Figure 46C). The variability 
in response to either antibody suggests that there are other intrinsic factors that 
contribute to phagocytosis of AML that are differentially regulated between 
CD200+ and CD200- cells as well as between different AML subtypes. Elucidating 
these unknown factors and understanding potential interactions between CD200-




Figure 46. Comparison of CD200 and CD47 expression and antibody 
therapies. A. RNA-seq gene expression of either CD47 (green) or CD200 (red) 
across healthy components of hematopoiesis ordered by increasing differentiation 
from Corces et al88. CD200+ and CD200- Kasumi (B) or OCI-AML3 (C) cells were 
co-cultured with monocyte-derived human macrophages and treated with 10 
μg/mL or either CD200-IgG1 or 5F9. Phagocytosis was assessed by flow 
cytometry after 4 hours. 
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Assess the contribution of complement to CD200+ AML protection and CD200-
IgG1 therapy. 
 While Chapter IV investigated the role of CD200-IgG1 in NK cell-mediated 
ADCC and macrophage-mediated ADCP, complete characterization of this 
antibody requires the evaluation of complement dependent cytotoxicity (CDC). The 
complement system is comprised of over 30 proteins that function as one of the 
primary mechanisms of antibody-mediated immunity
198
. The classical complement 
pathway is activated when C1q proteins recognize and bind the constant region of 
IgG1, IgG3, or IgM antibodies resulting in the formation of membrane attack 
complexes and ultimate cell lysis
199
. To assess CDC in vitro, we will treat CD200+ 
and CD200- AML cells with either the CD200-IgG1, samalizumab, or control 
antibodies in the presence or absence of human serum. Cell membrane integrity 
will be assessed by propidium iodide uptake
200
. We expect that only the CD200-
IgG1 antibody will result in specific CD200+ AML cell lysis, as the constant region 
of samalizumab will not be recognized by complement. In vivo validation of CDC 
will be more challenging as the majority of immunocompromised mice, including 




 Unrelated to antibody function, we were surprised to find that the 
complement component 3 gene, C3, was one of the most significantly 
downregulated genes in pCD200 OCI-AML3 cells when compared to pGFP OCI-
AML3 by genome-wide RNA-seq (Figure 47A). While this pattern was consistent 
in Kasumi, neither CD200+ nor CD200- cells expressed high levels of the C3 
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transcript. C3 is a critical member of both the classical and alternative complement 
activation pathways. We attempted to confirm this finding in OCI-AML3 at the 
protein level by measuring one of the prominent cleavage products, C3b, using 
cell surface flow cytometry (Figure 47B). In media with heat-inactivated serum, 
there was negligible detection of surface C3b protein in either cell line model. 
However, when cultured in media with activated human serum, pGFP OCI-AML3 
cells bound significantly more surface C3b than pCD200 cells. C3b is a potent 
opsonizing agent that contributes to enhanced phagocytosis of flagged 
antigens
202
. Again, using the Corces et al RNA-seq dataset, we observed that C3 
transcript is expressed exclusively in healthy monocytes and leukemia blast cells 
(Figure 47C)
88
. The almost complete lack of C3 expression in LSCs when 
compared to blasts is consistent with the pattern seen in OCI-AML3 cells where 
the introduction of the stem cell marker, CD200, results in downregulation of C3. 
The mechanisms by which CD200 regulates C3 transcription as well as the 
interaction between CD200 and C3b protein at the cell surface both require further 
investigation.   
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Figure 47. Complement C3 is altered in CD200+ AML. A. C3 RPKM levels in 
CD200+ (red) and CD200- (green) in Kasumi and OCI-AML3 cells. B. Cell surface 
C3b protein expression in pCD200 (red) and pGFP (green) OCI-AML3 cells 
cultured with inactive (baseline) and active (+serum) human serum. C. RNA-seq 
C3 gene expression in healthy (green) and leukemia (red) cell populations.   
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Investigate alternative CD200 antibody therapeutics strategies.  
 Bi-specific antibodies. While the CD200-IgG1 initiated potent and specific 
antibody-mediated cytotoxicity of CD200 positive leukemia cells, there are 
emerging avenues that allow for the strategic improvement of antibody-alone 
therapy. One such strategy involves fusing the binding regions of two antibodies 
to one common IgG backbone, thus allowing for the simultaneous targeting of two 
epitopes with a single antibody. This can be used to target multiple AML LSC 
markers at once; for example, dual targeting of CD200 along with another known 
leukemia specific marker like CLEC12A
203
. However, bi-specific antibodies are 
more commonly employed to bridge together AML cells and effector T or NK cells. 
AMG330 is an example of a bi-specific T cell engager (BiTE) antibody against AML 
that functions by simultaneously binding the CD3 epitope on T cells and CD33 on 
AML and encouraging a cytotoxic synapse
204
. There are two immediate 
shortcomings of the engager antibody approach. First, for this therapy to effective 
as a single agent, it requires that all leukemia cells express the same target 
epitope. While this may be applicable in lymphoid malignancies, like B cell 
leukemia where all cells express CD19, we now appreciate that such strategies 
are not feasible in AML due to the vast heterogeneity of disease. Second, this 
therapeutic strategy relies on the assumption that the engaged effector cell alone 
is capable of killing leukemia cells. The data presented in this dissertation suggests 
that not all AML cells are sensitive to T cell mediated cytotoxicity.      
 Toxin-conjugated antibodies. The epitope-specificity of antibodies can also 
be harnessed for targeted drug delivery. By conjugating a drug to a known 
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antibody, we can better guarantee that the drug makes it to the cell of interest while 
limiting off-target effects. Gemtuzumab ozogamicin is a calicheamicin-conjugated 
CD33 antibody that aims to specifically deliver the chemotherapeutic payload to 
CD33+ cells that is FDA approved for the treatment of AML
205
. While this approach 
is also limited by the ability to deliver to only a single epitope, it does allow for a 
higher dose of delivery than could be achieved by administering the chemotherapy 
systemically. In the context of the data presented here, I would propose 
conjugating a known AML LSC-specific therapeutic agent, like the BCL-2 mimetic, 
venetoclax, to the CD200-IgG1 antibody. We have preliminary data suggesting 
that CD200+ leukemia cells are more sensitive venetoclax than CD200- cells from 
the same patient. This therapeutic could be administered after induction 
chemotherapy to specifically eliminate residual AML LSCs and reduce likelihood 
of relapse.    
 
Investigate novel uses for CD200-antibody therapy.  
 This body of work demonstrates the rationale and utility of therapeutically 
targeting CD200 in the context of AML. However, the inhibitory mechanisms and 
CD200 antibody efficacy described here could likely be extrapolated to any tumor 
type with overexpression of CD200 including melanoma, glioblastoma, colon, 
prostate, and breast cancers
55,206-208
. However, we also posit that CD200 therapy 
could be utilized outside the context of cancer alone.  
CD200 antibody as checkpoint therapy in activated T cells. While PD-1 and 
CTLA-4 are the most well-understood checkpoints of immune activation, control of 
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adaptive T cell response complex and involves many emerging players
209
. It was 
previously reported that CD200 and CD200R were both upregulated on T cells in 
response to stimulation by mesenchymal stromal cells in vitro but were not 
involved in T cell proliferation
210
. Furthermore, Zappasodi et al identified a 
population of CD4+FOXP3-PD1
hi
 cells that transcriptionally resembled follicular 
helper T cells and significantly impaired T cell effector functions
211
. This novel 
immune cell subset exclusively upregulated CD200 in both human and mice. 
These data point to CD200 as a novel immune checkpoint with uncharacterized 
function.   
 Using western blot and flow cytometry, we independently confirmed that 
CD200 expression is upregulated in T cells, particularly those of CD4 lineage, upon 
CD3/CD28 stimulation (Figure 48A-B). To determine the functional effect of CD200 
upregulation on activated T cells, we treated both resting and stimulated cells with 
either a blocking CD200 antibody or nanobody and measured secreted cytokine 
abundance (Figure 48C). As expected, T cells exposed to CD3/CD28 activating 
beads almost universally upregulated inflammatory cytokines and cytotoxic 
enzymes. Activated T cells treated with either the antibody or nanobody approach, 
when compared to the PBS control, resulted in enhanced cytotoxic potential. The 
similar results seen between antibody and nanobody treated cells indicate that 
response is most likely through blocking the CD200/CD200R interaction. Further, 
the functional recovery of activated T cells indicates that CD200 is induced as a 
mechanism of controlling T cell response through autocrine or paracrine signaling. 
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Further studies to better characterize CD200 as a novel T cell checkpoint should 




Figure 48. CD200 regulates T cell activity. CD200 expression in T cells artificially 
activated using CD3/CD38 beads for 24 hours by western blot (A) and flow 
cytometry (B). C. Cytokine production from unstimulated and CD3/CD28 
stimulated T cells treated with either anti-CD200 blocking antibody or nanobody.  
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CD200 therapy to neutralize viral orthologues. The evolution of viruses also 
provides insight into the function and importance of CD200. Natural selection 
results in viruses that are capable of avoiding detection and destruction by the host 
immune system. Viruses evade the antiviral response by mimicking important host 
immunosuppressive strategies. Full genomic sequencing of viruses has identified 
multiple, homologous immunomodulatory genes. Viral homologs of CD200, 
termed viral OX-2 (vOX-2), have now been identified in a subset of double-strand 
DNA viruses including poxviruses, herpesviruses, and adenoviruses
212-214
. The 
broad acquisition of a version of CD200 across virus families points to a strong 
selective advantage provided by the protein. However, that a viral homolog of 
CD200 is not found in every virus type suggests that it is likely not essential doe 
viral entry or replication
215
. Functional studies of these homologs support the 
hypothesis that viruses utilize the CD200-like genes to obtain an immune 
advantage by suppressing both innate and adaptive cells through interaction with 
the CD200 receptor.    
 The viral homolog of CD200 in myxoma viruses, M141R, is essential for 
lethal infection in vivo but is dispensable for viral replication in vitro215. Further, 
M141R was capable of down-regulating both macrophage and T cell activity and 
suppressed IFNγ production in a rabbit model of disease. The Kaposi’s sarcoma-
associated herpesvirus (KSHC) homolog, K14, shares 40% protein identity with 
CD200 and binds the CD200R with high affinity
213
. K14 has also been shown to 
directly interact with and inhibit effector functions of neutrophils, basophils, 
macrophages, and antigen specific T cells
213,216-218
. In summary, this data 
	 193	
suggests in the case of certain DNA viruses, CD200-like proteins may be 
overexpressed on the surface of infected cells undergoing viral replication. This 
may represent a therapeutic window whereby viral burden could be reduced by 
eliminating these cells with antibody therapy targeting the CD200 homolog. Such 
an antibody strategy could also eliminate the immune advantage provided these 
cells by blocking CD200R interactions.  
While a viral homolog of CD200 has not yet been described in severe acute 
respiratory syndrome coronavirus, SARS-CoV or SARS-CoV2, the 
CD200/CD200R axis still plays a critical role in this RNA virus setting. CD200R 
has been shown to control the TLR7 response to single stranded RNA detection. 
In a mouse model of hepatitis coronavirus (MHV), the existing in vivo model for 
SARS-CoV, elimination of CD200R signaling resulted in a significant decrease in 
viral load and had a positive effect on MHV clearance
219,220
. The mechanism of 
viral reduction was through an unabated type I interferon response. It was further 
shown that infection of a mouse-adapted strain of SARS-CoV (MA15) required the 
presence of alveolar macrophages that expressed high levels of CD200R, even 
though direct interaction between MA15 and the innate cell was not observed
221
. 
Thus, CD200 antibody therapy presents a possible treatment strategy for SARS-
CoV2 infection by inhibiting the repressive CD200R signaling in effector cells and 
promoting robust interferon production.   
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5.3 Significance and Impact 
	
 Understanding the unique immune properties of hematopoietic and 
leukemic stem cells is critical to developing targeted immunotherapeutic strategies 
to eradicate LSCs and cure AML. In this body of work, we bridged the research 
between stem cell biology and immunology to propose CD200 as an AML LSC-
specific mechanism of evading detection and destruction by the neighboring 
immune system. CD200+ cells uniquely demonstrate functional stem cell 
properties while also directly interacting with and suppressing members of both the 
innate and adaptive immune systems.  
 This dissertation also highlights the power of leveraging publicly available 
datasets for hypothesis generation. Our initial identification of CD200 was based 
on a substantial amount of data generated by labs across the world that we alone 
would never have been able to produce. By agreeing to share genome-wide data, 
we allow for fruit of our labors to become the seeds of scientific discovery for 
others. 
 Finally, clinically feasible therapies for targeting AML LSCs are urgently 
needed. We present here a novel CD200 antibody that could be rapidly translated 
to the clinic. Our data demonstrate potent anti-leukemic activity of CD200 antibody 
therapy mediated by both blocking the repressive CD200R signaling as well as 
engaging effector NK cells and macrophages.  Our humanized model systems 
suggest that successful CD200 antibody requires the interplay between both the 
innate and adaptive immune cells.  
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 While this body of work is focused on the role of CD200 on AML stem cells, 
the implications of stem cell-specific immunobiology are extensive. It is my hope 
that the studies presented in this dissertation help lay the groundwork for novel 
immunotherapies specifically designed eliminate the most evasive cancer stem 
cells and to, ultimately, help alleviate the heavy burden of cancer.     
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Appendix A  
LSC mRNA expression analysis 
1 Executive Summary 
1.1 Introduction 
Novel immunotherapeutic targets for AML LSCs are critical. To identify such 
potential candidates, we mined 3 large, publicly available datasets which contained 
whole genome expression data for paired leukemia stem cells and blasts from the 
same patient, as well as healthy hematopoietic controls. 
1.2 Datasets 
1) Corces et al: GSE74246 This dataset contains pre-aligned RNA-seq data for 
healthy hematopoietic cell subsets from 5 healthy individuals and paired 
leukemia stem cells and blasts from 10 AML patient samples. 
2) Jung et al: GSE63270 This dataset contained Affymetrix HG U133Plus 2.0 
array data for healthy hematopoietic cell subsets from 7 healthy bone marrow 
biopsies and paired leukemia stem/progenitor cells and blasts from 21 AML 
patient samples 
3) de Jonges et al: GSE30029 This dataset contains Illumina BeadChip Arrays 
(HT12 v3) array data for the CD34+ and CD34- subfractions of 46 AML patient 
samples and 31 normal CD34+ samples. 
1.3 Analysis 
For each dataset, we performed 2 ANOVA tests to; 
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1) identify of genes significantly overexpressed in LSC compared to the patient’s 
paired blast cells (using ANOVA to account for inter-patient variability) and 
2) identify of genes significantly overexpressed in LSCs when compared to un-
matched healthy HSCs 
We scored each gene as the product of the fold change and –log10 p-value. Genes 
with scores that exceeded the threshold defined below were deemed significant. 
!ℎ#$%ℎ&'( = *$(+,-(.$-$%/&#$) + 10 ∗ 456(.$-$%/&#$)1.35 	
1.4 Discussion 
Using this approach, we identified 43 genes in the intersection of all 3 datasets. 
2 Setup 











3 Corces et al analysis 
For this analysis, we can download the preprocessed RNA-seq count data from 
the supplementary files through NCBI GEO. Sample annotation can be extracted 
from the column names.  
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## load RNA-seq data 
filePaths = getGEOSuppFiles("GSE74246") 
dat <- read.delim("GSE74246_RNAseq_All_Counts.txt", header = TRUE, s
tringsAsFactors = FALSE) 
genes <- dat[,1] 
rownames(dat) <- dat$X_TranscriptID 
dat <- data.matrix(dat[,-1]) 
 
## format variable 
id <- sapply(colnames(dat), function(x) strsplit(x, "\\.")[[1]][1]) 
cell_type <- sapply(colnames(dat), function(x) strsplit(x, "\\.")[[1
]][2]) 
cell_type[which(cell_type=="Blast")] <- "Blasts" 
 
tmp_type <- cell_type 
tmp_type[which(tmp_type=="rHSC")] <- "HSC" 
keep_these <- which(!(tmp_type %in% c("CD4Tcell", "CD8Tcell", "NKcel
l", "Bcell", "Ery", "CLP"))) 
 




status <- rep("normal",length=nrow(df)) 
status[which(df$cellType %in% c("LSC","Blasts"))] <- "AML" 
df <- data.frame(df,status) 
 
p <- ggplot(df, aes(x=cellType, y=mRNA, fill=status)) + geom_boxplot
(outlier.shape = NA) +  
  geom_jitter(shape=16, size=2,position=position_jitter(0.2)) + scal
e_fill_manual(values=c("#cc0000", "#999999")) + 
  theme(text = element_text(size=20), legend.position="none",axis.ti
tle.x=element_blank()) + theme_classic() 
p 
 
3.1 Corces et al; LSC vs Blasts 
## subset cell types of interest 
ind <- which(cell_type %in% c("LSC", "Blasts")) 
sub_id <- id[ind] 
sub_cell_type <- cell_type[ind] 
sub_dat <- dat[,ind] 
 
paired_samples <- names(table(sub_id)[which(table(sub_id)==2)]) 
ind <- which(sub_id %in% paired_samples) 
sub_id <- sub_id[ind] 
sub_cell_type <- sub_cell_type[ind] 
sub_dat <- sub_dat[,ind] 
 
aovDat <- t(apply(sub_dat,1,function(x) summary(aov(x~factor(sub_id)
+factor(sub_cell_type)))[[1]][,5])) 
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aovDat <- aovDat[,-3] #subtract empty column 
colnames(aovDat) <- c("patient","lsc") 
 
diffs <- t(apply(sub_dat,1, function(tt){ 
  df <- data.frame(exp=tt,LSC=sub_cell_type) 
  mean(sapply(split(df,factor(sub_id)), function(t) diff(sapply(spli
t(t[,"exp"],t[,"LSC"]),mean)))) 
})) 
diffs <- as.numeric(diffs) 
names(diffs) <- rownames(sub_dat) 
 
gene_score <- -log10(aovDat[,2]) * diffs 










3.2 Corces et al; LSC vs HSC 
## subset cell types of interest 
tmp_type[which(tmp_type=="rHSC")] <- "HSC" 
ind <- which(tmp_type %in% c("LSC", "HSC")) 
sub_id <- id[ind] 
sub_cell_type <- tmp_type[ind] 
sub_dat <- dat[,ind] 
 
aovDat_lscVhsc <- t(apply(sub_dat,1,function(x) summary(aov(x~factor
(sub_cell_type)))[[1]][,5])) 
aovDat_lscVhsc <- aovDat_lscVhsc[,-2] #subtract empty column 
colnames(aovDat_lscVhsc) <- c("lsc") 
 
diffs <- as.numeric(apply(sub_dat,1, function(tt){ 
  mean(tt[which(sub_cell_type=="LSC")]) - mean(tt[which(sub_cell_typ
e=="HSC")]) 
  })) 
names(diffs) <- rownames(sub_dat) 
 
hsc_score <- -log10(aovDat_lscVhsc) * diffs 





threshold <- median(sub_hsc_score) + 10*IQR(sub_hsc_score)/1.35 
 
hsc_genes <- names(sub_hsc_score[which(sub_hsc_score>threshold)]) 
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corces_genes <- intersect(hsc_genes, blast_genes) 
 
save(aovDat, aovDat_lscVhsc, corces_genes, file="corces_data.RData") 
	
4 de Jonges et al analysis 
For this analysis, we download the preprocessed expression array data and 
sample annotation available directly from GEO. 
# load series and platform data from GEO 
gset <- getGEO("GSE30029", GSEMatrix =TRUE, getGPL=FALSE) 
gset <- gset[[1]] 
 
# extract expression data and annotation 
dat <- exprs(gset) 
annot <- phenoData(gset) 
annot <- annot@data 
 
## deal with garbage annotation 
sample_annot <- data.frame(matrix(ncol = 3, nrow = nrow(annot))) 
colnames(sample_annot) <- c("year", "ID","cell_type") 
for(i1 in 1:nrow(annot)){ 
  split <-  strsplit(as.character(annot$description[i1]), " ")[[1]] 
  if (length(split) == 3){ 
      sample_annot[i1,] <- split 
  }else{ 
      sample_annot[i1,] <- c( "NA", split[1:2]) 
  } 
} 
sample_annot <- data.frame(status, sample_annot) 
 
# construct probe annotation for illumina_humanht_12_v3 
ensembl = useMart("ENSEMBL_MART_ENSEMBL",dataset="hsapiens_gene_ense
mbl", host='www.ensembl.org') 
probe_annot <- biomaRt::getBM( 
  attributes = c("illumina_humanht_12_v3", "external_gene_name"), 
  mart = ensembl) 
probe_annot <- dplyr::rename(probe_annot, probe_id = illumina_humanh
t_12_v3, ext_gene = external_gene_name) 
probe_annot <- dplyr::select(probe_annot, c('probe_id', 'ext_gene')) 
ilmn_annot <- probe_annot[which(probe_annot!=""),] 
ilmn_annot <- ilmn_annot[!is.na(ilmn_annot$probe_id),] 
 
# for now we will remove promiscuous probes 
ilmn_annot <- ilmn_annot[isUnique(ilmn_annot$probe_id),] 
rownames(ilmn_annot) <- ilmn_annot$probe_id 
 
## scripts for plotting CD200 in the deJonges dataset 
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p <- ggplot(df, aes(x=cellType, y=mRNA, fill=status)) + geom_boxplot
(outlier.shape = NA) +  
  geom_jitter(shape=16, size=2,position=position_jitter(0.2)) + scal
e_fill_manual(values=c("#cc0000", "#999999")) + theme(text = element




4.1 de Jonges et al; LSC vs Blasts 
## subset cell types of interest 
sub_dat <- dat[rownames(dat) %in% ilmn_annot$probe_id,] 
ind <- which(sample_annot$status == "AML") 
sub_annot <- sample_annot[ind,] 




ind <- which(sub_annot$ID %in% paired_samples) 
 
sub_annot <- sub_annot[ind,] 
sub_dat <- sub_dat[,ind] 
 
dj_blast_aov <- t(apply(sub_dat,1,function(x) summary(aov(x~factor(s
ub_annot$ID)+factor(sub_annot$cell_type)))[[1]][,5])) 
dj_blast_aov <- dj_blast_aov[,-3] #subtract empty column 
colnames(dj_blast_aov) <- c("patient","lsc") 
 
bdj_blast_diffs <- t(apply(sub_dat,1, function(tt){ 
  df <- data.frame(exp=tt,LSC=sub_annot$cell_type) 
  mean(sapply(split(df,factor(sub_annot$ID)), function(t) diff(sappl
y(split(t[,"exp"],t[,"LSC"]),mean)))) 
})) 
bdj_blast_diffs <- as.numeric(bdj_blast_diffs) 
names(bdj_blast_diffs) <- rownames(sub_dat) 
 
dj_blast_score <- -log10(dj_blast_aov[,"lsc"]) * bdj_blast_diffs 










dj_blast_genes <- ilmn_annot[dj_blast_genes,"ext_gene"] 
 
4.2 de Jonges et al; LSC vs HSC 
## subset cell types of interest 
sub_dat <- dat[rownames(dat) %in% ilmn_annot$probe_id,] 
ind <- which(sample_annot$cell_type == "CD34+") 
sub_annot <- sample_annot[ind,] 
sub_dat <- sub_dat[,ind] 
 
dj_hsc_aov <- t(apply(sub_dat,1,function(x) summary(aov(x~factor(sub
_annot$status)))[[1]][,5])) 
dj_hsc_aov <- dj_hsc_aov[,-2] #subtract empty column 
 
 
dj_hsc_diffs <- as.numeric(apply(sub_dat,1, function(tt){ 
  mean(tt[which(sub_annot$status=="AML")]) - mean(tt[which(sub_annot
$status=="normal")]) 
  })) 
names(dj_hsc_diffs) <- rownames(sub_dat) 
 
dj_hsc_score <- -log10(dj_hsc_aov) * dj_hsc_diffs 





threshold <- median(dj_hsc_score) + 10*IQR(dj_hsc_score)/1.35 
 
dj_hsc_genes <- names(dj_hsc_score[which(dj_hsc_score>threshold)]) 
dj_hsc_genes <- ilmn_annot[dj_hsc_genes,"ext_gene"] 
 
dj_genes <- intersect(dj_hsc_genes, dj_blast_genes) 
 
save(dj_blast_aov, bdj_blast_diffs, dj_hsc_aov, dj_hsc_diffs, dj_gen
es, file="dj_data.RData") 
	
5 Jung et al analysis 
For this analysis, we cannot use the preprocessed data available through NCBI 
GEO because it uses the wrong Affymetrix CDF. Instead, we will download the 
original .cel files and perform RMA to generate the expression dataset. The original 
.cel file names contain descriptions adequate to extract sample annotation. 
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filePaths = getGEOSuppFiles("GSE63270") 
 
cel_files <- list.files(pattern=".CEL" ,full.names=TRUE) 
cel_sample_list <- list.files(pattern=".CEL") 
cel_samples <- substr(cel_sample_list,1,10) 
cel_batch <- read.celfiles(cel_files[1]) 
  
dat <- rma(cel_batch) 
dat <- exprs(dat) 
colnames(dat) <- substr(colnames(dat),1,10) 
save(dat,file="jungRMAData.RData") 
load(file="jungRMAData.RData") 
# grab sample id, disease state, and cell type 
sample_ID <- sapply(colnames(dat),function(x) strsplit(x,"_")[[1]][2
]) 
cell_type <- sapply(colnames(dat),function(x) strsplit(x,"_")[[1]][3
]) 
cell_type <- sapply(cell_type,function(x) strsplit(x,"\\.")[[1]][1]) 
cell_type[which(cell_type=="L")] <- "LMPP" 
disease_stat <- rep("control",length(sample_ID)) 








probe_annot <- biomaRt::getBM( 
  attributes = c("affy_hg_u133_plus_2", "external_gene_name","descri
ption"), 
  mart = ensembl) 
probe_annot <- dplyr::rename(probe_annot, probe_id = affy_hg_u133_pl
us_2, ext_gene = external_gene_name) 
probe_annot <- dplyr::select(probe_annot, c('probe_id', 'ext_gene')) 
affy_annot <- probe_annot[which(probe_annot!=""),] 
affy_annot <- affy_annot[!is.na(affy_annot$probe_id),] 
 
# for now we will remove promiscuous probes 
affy_annot <- affy_annot[isUnique(affy_annot$probe_id),] 
rownames(affy_annot) <- affy_annot$probe_id 
 
# scripts for plotting CD200 in the Jung dataset 




status <- rep("normal",length=nrow(df)) 
status[which(df$cell_type %in% c("LSC","LPC","Blast"))] <- "AML" 
df <- data.frame(df,status) 
 
p <- ggplot(df, aes(x=cell_type, y=CD200_mRNA, fill=status)) + geom_
	 204	
boxplot(outlier.shape = NA) +  
  geom_jitter(shape=16, size=2,position=position_jitter(0.2)) + scal
e_fill_manual(values=c("#cc0000", "#999999")) + 
  theme(text = element_text(size=20), legend.position="none",axis.ti
tle.x=element_blank()) + theme_classic() 
p 
 
5.1 Jung et al; LSC vs Blasts 
## subset cell types of interest 
ind <- which(cell_type %in% c("LSC","Blast")) 
sub_cell_type <- cell_type[ind] 
sub_id <- sample_ID[ind] 
sub_dat <- dat[,ind] 
 
paired_samples <- names(table(sub_id)[which(table(sub_id)==2)]) 
ind <- which(sub_id %in% paired_samples) 
 
sub_cell_type <- sub_cell_type[ind] 
sub_id <- sub_id[ind] 
sub_dat <- sub_dat[,ind] 
 
jung_blast_aov <- t(apply(sub_dat,1,function(x) summary(aov(x~factor
(sub_id)+factor(sub_cell_type)))[[1]][,5])) 
jung_blast_aov <- jung_blast_aov[,-3] #subtract empty column 
colnames(jung_blast_aov) <- c("patient","lsc") 
 
jung_blast_diffs <- t(apply(sub_dat,1, function(tt){ 
  df <- data.frame(exp=tt,LSC=sub_cell_type) 
  mean(sapply(split(df,factor(sub_id)), function(t) diff(sapply(spli
t(t[,"exp"],t[,"LSC"]),mean)))) 
})) 
jung_blast_diffs <- as.numeric(jung_blast_diffs) 
names(jung_blast_diffs) <- rownames(sub_dat) 
 
jung_blast_score <- -log10(jung_blast_aov[,"lsc"]) * jung_blast_diff
s 










jung_blast_genes <- affy_annot[jung_blast_genes,"ext_gene"] 
jung_blast_genes <- jung_blast_genes[!is.na(jung_blast_genes)] 
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5.2 Jung et al; LSC vs HSC 
## subset cell types of interest 
tmp_type <- cell_type 
tmp_type[which(tmp_type %in% c("LMPP","MPP"))] <- "HSC" 
tmp_type[which(tmp_type %in% c("LPC"))] <- "LSC" 
ind <- which(tmp_type %in% c("LSC","HSC")) 
sub_cell_type <- tmp_type[ind] 
sub_id <- sample_ID[ind] 
sub_dat <- dat[,ind] 
 
jung_hsc_aov <- t(apply(sub_dat,1,function(x) summary(aov(x~factor(s
ub_cell_type)+factor(sub_id)))[[1]][,5])) 
jung_hsc_aov <- jung_hsc_aov[,-2] #subtract empty column 
 
 
jung_hsc_diffs <- as.numeric(apply(sub_dat,1, function(tt){ 
  mean(tt[which(sub_cell_type=="LSC")]) - mean(tt[which(sub_cell_typ
e=="HSC")]) 
  })) 
names(jung_hsc_diffs) <- rownames(sub_dat) 
 
jung_hsc_score <- -log10(jung_hsc_aov[,1]) * jung_hsc_diffs 
names(jung_hsc_score) <- names(jung_hsc_diffs) 









jung_hsc_genes <- affy_annot[jung_hsc_genes,"ext_gene"] 
jung_hsc_genes <- jung_hsc_genes[!is.na(jung_hsc_genes)] 
 
jung_genes <- intersect(jung_hsc_genes, jung_blast_genes) 
 
save(jung_blast_aov, jung_blast_diffs, jung_hsc_aov, jung_hsc_diffs, 
jung_genes, file="jung_data.RData") 
	
5 Compute overlap 




6.1 File location 
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getwd() 
## [1] "/Users/smherbrich/Box Sync/Konopleva/manuscripts/thesis/scri
pts" 
6.2 Session info 
sessionInfo() 
## R version 3.6.1 (2019-07-05) 
## Platform: x86_64-apple-darwin15.6.0 (64-bit) 
## Running under: macOS Sierra 10.12.6 
##  
## Matrix products: default 






## [1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8 
##  
## attached base packages: 
## [1] stats     graphics  grDevices utils     datasets  methods   b
ase      
##  
## loaded via a namespace (and not attached): 
##  [1] compiler_3.6.1  magrittr_1.5    tools_3.6.1     htmltools_0.
4.0 
##  [5] yaml_2.2.0      Rcpp_1.0.3      stringi_1.4.5   rmarkdown_2.
1   
##  [9] knitr_1.27      stringr_1.4.0   xfun_0.12       digest_0.6.2
3   
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